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The cancer incidence in the Netherlands is high, causing a considerable social and economic 
burden [1-3]. After years of increase, the age-standardized incidence rate (ESR) of cancer in 
the Netherlands has stabilized recently to 477 per 100000 people in 2018 [4, 5]. A decreasing 
trend has been reported for the age-standardized mortality (ESR) of cancer [5]. Since 2008, 
cancer has replaced cardiovascular disease (CVD) as the leading cause of death in the Dutch 
population [6].
According to estimations, approximately 10% of the cancers diagnosed in the Netherlands 
in 2010 could be attributed to suboptimal dietary habits and were therefore preventable 
[7]. Recently, the traditional Mediterranean diet (MD) has gained attention as a healthy and 
appetizing dietary pattern. This thesis is focused on the association between MD adherence 
and cancer risk in the Netherlands.  
1. The Mediterranean diet
The traditional Mediterranean diet can be defined as the dietary pattern typical of the 
Mediterranean regions traditionally known for olive cultivation (e.g., a large part of Greece 
and southern Italy) in the late 1950s and the early 1960s. In these years, areas along the 
Mediterranean shore had recovered from World War II, while their inhabitants had not yet 
adopted a more Western lifestyle characterized by fast food [8, 9].     
Formulating a definition of the MD was a challenging task for experts in the field, since 
there was not one true MD. Dietary patterns varied slightly across different areas in the 
Mediterranean basin. To illustrate this, the Greek variant of the MD was characterized 
by its high total fat intake (±40% of total energy intake), resulting from the generous 
consumption of olive oil. The Italian diet, on the other hand, was known for an exceptionally 
high consumption of pasta. Differences were also noticed between dietary patterns of 
other Mediterranean countries, for instance, the intake of fish was rather high in Spain [9]. 
However, for these areas, dietary patterns have not been described as exhaustively [8]. 
At the International Conference on the Diets of the Mediterranean in 1993, international 
experts agreed to use the typical dietary patterns of Crete, other parts of Greece, and 
southern Italy in the late 1950s and the early 1960s as a basis for the development of the 
cultural model for the MD [8], which was graphically presented by the “Mediterranean diet 
pyramid” (Figure 1.1). Despite inferior health care facilities, adult life expectancy was high 
in the abovementioned Mediterranean regions in the early 1960s, whereas diet-related 
chronic disease rates were low. Additionally, there was epidemiological evidence available 
suggesting that comparable dietary patterns were associated with several health benefits 
[8]. Because the diets of Crete, other parts of Greece, and southern Italy were characterized 
by the use of olive oil as the principal source of fat, the definition of the MD was extended 
to refer to the dietary patterns observed in all olive-cultivating areas bordering the 
Mediterranean Sea [8, 10]. Accordingly, the MD was defined in this thesis as “the dietary 
pattern typical of the Mediterranean regions traditionally known for olive cultivation in the 
late 1950s and the early 1960s”.   
Despite their differences, dietary patterns found in the olive-growing areas of the 
Mediterranean basin generally shared the following key components: The traditional MD 
was mainly a plant-based diet characterized by the consumption of large amounts of fruits, 
vegetables, legumes, nuts and seeds, and whole grains. Total fat intake varied from moderate 
to high depending on the specific Mediterranean area. However, the monounsaturated to 
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saturated fatty acid ratio (MUFA:SFA ratio) was high in all cases, as olive oil, which is rich in 
monounsaturated lipids, was the principal source of fat in the MD. Intake of milk and dairy 
products, poultry, and eggs was low to moderate, whereas red and processed meats, sweets, 
and refined grains were consumed in low quantities. Fish consumption was generally low 
to moderate as well, but depended largely on the distance to the sea. Finally, the MD was 
characterized by a moderate alcohol consumption, usually in the form of red wine during 
meals. In general, foods consumed in the Mediterranean region were minimally processed, 
fresh, seasonal, organic, and cultivated by local farmers [8, 9]. 
2. Health benefits of the Mediterranean diet 
Despite the inferior health care facilities in Mediterranean regions, Mediterranean 
populations between 1960 and 1990 experienced lower mortality rates and a higher adult 
life expectancy than populations of northern Europe and North-America [9]. One of the 
candidate factors proposed to explain this remarkable finding was the plant-based dietary 
pattern to which Mediterranean populations adhered [9]. 
Groundbreaking in the discovery of the beneficial health effects of the MD was the Seven 
Countries Study, initiated mid-twentieth century by Ancel Keys. This study followed 
almost 13000 men between the ages of 40 and 59 years, who were enrolled in 16 centers, 
distributed over seven countries, for up to 30 years. The main goal was to investigate the 
relationship between diet and the incidence of coronary heart disease (CHD). Based on the 
Figure 1.1  Mediterranean diet pyramid (https://oldwayspt.org)
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results, Keys concluded that the lower rates of CHD observed in Mediterranean populations 
could be attributed to low dietary levels of saturated fat [9, 11]. 
Since the Seven Countries Study, the association between adherence to the MD and 
numerous health outcomes has been investigated extensively in observational studies and 
a number of randomized controlled trials (RCTs). The current scientific evidence suggests 
that higher MD adherence might be associated with reduced rates of overall mortality, CVD 
incidence and mortality, overall cancer incidence, neurodegenerative diseases, and diabetes 
[12-14]. However, the evidence for other health outcomes, e.g., many specific cancer types, 
metabolic risk factors, and inflammatory parameters, is weaker or controversial [12-14]. 
So far, several RCTs have been conducted on this topic, primarily investigating the effect of 
the MD pattern on CVD risk (factors) [14]. Particularly noteworthy are the Lyon Diet Heart 
Study (secondary prevention trial among survivors of a first acute myocardial infarction, [15, 
16]) and the Prevención con Dieta Mediterránea trial (PREDIMED, primary prevention trial 
among participants who were at high risk for CVD, [17]). In these RCTs, MD interventions 
enriched with α-linolenic acid (Lyon Diet Heart Study) or supplemented with either extra-
virgin olive oil or nuts (PREDIMED) were compared to a prudent Western-type diet (Lyon 
Diet Heart Study) and a low-fat control diet (PREDIMED), respectively. In addition to reduced 
risks of composite outcomes of major cardiovascular events [16, 18], participants in the MD 
intervention groups seemed to have (non-)significantly lowered risks of overall cancer (Lyon 
Diet Heart Study) and postmenopausal breast cancer (PREDIMED) [19, 20]. 
Though results of the Lyon Diet Heart Study and PREDIMED trial indicated that adherence 
to a MD might lower cancer risk, the analyses were based on small numbers of incident 
cancer cases. The large majority of the evidence for the potential relation between MD 
adherence and cancer risk has been gathered from observational studies. MD adherence 
(highest vs. lowest quantile) was associated with a statistically significantly reduced overall 
cancer incidence (4%) and mortality (14%) in cohort studies [21]. Additionally, a recent meta-
analysis of observational studies by Schwingshackl and colleagues [22] showed statistically 
significant inverse associations between MD adherence and incidence of cancers of the 
colorectum, breast (postmenopausal), prostate, stomach, liver, head and neck, gallbladder, 
and biliary tract. However, the evidence was limited for most of the investigated cancer 
sites, individual studies sometimes had inconsistent results, and many of the included 
studies had case-control designs. Due to the retrospective nature of the case-control design 
and the associated vulnerability of this design to several types of bias (e.g., recall and 
selection biases), the prospective cohort design is preferred. Different etiologies have been 
suggested for subtypes of several cancer sites, such as the lung [23], breast [24], esophagus 
[25], stomach [26], and colorectum [27, 28]. Nevertheless, prospective studies rarely 
evaluated associations with MD adherence separately for subtypes of cancer sites, which 
could have contributed to the inconsistent findings. Furthermore, potential heterogeneity 
of associations across the sexes requires more attention. Accordingly, additional research 
evaluating the association of MD adherence with cancer risk is desired. Ideally, future 
studies would have a prospective design and would differentiate between men and women 
as well as cancer subtypes. 
The potentially beneficial influence of MD adherence on cancer risk seems biologically 
plausible. Nevertheless, the specific pathways involved still remain to be elucidated. Two of 
the more established mechanisms of action concern the antioxidant and anti-inflammatory 
properties of the MD, which could counteract oxidative damage to DNA, proteins, and lipids, 
and reduce inflammation, respectively [29, 30]. The plant-based nature of the MD ensures 
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a high intake of antioxidants (e.g., vitamins, minerals, and polyphenols) derived from the 
consumption of vegetables, fruits, nuts, whole grains, olive oil, and other plant foods 
[29-32]. Correspondingly, elevated total antioxidant capacity levels have been observed 
in subjects with higher MD adherence [33]. Furthermore, adherence to the MD has 
generally been associated with reduced levels of markers of low-grade inflammation (e.g., 
interleukin-6 and C-reactive protein) [34]. The ability of the MD to reduce inflammation 
might (partly) be attributed to the abundance of polyphenols and omega-3 polyunsaturated 
fatty acids (PUFA) in this dietary pattern [29-31, 35]. In addition to its antioxidant and anti-
inflammatory effects, MD adherence might reduce the biological activity of hormones 
and growth factors that have been implicated in the stimulation of tumor development 
and growth, such as insulin, estrogens, androgens, and insulin-like growth factor 1 [29]. 
Other proposed mechanisms that might mediate the potential cancer-protective effect of 
the MD are among others related to the high intake of dietary fiber, the low intake of red 
and processed meats, body weight regulation, decreased activation of nutrient sensing 
pathways [e.g., the pro-carcinogenic mechanistic target of rapamycin (mTOR) pathway] 
through amino acid restriction, and modulation of the composition and function of the gut 
microbiota influencing their metabolite secretion [29, 30, 32, 36-38]. 
3. Methods to assess Mediterranean diet adherence
To investigate the association of the MD with cancer risk, researchers usually assess the level 
of adherence to the MD of study participants: In other words, the extent to which a subject’s 
diet resembled the MD pattern.
The level of MD adherence in a certain population can be assessed using either a priori or 
a posteriori scores [39, 40]. In case of the MD, the a priori approach seems to have been 
applied most frequently. In this approach, food groups characteristic of the MD, because 
of their relatively high or low consumption in this dietary pattern, are selected based on 
scientific knowledge and evidence, and are combined into indexes assessing the overall 
level of MD adherence. Subsequently, an individual’s level of MD adherence is derived 
from his/her dietary information using the created index and associations between MD 
adherence and health outcomes are investigated. Generally, a priori defined indexes assess 
MD adherence in a rather qualitative way [40].
As an alternative to the usage of a priori defined indexes, the health effects of the MD 
have occasionally been investigated in studies that observed a MD-like dietary pattern in 
their study population after applying a posteriori methods. Using the a posteriori approach, 
e.g., factor or cluster analysis is carried out to empirically derive dietary patterns from 
the collected dietary data. In factor analysis, correlations between food groups are used 
to extract food patterns with the goal to explain as much of the variance in the dietary 
data as possible. Subsequently, a summary score is calculated for each of the extracted 
food patterns. Furthermore, dietary patterns in the study population can be obtained 
by grouping individuals based on their food intakes into mutually exclusive clusters, as 
is done in cluster analysis [39, 41, 42]. The a posteriori approach has some limitations, 
the major one being its subjectivity. It is up to the researchers to decide upon, e.g., the 
categorization of the dietary data into food groups, the number of dietary patterns observed 
in the study population, and the interpretation and naming of the derived patterns. 
Additionally, a posteriori defined dietary patterns are specific for the study population, 
making comparison with dietary patterns observed in other studies challenging. Finally, 
the observed dietary pattern does not necessarily reflect an “ideal” MD [39, 41-43]. 
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From this point onwards, this thesis will focus on a priori defined indexes used in the 
assessment of MD adherence.
3.1 The Mediterranean diet score by Trichopoulou et al. 
The a priori defined traditional Mediterranean diet score (tMED) created by Trichopoulou et 
al. [44, 45] is a straightforward and convenient tool to measure the level of MD adherence. 
tMED [44] assesses the relative level of MD adherence based on the mean daily intakes of 
eight dietary components, which are characteristically consumed in relatively high or low 
amounts in the traditional Greek MD. Each dietary component receives a score of 0 or 1 
point using sex-specific median values in the study population as cut-offs (except for alcohol 
intake). Subsequently, the scores of the individual components are added to create a sum 
score, with the maximum value of 8 points reflecting closest adherence to the MD. A score 
of 1 point is assigned to mean daily intakes at or above the sex-specific median of presumed 
beneficial dietary components, which include vegetables (excluding potatoes), fruits and 
nuts, legumes, and cereals (including potatoes). Inverse scoring is applied to the meat and 
dairy components, which are presumed to have detrimental health effects. Finally, 1 point 
is assigned to a moderate alcohol intake (men: 10-50 g/day, women: 5-25 g/day) and a high 
(≥ sex-specific median) MUFA:SFA ratio [44]. Before calculation of tMED, dietary intakes are 
standardized to energy intakes of 2500 kcal and 2000 kcal per day for men and women, 
respectively, to correct for differences in daily energy intake [44, 46]. 
tMED is the most widely used index in the assessment of MD adherence and numerous 
variants have appeared since its introduction in 1995 [40]. In this paragraph, we will 
discuss the most important tMED variants, which are summarized in Table 1.1. The dietary 
components composing the original tMED are displayed in bold in this table. Scores are 
displayed for intakes at or above the sex-specific median, unless otherwise specified.
Firstly, a revised version of tMED was proposed by Trichopoulou et al. in 2003, which 
included fish as an additional beneficial component, whereas potato intake was removed 
from the cereal group [45]. In 2005, two frequently used variations of the revised tMED 
were independently introduced, namely the modified Mediterranean diet score (mMED, 
[47]) and the alternate Mediterranean diet score (aMED, [46, 48]). In mMED, the ratio of 
unsaturated fatty acids (MUFA + PUFA) to SFA replaces the MUFA:SFA ratio to increase the 
usability of the score in non-Mediterranean populations [47]. Dietary patterns consistently 
proven to decrease chronic disease risk formed the foundation for the formulation of 
aMED, which was particularly developed for use in the US [46, 48]. In aMED, fruits and nuts 
are included as two separate components, only whole grains are considered in the cereal 
group, the meat component is restricted to red and processed meats, and dairy products 
are excluded from the score. Furthermore, moderate alcohol consumption is defined as 
5-25 g/day for both men and women [46, 48]. Revised tMED, mMED, and aMED range from 
0 to 9 points. A final and less commonly applied variant of revised tMED is the relative 
Mediterranean diet score (rMED), introduced by Buckland et al. in 2009 [49]. Different from 
the other scores, rMED uses a tertile-based scoring for all components (except alcohol) and 
accordingly has a maximum value of 18 points. Additionally, rMED directly scores olive oil 
consumption instead of using the MUFA:SFA ratio as a substitute [49].
14
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Table 1.1  The five major variants of the Mediterranean diet score initially developed by Trichopoulou et al. in 
1995 (scores are displayed for intakes ≥ sex-specific median, unless otherwise specified)
Dietary component tMEDa
(1995)
Revised tMEDa
(2003)
mMEDa
(2005)
aMEDa
(2005)
rMEDb
(2009)
Vegetables (excl. potatoes) 1 1 1 1 2
Fruits and nuts 1 1 1 2
Fruits (incl. juices) 1
Nuts 1
Legumes 1 1 1 1 2
Cereals (incl. potatoes) 1
Cereals (excl. potatoes) 1 1 2
Whole grains 1
Fish and seafood 1 1 1 2
Meat and meat products 0 0 0 0
Red and processed meat 0
Dairy products 0 0 0 0
MUFA:SFA ratio 1 1 1
(MUFA + PUFA):SFA ratio 1
Olive oil 2
Moderate alcohol intake
Men: 10-50 g/day 1 1 1 1: 5-25 g/day 2c
Women: 5-25 g/day 1 1 1 1: 5-25 g/day 2c
Range score 0-8 0-9 0-9 0-9 0-18
Abbreviations: tMED, traditional Mediterranean diet score; mMED, modified Mediterranean diet score; aMED, 
alternate Mediterranean diet score; rMED, relative Mediterranean diet score; MUFA, monounsaturated fatty 
acids; SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids 
a Scores of 0 or 1 point were assigned to each dietary component using sex-specific median values as cut-off, 
unless otherwise specified. Scores are displayed for intakes ≥ sex-specific median.  
b Scores ranging from 0 to 2 points were assigned based on tertiles of intakes, unless otherwise specified. Scores 
for the highest tertiles are displayed.  
c A score of 0 was assigned to alcohol consumption levels outside this range. 
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Overall, evidence on the validity and reliability of tMED (variants) and other MD scores is 
scarce [50]. High intakes of typically Mediterranean foods (e.g., vegetables, legumes, fruits 
and nuts, and olive oil) were, as expected, increasingly common among Greek subjects with 
greater MD adherence according to revised tMED, whereas opposite trends were observed 
for intakes of meat and dairy products [45]. Additionally, the ability of the food frequency 
questionnaire (FFQ) to rank subjects according to their level of MD adherence has been 
studied by comparing MD scores (tMED variants) derived from FFQ data to MD scores based 
on ten or more 24-hour dietary recalls, and was judged to be reasonable [51]. Finally, the 
validity of tMED and variants has been confirmed by examining their competence to predict 
various health outcomes. For instance, higher MD adherence, measured by tMED (variants), 
has been associated with reduced all-cause mortality and, more specifically, reduced risks of 
and mortality from CVD and cancer, in a variety of Mediterranean and non-Mediterranean 
populations (e.g., [44-47, 49, 52-56]). To the best of our knowledge, no studies have been 
published yet evaluating the reliability, in the sense of reproducibility, of tMED or variants 
[50].  
A potential limitation of tMED (variants) is the use of population medians as cut-offs to 
distinguish between subjects with high and low intakes of (non-)Mediterranean foods. 
Although subjects with high MD scores adhere more closely to the MD than subjects with 
lower scores, their dietary intakes do not necessarily comply with a traditional MD. This 
is particularly relevant in non-Mediterranean study populations. Furthermore, the use of 
population-specific cut-offs might hamper between-study comparisons and generalizability 
of study results. Another potential weakness is the assignment of equal weights to all 
dietary components. Finally, tMED and the majority of its variants categorize subjects as 
having either high or low intakes of the individual dietary components. This binary approach 
may result in a loss of information and reduce the discriminative capacity of the score.  
In this thesis, we used aMED and mMED to determine the level of MD adherence, as will be 
discussed more comprehensively in the paragraph concerning the study design.  
4. Rationale and aims of the thesis
Despite the increasing interest in the potentially favorable effect of MD adherence on cancer 
risk, the current evidence is still insufficient, sometimes inconsistent, and predominantly 
based on case-control studies. Additional prospective studies are desired, which might 
enable the formulation of more definitive conclusions.  
The general aim of this thesis was to prospectively investigate the association between MD 
adherence and cancer incidence in the Netherlands. Analyses were conducted considering 
the incidence of overall cancer, and cancers of the lung, breast, esophagus, stomach, 
pancreas, colorectum, prostate, and bladder as primary outcomes. The specific cancer types 
of interest were selected because of their high incidence, expected relation with the MD, 
or poor prognosis. In view of the potential role of the MD in cancer prevention, it is also 
interesting to evaluate the relation of this dietary pattern with overall cancer incidence. 
We specifically addressed subtypes of the selected cancer sites and estimated associations 
separately for men and women, whenever possible. Furthermore, model performances of 
two MD scores (aMED and mMED) were compared and the effect of exclusion of alcohol 
from the MD scores was evaluated. As a final aim of this thesis, we compared the population-
dependent MD scores to absolute scores based on the dietary recommendations for cancer 
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prevention issued by the World Cancer Research Fund/American Institute for Cancer 
Research (WCRF/AICR) in 2007 [57]. 
5. Study design
The aims of this thesis were primarily investigated within the context of the large prospective 
Netherlands Cohort Study on Diet and Cancer (NLCS). The association of MD adherence 
with pancreatic cancer risk was evaluated by pooling results from the NLCS and the Dutch 
cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-NL) to 
increase the statistical power. Detailed descriptions of the population-based NLCS and EPIC-
NL cohorts have been published previously [58-64]. 
The study population of the NLCS consists of 58279 men and 62573 women, who originated 
from 204 Dutch municipalities and were aged 55 to 69 years at the initiation of the study in 
September 1986 [58]. NLCS participants filled out a self-administered baseline questionnaire 
on cancer risk factors, which included a FFQ [60, 65]. To allow for efficient data processing 
and analysis, the NLCS used the nested case-cohort design [58, 61, 66]. Accordingly, incident 
cancer cases were detected in the entire NLCS cohort, while accumulated person-years at 
risk in the cohort were estimated based on a random subcohort (N=5000) that was sampled 
immediately after baseline. Vital status of subcohort members was checked biennially using 
municipal population registries. 
The EPIC-NL cohort is composed of the EPIC-Prospect and EPIC-MORGEN cohorts, which 
collectively enrolled 40011 subjects [62-64]. EPIC-Prospect includes 17357 women, aged 49 
to 70 years, who participated in a breast cancer screening program in the region of Utrecht. 
EPIC-MORGEN encompasses 10260 men and 12394 women, aged 20 to 65 years, who 
were randomly sampled from the general population of three Dutch towns (Amsterdam, 
Maastricht, and Doetinchem). Between 1993 and 1997, baseline data were obtained using 
a general questionnaire, a FFQ, and a physical examination. EPIC-NL participants were 
followed up for vital status using municipal population registries. 
In both cohorts, incident cancer diagnoses were identified annually by record linkage with 
the Netherlands Cancer Registry and the nationwide Dutch Pathology Registry (PALGA) [59, 
64]. NLCS participants were followed up for 20.3 years until December 31, 2006. The median 
follow-up in EPIC-NL was 19.2 years (baseline to December 31, 2014). 
Information concerning the dietary habits of NLCS and EPIC-NL participants during the 
year preceding enrolment was acquired using semi-quantitative FFQs. These FFQs were 
study-specific, and their validity and reproducibility have been evaluated [60, 65, 67, 68]. 
Additionally, Dutch food composition (NEVO) tables were utilized to derive mean daily 
nutrient intakes from the FFQ data [69].
This thesis is mainly focused on the MD pattern as a whole, rather than its individual nutritional 
components. The pattern-based approach allowed us to investigate the combined effect of 
all aspects of the MD taking potential interactions between single dietary factors or food 
groups into account. In order to assess the relative level of MD adherence, we used aMED 
[46, 48] and mMED [47], which are both variants of tMED [44, 45]. As described above, 
tMED and variants are straightforward and user-friendly tools to assess MD adherence. 
Additionally, the wide usage of these MD scores facilitates the comparability of our study 
results to previously published findings on the topic. The decision to use aMED instead 
of revised tMED was based on the consistently better model fit of aMED in earlier NLCS 
mortality analyses [54]. Additionally, we included mMED, which was specifically adapted to 
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measure MD adherence in non-Mediterranean populations. Because alcohol may increase 
risks of multiple types of cancer even at low or moderate levels of consumption [36, 70], we 
created reduced variants of aMED and mMED (aMEDr and mMEDr, respectively) that did 
not contain the alcohol component.
6. Outline of the thesis
The following chapters of this thesis (Chapter 2-7) focus on associations of MD adherence with 
risks of specific cancer sites. We investigated relations of MD adherence with risks of cancers 
of the lung (Chapter 2), breast (Chapter 3), esophagus and stomach (Chapter 4), pancreas 
(Chapter 5), colorectum (Chapter 6), and prostate and bladder (Chapter 7). Associations with 
MD adherence may differ across (subtypes of) cancer sites. Therefore, from the perspective 
of cancer prevention, it would be helpful to get an impression of the association between 
MD adherence and overall cancer risk, which is the topic of Chapter 8. Chapter 9 concludes 
this thesis with a reflection on the main findings and some methodological considerations. 
Furthermore, implications for public health and recommendations for future research are 
discussed in this final chapter. 
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Abstract 
The evidence on a cancer-protective effect of the Mediterranean diet (MD) is still limited. 
Therefore, we investigated the association between MD adherence and lung cancer risk. 
Data were used from 120852 participants of the Netherlands Cohort Study (NLCS), aged 55-
69 years. Dietary habits were assessed at baseline (1986) using a validated food frequency 
questionnaire and alternate and modified Mediterranean diet scores (aMED and mMED, 
respectively), including and excluding alcohol, were calculated. After 20.3 years of follow-
up, 2861 lung cancer cases and 3720 subcohort members (case-cohort design) could 
be included in multivariable Cox regression analyses. High (6-8) versus low (0-3) aMED 
excluding alcohol was associated with non-significantly reduced lung cancer risks in men 
and women with hazard ratios of 0.91 (95% confidence interval (CI): 0.72 – 1.15) and 0.73 
(95% CI: 0.49 – 1.09), respectively. aMED-containing models generally fitted better than 
mMED-containing models. In never smokers, a borderline significant decreasing trend in 
lung cancer risk was observed with increasing aMED excluding alcohol. Analyses stratified 
by the histological lung cancer subtypes did not identify subtypes with a particularly strong 
inverse relation with MD adherence. Generally, the performance of aMED and WCRF/AICR 
dietary score variants without alcohol was comparable. In conclusion, MD adherence was 
non-significantly inversely associated with lung cancer risk in the NLCS. Future studies should 
focus on differences in associations across the sexes and histological subtypes. Furthermore, 
exclusion of alcohol from MD scores should be investigated more extensively, primarily with 
respect to a potential role of the MD in cancer prevention.   
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Introduction 
Lung cancer was the leading cause of cancer death in the world in 2012. In that year, 1.8 
million people were diagnosed, making lung cancer the most frequently diagnosed cancer 
in men and the third most common cancer in women worldwide [1]. The prognosis of lung 
cancer is poor, with five-year survival rates of 19% in the US [2] and 17% in the Netherlands 
[3] for lung cancers diagnosed around 2010. Tobacco smoking is the primary risk factor, but 
diet may influence lung cancer risk as well [4].
The traditional Mediterranean diet (MD) is a plant-based diet. Vegetables, legumes, fruits, 
nuts, whole grains and fish are consumed in large amounts in this dietary pattern, whereas 
consumption of red and processed meats, high-fat dairy products, refined grains and 
sweets is limited. Olive oil is the principal source of fat resulting in a relatively high ratio of 
monounsaturated fatty acids (MUFA) to saturated fatty acids (SFA). A final characteristic of 
this diet is the moderate consumption of red wine, mainly during meals [5-7]. Higher MD 
adherence has been associated with numerous health benefits including reduced all-cause 
mortality, and decreased incidence of and mortality from cardiovascular diseases [8-10]. 
Recently, higher MD adherence has been associated with a reduced lung cancer risk in three 
different cohort studies [11-13]. However, the number of lung cancer cases was small in two 
of the three studies, and sex-specific associations and possible differences in associations of 
MD adherence with the four major histological lung cancer subtypes were not investigated 
elaborately. Even though the association between alcohol consumption and lung cancer risk 
is still unclear, these previous studies included alcohol in the MD score used [14].  
The present study was conducted among men and women between the ages of 55 and 69 
years, who participated in the Netherlands Cohort Study (NLCS). In this paper, we aimed to 
investigate the association between MD adherence and the risk of lung cancer. Age-specific 
incidence rates of lung cancer in the Netherlands in the study period (1986-2006) were 
281 per 100000 for people aged between 60 and 74 years in 1990 and 318 per 100000 for 
people aged 75 years or older in 2005 [3].  Additionally, we tested the heterogeneity of 
the association of MD adherence with lung cancer risk between the sexes and four major 
histological lung cancer subtypes, and evaluated the effect of exclusion of alcohol from the 
MD scores. 
Methods 
Study design and lung cancer follow-up
The NLCS is a prospective population-based cohort study that was initiated in September 1986 
and has been described previously [15-18]. At enrollment, 58279 men and 62573 women, aged 
between 55 and 69 years, filled out a self-administered questionnaire regarding their dietary 
habits and other cancer risk factors. The NLCS was approved by the institutional review boards 
from Maastricht University and the Netherlands Organization for Applied Scientific Research. 
To allow efficient data processing, the nested case-cohort approach was applied, in which 
the number of person-years at risk is estimated based on a subcohort (N=5000) that was 
randomly sampled just after baseline. Vital status of subcohort members was biennially 
verified [15, 18]. Incident cancers in the NLCS cohort were detected by annual computerized 
record linkage with the Netherlands Cancer Registry and the Dutch Pathology Registry 
(‘Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief’, PALGA) [16]. Reported 
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computer matches, based on a linkage key, were estimated to have a sensitivity and positive 
predictive value of 98% [16]. Computerized linkage was followed by visual inspection in 
order to distinguish true matches from false positives, which maximized the positive 
predictive value to 100%, while remaining the sensitivity unaltered [16]. It was estimated 
that the completeness of follow-up through record linkage with the Netherlands Cancer 
Registry and PALGA exceeded 95% [19]. Incident lung cancers (International Classification of 
Diseases for Oncology, Third Edition, code C34) were detected until 20.3 years of follow-up. 
Cases with lung cancers other than carcinoma, in situ lung carcinoma or not microscopically 
confirmed lung cancer were excluded. Cases and subcohort members with prevalent cancer 
at baseline (except skin cancer), and incomplete or inconsistent (dietary) questionnaires 
were not eligible as well. In the end, 4084 subcohort members and 3261 lung cancer cases 
were eligible for inclusion in the analyses. Of the eligible study population, 2861 lung cancer 
cases and 3720 subcohort members were included in the Cox proportional hazards models 
as a result of missing values in covariates (Figure 2.1).  
Exposure assessment 
At baseline, NLCS participants completed a self-administered, 150-item, semi-quantitative 
food frequency questionnaire (FFQ) measuring dietary habits over the preceding year, 
which was validated by nine-day dietary records filled out over three different seasons [17]. 
Additionally, reproducibility of the single baseline measurement of the FFQ was investigated 
by means of five annually repeated measurements of dietary intake in independent random 
samples from the subcohort. Considering all nutrients, the average test-retest correlation 
of the FFQ was 0.66. Over five years, the correlation between the baseline and repeated 
measurement of the FFQ had declined on average 0.07, suggesting that the FFQ was able to 
rank subjects according to their nutrient intake relatively well over at least a five-year period 
[20]. In order to derive mean daily nutrient intakes from the questionnaire data, the 1986 
Dutch food composition (NEVO) table was utilized [21].
Mediterranean diet adherence
The alternate and modified Mediterranean diet scores (aMED and mMED, respectively), 
which were both derived from the traditional Mediterranean diet score (tMED) developed 
in 1995 by Trichopoulou et al., were applied to measure relative MD adherence [22-26]. 
Before calculation of the aMED and mMED, dietary intakes were standardized to a total daily 
energy intake of 2000 kilocalories (kcal) for women and 2500 kcal for men [22, 26].
aMED considers the intake of nine food components, which are scored as either 0 or 1 using 
population-based cut-offs, resulting in a sum score varying from 0 (minimal adherence) to 
9 (maximal adherence) [25, 26]. A score of 1 is assigned to daily intakes at or above the sex-
specific median for components presumed to be beneficial (vegetables (excluding potatoes), 
legumes, fruits, nuts, whole grains, fish, and MUFA:SFA ratio), whereas the intake of red and 
processed meats is scored inversely. Finally, moderate alcohol consumption (5-25 grams per 
day for both men and women) is assigned 1 point as well [25, 26].
mMED [24], developed for usage in non-Mediterranean populations, differs from aMED 
with regard to the food components included. In mMED, fruits and nuts are considered 
as one component, the cereal component includes whole and refined grains, total meat 
consumption is scored, dairy consumption is included as component, and the unsaturated 
Mediterranean diet and lung cancer risk
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(MUFA + polyunsaturated fatty acid (PUFA)) fatty acid to SFA ratio is used. Also, the definition 
of moderate alcohol consumption is different (men: 10-50 grams per day; women: 5-25 
grams per day) [24]. 
Because of the unclear association between alcohol intake and lung cancer risk [14] and 
variability in the definition of moderate alcohol consumption, aMED and mMED variants 
without alcohol were created, resulting in sum scores ranging from 0 to 8 points. We refer 
to these reduced scores as aMEDr and mMEDr, respectively.  
Statistical analyses
Initially, all analyses were performed separately for men and women. Descriptive statistics 
were used to assess baseline characteristics of the subcohort. 
The relation between MD adherence and lung cancer incidence was evaluated by running 
Cox proportional hazards models with follow-up as the timing variable to estimate hazard 
ratios (HRs) and 95% confidence intervals (95% CIs). Person-years at risk of subcohort 
members were calculated from baseline until lung cancer diagnosis, death, emigration, loss 
to follow-up, or end of follow-up, whichever occurred first. Because the variance is increased 
in a case-cohort design, standard errors were calculated using the Huber-White sandwich 
estimator [27]. Scaled Schoenfeld residuals tests, smoothed scaled Schoenfeld residuals 
plots and -ln(-ln) survival plots confirmed that the proportional hazards assumption was 
met [28]. aMEDr and mMEDr were included in the analyses as categorical (low: 0-3; middle: 
4-5; high: 6-8 points) and continuous (per 2-point increment) variables. For each exposure, 
three models were run, varying with respect to the covariates (literature-based) included. 
The age-adjusted analyses were adjusted for age at baseline (years) and sex (except sex-
specific models). Additional adjustment for cigarette smoking status (never, former, current), 
duration (years, centered) and frequency (cigarettes smoked per day, centered) was applied 
in the smoking-adjusted models. The fully adjusted analyses were also adjusted for daily 
energy intake (kcal), alcohol consumption (0, >0-<5, ≥5-<15, ≥15-<30, ≥30 grams per day), 
body mass index (BMI, <18.5, ≥18.5-<25, ≥25-<30, ≥30 kg/m2), non-occupational physical 
activity (≤30, >30-≤60, >60-≤90, >90 minutes per day), highest level of education (primary 
school or lower vocational, secondary school or medium vocational, higher vocational or 
university), family history of lung cancer (no, yes) and history of physician-diagnosed chronic 
bronchitis (no, yes). Tests for trends were performed by considering the categorical MD 
score variables as continuous parameters. 
Performances of models with aMEDr and mMEDr were compared using Akaike’s Information 
Criterion (AIC) [29]. Additionally, AIC was used to compare the fit of models containing 
aMEDr and mMEDr, to the fit of models containing the original aMED and mMED including 
alcohol (categorized: 0-3 (low), 4-5 (middle) and 6-9 (high); continuous: per 2-point 
increment). The latter models did not include alcohol consumption as covariate. Based on 
these analyses, it was decided to assess MD adherence in the remainder of the analyses by 
aMEDr. Population attributable fractions (PAFs) were calculated using the STATA command 
punafcc, to determine the proportion of lung cancers that could be prevented if everyone 
had high MD adherence [30, 31]. The effects of an alternative scenario, in which subjects 
with low and middle MD adherence moved one category upwards, were evaluated by 
means of preventable proportions (PP) [32]. 
The relation between MD adherence and lung cancer was also evaluated separately for the 
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four major histological lung cancer subtypes: adenocarcinoma, squamous cell carcinoma, 
small cell carcinoma and large cell carcinoma. Heterogeneity across the subtypes was 
tested using a competing risks procedure. Standard errors of the difference were estimated 
using a bootstrapping method, especially developed for the case-cohort design, to prevent 
overestimation due to the absence of independence [33, 34].
Potential effect modification was evaluated by conducting Wald tests on interaction terms 
between the exposure of interest and age at baseline, smoking status, BMI, non-occupational 
physical activity, alcohol consumption and family history of lung cancer. Additionally, analyses 
were performed within strata of the same variables to illustrate potential modifications 
and to evaluate potential residual confounding by these lung cancer risk factors. Sensitivity 
analyses were conducted by dividing the follow-up in three periods (≤2 years, >2 to ≤10 
years, >10 years) and excluding cases diagnosed during the first two years of follow-up. 
Moreover, the potential impact of unmeasured confounders was evaluated using rule-out 
approach sensitivity analysis as proposed by Schneeweiss [35]. 
The contribution of the individual aMEDr components to the observed associations was 
investigated by alternately deleting each component from the sum score using the methods 
described by Trichopoulou et al. [36]. Because this procedure reduces the maximum score, 
we multiplied the regression coefficients per 2-point increment by 8/9 before exponentiating 
them, to obtain HRs that could be compared to effect estimates of the original score. 
Furthermore, the change in beneficial effect after deletion of one component was divided 
by the beneficial effect of the original score to acquire the percentage reduction of the 
inverse association. Analyses were adjusted by the subtracted component and all covariates 
included in the fully adjusted model.
Finally, the population-dependent assignment of scores is a potential drawback of the 
MD scores used, especially in non-Mediterranean populations. Therefore, we compared 
the performances of models containing the relative aMED variants and models containing 
absolute scores based on the dietary part of the recommendations to prevent cancer of 
the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) 
with and without alcohol [4]. We operationalized the recommendations concerning 
consumption of foods and drinks that promote weight gain, plant foods, red and processed 
meats, alcohol and salt. The absolute cut-offs used per (sub)recommendation as well as 
the calculation of the score have been described in detail in a previous NLCS article [37] 
and were based on the methods used in the EPIC cohort [38, 39]. This resulted in a score 
ranging from 0 to 5 points with higher scores reflecting higher adherence to the WCRF/AICR 
recommendations. Analogous to aMED, we also created a WCRF/AICR score excluding the 
alcohol recommendation, which had a maximum value of 4 points. The continuous WCRF/
AICR score variables were included in fully adjusted Cox proportional hazards models to 
estimate HRs and 95% CIs per SD increment (sex-specific). A similar approach was applied 
to aMED and aMEDr and the performances of models including WCRF/AICR score variables 
and aMED variables were compared using AIC. Analyses were carried out using STATA14 
(StataCorp LP, College Station, TX, USA) and Microsoft Excel 2010 (Microsoft Corporation, 
Redmond, WA, USA). P-values below 0.05 were considered to be statistically significant.
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Results 
After 20.3 years of follow-up, 3261 (men: 2777; women: 484) of the detected lung cancer 
cases met the eligibility criteria and were included in the present study. Squamous cell 
carcinoma (39.5%) was the most frequently diagnosed subtype in men, followed by 
adenocarcinoma (21.8%), small cell carcinoma (16.7%) and large cell carcinoma (15.0%). 
In women, these subtypes comprised 23.6%, 33.9%, 18.2% and 15.5%, respectively. The 
remainder of the carcinomas detected was categorized as unspecified (6.9% in men and 
8.9% in women). 
Subcohort members (50.4% male sex) had a median age of 61 years at baseline and the 
majority (64.9%) was a former or current smoker. Mean values of aMEDr and mMEDr 
were approximately 4 in both male and female subcohort members. Sex-specific baseline 
characteristics of subcohort members are presented by aMEDr and mMEDr category in 
Table 2.1. Subcohort members with higher MD adherence were more often highly educated, 
more physically active and less often current smokers. Lower mean daily energy intakes 
were reported in both men (aMEDr and mMEDr) and women (mMEDr) with higher MD 
adherence. Furthermore, inverse associations with MD conformity in men were observed 
for alcohol consumption and having a lung cancer family history. In contrast, women with 
higher MD adherence were younger, consumed more alcohol (aMEDr), more often had 
a positive lung cancer family history (mMEDr) and less often had suffered from chronic 
bronchitis (aMEDr). 
Because of missing values in covariates included in the multivariable analyses, 2861 lung 
cancer cases (men: 2413; women: 448) and 3720 subcohort members (men: 1834; women: 
1886) were included in the Cox models. Sex-specific HRs and 95% CIs for the association 
between MD adherence, measured by various MD scores, and lung cancer risk are displayed 
in Table 2.2. Statistically significant inverse associations of MD adherence with lung cancer 
risk were observed in all age-adjusted analyses in both sexes. After additional correction 
for cigarette smoking (cigarette smoking status, duration and frequency), the associations 
attenuated and were no longer statistically significant, but generally remained inverse. 
However, the association disappeared in men when conformity to MD was assessed using 
mMEDr. Additional adjustment for other potential confounders did not result in noticeable 
changes in the estimates. The inverse association between aMEDr and lung cancer risk 
seemed to be slightly stronger in women compared to men. However, this heterogeneity 
between the sexes was not statistically significant. Fully adjusted HRs (95% CI) for the middle 
and high adherence categories, respectively, were 0.87 (0.65 ; 1.15) and 0.73 (0.49 ; 1.09) 
in women, and 0.86 (0.73 ; 1.02) and 0.91 (0.72 ; 1.15) in men, using the low category as 
reference. Judged by AIC, models containing aMEDr had a better fit than mMEDr-containing 
models. Furthermore, model fits were worse when alcohol consumption was included in 
the score. Therefore, as was already mentioned in the Methods section, aMEDr was used 
to assess MD adherence in the remainder of the analyses. Assuming causality, PAFs showed 
that 18.9% (95% CI: -12.6% to 41.6%) and 2.0% (95% CI: -19.1% to 19.4%) of the lung cancers 
in women and men, respectively, would be prevented if the entire population had high MD 
adherence according to aMEDr. A more realistic scenario in which subjects with low and 
middle aMEDr values moved one category upwards would prevent 12.1% of the female and 
4.0% of the male lung cancer cases, respectively.
Table 2.3 displays the results of subtype-specific Cox regression analyses. Although there 
seemed to be some variations in the strength of the associations across the subtypes, 
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particularly in men, heterogeneity tests were not statistically significant. In men, aMEDr 
appeared to be non-significantly inversely associated with small cell carcinoma risk, but 
not with adenocarcinoma risk. Middle MD adherence was associated with (borderline) 
significantly reduced risks of squamous and large cell carcinoma in men. In women, higher 
aMEDr values were associated with non-significantly reduced risks of adenocarcinoma, 
squamous cell carcinoma and small cell carcinoma. 
Both sexes were combined in the subgroup analyses (Supplementary Table S2.1) to increase 
the power, since there was no evidence of heterogeneity. Stratification by smoking status 
showed a borderline statistically significant decreasing trend in lung cancer risk with 
increasing aMEDr in never smokers (p=0.07), but not in former (p=0.38) or current smokers 
(p=0.28). However, the interaction test was not statistically significant (pheterogeneity=0.07). The 
inverse association between MD adherence and lung cancer risk seemed to be limited to 
subjects with a normal BMI (pheterogeneity=0.03) and those who consumed 15 grams or more 
alcohol per day (pheterogeneity=0.02). Associations were similar across strata of age at baseline, 
level of non-occupational physical activity, lung cancer family history and duration of follow-
up. In addition, exclusion of cases diagnosed during the first two years of follow-up did not 
result in noteworthy changes of the effect estimates.
Rule-out approach sensitivity analyses showed that an unmeasured confounder, which 
increases lung cancer risk three times, would need to be 3.3 and 2.5 times more common in 
women and men with low MD adherence, respectively, to be able to explain the observed 
HRs (Supplementary Figure S2.1). A population prevalence of 10% for the confounder was 
assumed to obtain these results. 
The contribution of the individual aMEDr components to the observed HRs was evaluated 
and results are listed in Table 2.4. After exclusion of nuts from the score, the inverse 
association completely disappeared in men. Furthermore, a fully adjusted model including 
all aMEDr components as dichotomous variables showed that nut intake was statistically 
significantly associated with a reduced lung cancer risk in men (data not shown). Intakes of 
fruits and vegetables also considerably contributed to the inverse relation in men. Removal 
of one of these components weakened the strength of the relation by almost 50%. The 
inverse association in men gained strength when any of the other components was excluded 
from the score. In women, intakes of fruits and whole grains, and to a lesser extent the 
MUFA:SFA ratio, were most strongly associated with a reduced lung cancer risk.
We also compared performances of the relative aMED indices and the absolute WCRF/AICR 
scores (Table 2.5). HRs were estimated per SD increment to ensure comparability. Both 
scores showed inverse associations (mostly not statistically significant) with lung cancer risk 
in men and women, independently of whether alcohol consumption was taken into account 
in the sum score. HRs (95% CI) for the WCRF/AICR score without alcohol were 0.96 (0.88 ; 
1.04) and 0.92 (0.80 ; 1.07) in men and women, respectively. When the WCRF/AICR score 
including alcohol was considered, we observed a statistically significant inverse association 
with lung cancer risk in men (HR per SD increment, 95% CI: 0.90, 0.83 to 0.98), but not 
women. The similar AIC values indicated comparable fits of models containing WCRF/AICR 
score and aMED variables without alcohol in both sexes. 
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Table 2.5  Sex-specific associations of the absolute WCRF/AICR diet score and aMED (per SD-increment) with 
total lung cancer risk 
Men Women
HRSD (95% CI)
a b AIC HRSD (95% CI)
a b AIC
PYsubcohort / cases
c 28564/2341 32992/441
Excluding alcohol
WCRF/AICR diet scored 0.96 (0.88 ; 1.04) 31960 0.92 (0.80 ; 1.07) 5895
aMEDr 0.96 (0.89 ; 1.05) 31961 0.94 (0.83 ; 1.08) 5896
Including alcohol
WCRF/AICR diet scored e 0.90 (0.83 ; 0.98) 31960 0.94 (0.81 ; 1.08) 5902
aMEDe 0.97 (0.89 ; 1.05) 31980 0.94 (0.83 ; 1.07) 5902
Abbreviations: WCRF/AICR, World Cancer Research Fund/American Institute for Cancer Research; aMED, 
alternate Mediterranean diet score; AIC, Akaike’s Information Criterion; PYsubcohort, person-years in the 
subcohort; aMEDr, alternate Mediterranean diet score without the alcohol component 
 
a HRs were estimated per sex-specific SD-increment in the scores. 
b HRs were adjusted for age at baseline (years), cigarette smoking status (never, former, current), cigarette 
smoking duration (years, centered), cigarette smoking frequency (cigarettes smoked per day, centered), daily 
energy intake (kcal), alcohol consumption (0, >0-<5, ≥5-<15, ≥15-<30, ≥30 g/day), body mass index (<18.5, 
≥18.5-<25, ≥25-<30, ≥30 kg/m2), non-occupational physical activity (≤30, >30-≤60, >60-≤90, >90 min/day), 
highest level of education (primary school or lower vocational, secondary school or medium vocational, higher 
vocational or university), family history of lung cancer (no, yes), and history of physician-diagnosed chronic 
bronchitis (no, yes).  
c A lower number of subjects could be included in these analyses as a result of missing values for salt intake. 
d Score based on WCRF/AICR dietary recommendations to prevent cancer. 
e Not adjusted for alcohol consumption.  
Discussion 
Higher MD adherence was associated with a non-significantly reduced lung cancer risk in 
the NLCS. HRs (95% CI) for comparisons of high to low aMEDr values were 0.73 (0.49 ; 1.09) 
in women and 0.91 (0.72 ; 1.15) in men. Associations seemed to vary across the histological 
subtypes, though heterogeneity tests were not statistically significant. A borderline 
statistically significant inverse trend was observed in never smokers when the sexes were 
combined. In our study population, the performance of aMED was superior to that of mMED 
and better model fits were obtained when alcohol intake was not included in the score. 
The results of the present study were in line with those of previous prospective cohort studies 
[11-13]. Nonetheless, in contrast to these studies, the fully adjusted inverse associations 
observed in the present study lacked statistical significance. In the NIH-AARP study, a HR of 
0.85 (95% CI: 0.79 to 0.91) for lung cancer risk was observed when comparing the highest to 
the lowest aMED quintile [12]. An Australian study estimated a HR of 0.64 (95% CI: 0.45 to 
0.90) for high compared to low MD adherence, based on an adapted version of tMED [13]. 
Similarly, an inverse association was found in an Italian study among (former) heavy smokers 
[11]. HRs varied between 0.58 and 0.66 when comparing aMED values of 2-3, 4-5 and 6-7 to 
a value of 0-1. A substantial reduction in lung cancer risk (90%) was associated with having 
an aMED value of 8-9, but this was only based on one lung cancer case. 
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When we combined men and women, we found a HR of 0.89 (95% CI: 0.73 to 1.10) for 
high versus low MD adherence (aMEDr). Compared to our study, the inverse associations 
observed in previously conducted cohort studies were stronger [11-13]. This difference 
might be attributed to higher proportions of Mediterranean subjects, particularly in the 
Australian study [13, 40], which deliberately oversampled Italian and Greek migrants 
(approximately one-quarter of the cohort), and the Italian study [11], possibly resulting in 
larger contrasts in absolute food intakes between subjects with high and low MD adherence. 
Furthermore, wide intake distributions were noted in the NIH-AARP cohort [41]. Methods 
used to adjust for cigarette smoking in the NIH-AARP study and the Australian study seemed 
to be less comprehensive compared to the method used in the present study, increasing the 
likelihood that residual confounding by cigarette smoking could have impacted the results 
of these studies. The NIH-AARP cohort did not take the duration of smoking into account 
[12], while smoking duration and frequency were combined into the composite measure 
“pack-years” in the Australian study [13]. Nevertheless, non-significant inverse associations 
between MD adherence and lung cancer risk were present in never smokers in both studies, 
which is similar to observations in male and female NLCS participants who never smoked. 
Additionally, in never smoking NLCS participants, non-significant inverse associations were 
observed with all histological subtypes. Therefore, we consider a large impact of residual 
confounding by cigarette smoking on the results of our study unlikely. 
Sex-specific associations of MD adherence with lung cancer risk have seldom been reported 
in prior studies. Only the NIH-AARP study showed sex-specific associations and reported a 
statistically significant inverse relation between MD adherence and lung cancer risk in both 
sexes [12]. In our study, MD adherence seemed to have a slightly stronger inverse relation 
with lung cancer risk in women compared to men. Because this heterogeneity was not 
statistically significant and data from previous research is mostly lacking, additional research 
on sex-specific associations between MD adherence and lung cancer risk is required before 
any conclusions can be drawn regarding this topic. 
The association of MD adherence with the histological lung cancer subtypes has rarely 
been evaluated as well. Higher MD adherence was statistically significantly associated 
with a reduced risk of adenocarcinoma and squamous cell carcinoma, but not small 
cell carcinoma, in the NIH-AARP cohort [12]. Although the heterogeneity tests were not 
statistically significant, results of our study suggested that associations with MD adherence 
might vary across the lung cancer subtypes, particularly in men. However, the currently 
available evidence is not sufficient to conclude anything concerning possible variations in 
associations of the lung cancer subtypes with MD adherence. 
Results of the rule-out approach sensitivity analyses suggested that a strong unmeasured 
lung cancer risk factor with appreciable inequalities in its distribution over the MD adherence 
categories would be required to fully explain the observed associations. Occupational 
exposure to asbestos, for instance, substantially increases lung cancer risk [42]. However, 
it is questionable whether its association with MD adherence is sufficiently strong and we 
did adjust for level of education. Other lung cancer risk factors that remained unmeasured 
were assumed to generally be weak. So, it is unlikely that unmeasured confounders have 
substantially impacted our study results. 
A previous cohort study showed that, of the components included in aMEDr, whole grains 
and fruits had the strongest inverse relation with both male and female lung cancer risk 
[12]. We reported similar results with respect to female lung cancer risk. However, nut 
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intake seemed to be the most important driver of the inverse association observed in male 
NLCS participants. Some individual components were not associated with lung cancer risk 
or had associations in unexpected directions, emphasizing the potential advantages of 
analysis of dietary patterns as opposed to individual dietary components. Dietary pattern 
analysis takes into account that individual dietary components may interact synergistically 
or antagonistically while exerting their effects on health. Additionally, weak and otherwise 
undetectable effects of singular components may become detectable if they are combined 
in dietary patterns. Furthermore, foods are generally consumed in certain patterns, raising 
collinearity and confounding issues when individual components are evaluated. Finally, by 
grouping dietary components together, contrasts in healthiness of the diet within the study 
population will probably increase, thereby increasing the chance of detecting true effects, 
if present [23, 43, 44]. 
Evidence on the relation between alcohol consumption and lung cancer risk is inconclusive 
[14]. Therefore, we excluded alcohol from the MD scores and evaluated the effect of this 
exclusion. Both the present and a previous NLCS analysis showed better performances of 
models using MD scores without alcohol [37]. However, earlier cohort studies regarding 
MD adherence and lung cancer risk all considered moderate alcohol consumption as a 
beneficial component of the MD score used. Similar to a previous NLCS analysis concerning 
breast cancer risk, model performances were better when aMED variants were included 
compared to mMED variants [37]. aMED variants consider whole grains as a beneficial 
component, whereas whole grains and refined grains are combined in mMED variants, 
despite their potentially differential health effects [45]. Similarly, mMED variants include 
total meat consumption, while aMED variants consider the intake of red and processed 
meats, specifically [11, 46-48]. These and other differences in the composition of the food 
components included might explain the better performance of aMED variants in our study 
population.
Reduced levels of reactive oxygen species-induced DNA damage, oxidative stress, and 
inflammation may mediate the potential cancer-protective effect of the MD [44, 49]. 
Consumption of vegetables, legumes, fruits, nuts, whole grains and olive oil is high in 
the plant-based MD [5, 6]. These foods are rich in dietary fiber, vitamins, minerals and 
polyphenols and have been associated with high levels of antioxidants and low levels of 
oxidized LDL-cholesterol [44, 49-54]. Furthermore, polyphenols may exert anti-inflammatory 
effects [55].
It is a potential weakness that the interpretation of the value of aMEDr depends on the 
study population, particularly in a non-Mediterranean population. Therefore, we compared 
the performance of this score to that of an absolute WCRF/AICR score. Generally, the 
performance of the aMEDr and the WCRF/AICR score without alcohol was comparable. The 
WCRF/AICR score without alcohol showed a non-significant and weak inverse association 
with lung cancer risk in both sexes. A SD increment in WCRF/AICR score including alcohol was 
statistically significantly associated with a reduced lung cancer risk in men, but not women. 
Higher adherence to the WCRF/AICR recommendations has previously been associated with 
a reduced lung cancer risk in the EPIC cohort (HR per one-point increment, 95% CI: 0.92, 
0.89 to 0.96) [38]. In contrast, a WCRF/AICR score was not associated with lung cancer risk in 
the elderly according to a meta-analysis within the CHANCES consortium (HR per one-point 
increment, 95% CI: 0.99, 0.84 to 1.17) [56], indicating that additional research is warranted. 
The NLCS cohort has a high follow-up completion rate, which minimized the risk of 
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information and selection bias. Additionally, the large number of lung cancer cases allowed 
extensive adjustment for potential confounding, subtype-specific analyses and analyses 
stratified by smoking status. A potential weakness of the NLCS is the single assessment of 
dietary habits and potential confounders at baseline, which may have resulted in attenuated 
associations. Also, measurement errors in the assessment of dietary intake cannot fully be 
excluded and might have resulted in misclassification. The dependence of aMEDr on the 
study population is a final potential weakness. Because our study was conducted in a non-
Mediterranean population, one may question the extent to which high values of aMEDr 
reflected a truly Mediterranean way of eating.  
Though the inverse associations lacked statistical significance, the present study is in 
agreement with other cohort studies showing that high MD adherence might be associated 
with a reduced lung cancer risk and suggested that this inverse association might also be 
generalizable to non-Mediterranean populations. Additionally, we observed potential 
differences in associations between the sexes and histological subtypes warranting 
future research. Finally, exclusion of alcohol from MD scores should be investigated more 
extensively, primarily with respect to a potential role of the MD in cancer prevention.  
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Supplementary materials
Supplementary Table S2.1  Fully adjusted associationsa (men and women combined) between aMEDr and total 
lung cancer risk in various subgroups
Subgroup 0-3 4-5 6-8 Ptrend Pheterogeneity
b
Baseline age
55-59 years Cases 511 424 116
HR (95% CI) 1.00 0.98 (0.77 ; 1.25) 0.92 (0.64 ; 1.30) 0.667
60-64 years Cases 471 407 126
HR (95% CI) 1.00 0.78 (0.60 ; 1.00) 0.87 (0.61 ; 1.23) 0.137
65-69 years Cases 380 326 100
HR (95% CI) 1.00 0.78 (0.58 ; 1.06) 0.95 (0.63 ; 1.42) 0.356 0.564
Smoking statusc
Never Cases 82 88 28
HR (95% CI) 1.00 0.95 (0.67 ; 1.35) 0.60 (0.35 ; 1.01) 0.072
Former Cases 363 390 133
HR (95% CI) 1.00 1.08 (0.85 ; 1.36) 0.82 (0.61 ; 1.11) 0.382
Current Cases 917 679 181
HR (95% CI) 1.00 0.79 (0.64 ; 0.97) 1.02 (0.73 ; 1.43) 0.280 0.074
Body mass indexd
≥18.5 - <25.0 kg/m2 Cases 763 619 184
HR (95% CI) 1.00 0.74 (0.61 ; 0.91) 0.72 (0.54 ; 0.95) 0.003
≥25.0 kg/m2 Cases 593 521 156
HR (95% CI) 1.00 0.99 (0.80 ; 1.23) 1.10 (0.80 ; 1.51) 0.702 0.030
Physical activitye
≤30 min/day Cases 337 226 56
HR (95% CI) 1.00 0.99 (0.71 ; 1.39) 1.05 (0.61 ; 1.81) 0.919
>30 - ≤60 min/day Cases 413 351 108
HR (95% CI) 1.00 0.83 (0.63 ; 1.09) 1.03 (0.71 ; 1.49) 0.586
>60 - ≤90 min/day Cases 238 231 75
HR (95% CI) 1.00 1.08 (0.74 ; 1.59) 0.70 (0.42 ; 1.15) 0.285
>90 min/day Cases 374 349 103
HR (95% CI) 1.00 0.75 (0.58 ; 0.98) 0.78 (0.54 ; 1.11) 0.048 0.526
Alcohol consumptionf
0 g/day Cases 224 157 49
HR (95% CI) 1.00 0.91 (0.64 ; 1.30) 1.04 (0.64 ; 1.70) 0.892
>0 - <15.0 g/day Cases 498 521 161
HR (95% CI) 1.00 1.13 (0.90 ; 1.42) 1.05 (0.77 ; 1.43) 0.494
≥15.0 g/day Cases 640 479 132
HR (95% CI) 1.00 0.64 (0.50 ; 0.81) 0.75 (0.53 ; 1.04) 0.002 0.016
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Supplementary Table S2.1  (continued)
Subgroup 0-3 4-5 6-8 Ptrend Pheterogeneity
b
Lung cancer family 
historyg
No Cases 1177 1013 300
HR (95% CI) 1.00 0.89 (0.76 ; 1.05) 0.89 (0.72 ; 1.10) 0.155
Yes Cases 185 144 42
HR (95% CI) 1.00 0.67 (0.41 ; 1.09) 0.70 (0.32 ; 1.53) 0.153 0.438
Follow-up
0 - ≤2 years Cases 121 94 22
HR (95% CI) 1.00 0.88 (0.64 ; 1.21) 0.67 (0.41 ; 1.10) 0.113
>2 - ≤10 years Cases 604 508 148
HR (95% CI) 1.00 0.90 (0.75 ; 1.08) 0.92 (0.71 ; 1.19) 0.316
>10 - 20.3 years Cases 637 555 172
HR (95% CI) 1.00 0.83 (0.70 ; 1.00) 0.91 (0.71 ; 1.18) 0.152 0.678
Abbreviation: aMEDr, alternate Mediterranean diet score without the alcohol component 
 
a HRs were adjusted for age at baseline (years), sex (men, women), cigarette smoking status (never, former, 
current), cigarette smoking duration (years, centered), cigarette smoking frequency (cigarettes smoked per 
day, centered), daily energy intake (kcal), alcohol consumption (0, >0-<5, ≥5-<15, ≥15-<30, ≥30 g/day), body 
mass index (<18.5, ≥18.5-<25, ≥25-<30, ≥30 kg/m2), non-occupational physical activity (≤30, >30-≤60, >60-≤90, 
>90 min/day), highest level of education (primary school or lower vocational, secondary school or medium 
vocational, higher vocational or university), family history of lung cancer (no, yes), and history of physician-
diagnosed chronic bronchitis (no, yes).  
b P-values for heterogeneity were obtained by fitting interaction terms between aMEDr and the stratifying 
covariates in fully adjusted models. 
c Not adjusted for cigarette smoking status. 
d Not adjusted for body mass index. 
e Not adjusted for non-occupational physical activity. 
f Not adjusted for alcohol consumption. 
g Not adjusted for family history of lung cancer. 
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Supplementary Figure S2.1  Results of the rule-out approach sensitivity analyses in men (A) and women (B) to 
evaluate the potential impact of unmeasured confounders 
Unmeasured confounders with OREC and RRCD combinations that lie in the upper right areas above the curves are 
sufficiently strong to cause us to find the observed ARR in case of a ‘true’ hazard ratio of 1.00.  
Note: aMEDr was dichotomized into low (0-3) and middle/high (4-8) scores in order to perform the rule-out 
approach sensitivity analyses. ARR was calculated using middle/high aMEDr values as reference. Prevalences of 
exposure (low aMEDr) were 41% in men and 37% in women, respectively, whereas a confounder prevalence of 
10% was assumed. 
 
Abbreviations: ARR, apparent relative risk; OREC, odds ratio exposure-confounder association; RRCD, relative risk 
confounder-disease association; aMEDr, alternate Mediterranean diet score without the alcohol component 
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Abstract
The Mediterranean diet (MD) has been associated with reduced mortality and risk of 
cardiovascular diseases, but there is only limited evidence on cancer. 
We investigated the relationship between adherence to MD and risk of postmenopausal 
breast cancer (and estrogen/progesterone receptor subtypes, ER/PR). In the Netherlands 
Cohort Study, 62573 women aged 55-69 years provided information on dietary and lifestyle 
habits in 1986. Follow-up for cancer incidence until 2007 (20.3 years) consisted of record 
linkages with the Netherlands Cancer Registry and the Dutch Pathology Registry PALGA. 
Adherence to MD was estimated through the alternate Mediterranean Diet Score excluding 
alcohol. Multivariate case-cohort analyses were based on 2321 incident breast cancer cases 
and 1665 subcohort members with complete data on diet and potential confounders. We 
also conducted meta-analyses of our results with those of other published cohort studies.
We found a statistically significant inverse association between MD adherence and risk of 
ER negative (ER-) breast cancer, with a hazard ratio (HR) of 0.60 (95% confidence interval: 
0.39, 0.93) for high versus low MD adherence (p-trend=0.032). MD adherence showed 
only non-significant weak inverse associations with ER positive (ER+) or total breast cancer 
risk. In meta-analyses, summary HRs for high versus low MD adherence were 0.94 for total 
postmenopausal breast cancer, 0.98 for ER+, 0.73 for ER- and 0.77 for ER-PR- breast cancer. 
Our findings support an inverse association between MD adherence and, particularly, 
receptor negative breast cancer. This may have important implications for prevention 
because of the poorer prognosis of these breast cancer subtypes.
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Introduction
Breast cancer is the most commonly diagnosed cancer in Western countries, and prevention 
is of paramount importance to reduce the burden of this disease. Thus far, very few 
modifiable (lifestyle) risk factors, such as overweight and alcohol consumption, have been 
identified. Intake of individual dietary factors has been extensively studied in relation to 
breast cancer risk, but only for alcohol there is convincing evidence for an increased risk [1]. 
Because individuals do not consume isolated foods or nutrients, studying dietary patterns in 
relation to breast cancer seems more fruitful, thereby acknowledging interactions between 
individual components as well as existing collinearity between components. Dietary patterns 
might also yield more actionable information on dietary change needed for prevention.
In contrast with dietary patterns that are a posteriori derived from factor or cluster 
analyses of a dataset, the Mediterranean diet (MD) score is a dietary quality index, 
a priori constructed on the basis of dietary recommendations [2]. The traditional MD is 
characterized by a high intake of plant proteins, whole grains, fish, and monounsaturated 
fat, moderate alcohol intake and low intake of refined grains, red meat, and sweets [3, 4]. 
MD adherence is associated with decreased risk of mortality and cardiovascular diseases; 
however, for cancer risk, results are still rather limited. A recent meta-analysis [5] reported 
a lower incidence of overall breast cancer for women adhering to the highest category of 
MD-scores in case-control studies, but not in cohort studies. It is important to distinguish 
between pre- and postmenopausal breast cancer, as well as hormone receptor subtypes, 
because of differences in etiology. The meta-analysis suggested that evidence for an inverse 
association with MD was more convincing for postmenopausal breast cancer. Furthermore, 
differences were noted between different estrogen/progesterone receptor (ER/PR) subtypes 
of breast cancer in the associations with MD, but this observation was based on very few 
cohort studies. Recent evidence from a randomized controlled trial (RCT) on primary 
prevention of cardiovascular diseases indicated a strong protective effect of MD on the risk 
of postmenopausal breast cancer in Spain [6]. 
We investigated the association between adherence to MD and postmenopausal breast 
cancer risk, overall and stratified by hormone receptor status, in the Netherlands Cohort 
Study (NLCS). Based on earlier findings [7], we hypothesized that MD adherence would 
show a stronger inverse association with ER negative (ER-) breast cancer than ER positive 
(ER+) breast cancer, which may have important implications for prevention because of the 
poorer prognosis of ER- breast cancer. Because alcohol is a risk factor for breast cancer [8], 
we excluded it from the MD-score that normally includes moderate alcohol consumption, 
and tested the effect of this exclusion. We also conducted meta-analyses on MD adherence 
and breast cancer risk by subtype.
Materials and methods
Study design and cancer follow-up
The NLCS started in September 1986 and the female part included 62573 women aged 55-
69 years [9]. At baseline, participants completed a mailed, self-administered questionnaire 
on cancer risk factors. The NLCS study was approved by institutional review boards from 
Maastricht University and the Netherlands Organization for Applied Scientific Research. 
All cohort members consented to participation by completing the questionnaire. For data 
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processing and analysis the case-cohort method was used [10]. Accumulated person-years 
in the cohort were estimated from a subcohort (N=2589 women), randomly sampled from 
the cohort immediately after baseline. These subcohort members were actively followed up 
biennially for vital status information. The follow-up of the subcohort was 100% complete 
at 20.3 years of follow-up.
Follow-up for cancer incidence was established by annual record linkage with the Netherlands 
Cancer Registry and PALGA, the nationwide Dutch Pathology Registry [11]. Completeness 
of follow-up through record linkage with cancer registries and PALGA was estimated to be 
greater than 95% [12]. After 20.3 years of follow-up (September 17, 1986 until January 1, 
2007), a total of 3354 incident breast cancer cases were detected among women. Cases 
and subcohort members were excluded if they reported a history of cancer (except skin 
cancer) at baseline and if their dietary data were incomplete or inconsistent. Supplementary 
Figure S3.1 shows the selection and exclusion steps that resulted in the number of cases and 
female subcohort members that were included in the analysis. There were 1665 subcohort 
members and 2321 breast cancer cases available for analysis.
Exposure assessment 
The 11-page baseline questionnaire measured dietary intake, detailed smoking habits, 
anthropometry, physical activity and other risk factors related to cancer [9]. Habitual 
consumption of food and beverages during the year preceding baseline was assessed using 
a 150-item semi-quantitative food frequency questionnaire, which was validated against a 
nine-day diet record [13]. Nutrient intakes were calculated using the computerized Dutch 
food composition table [14]. Non-occupational physical activity was calculated by adding 
the minutes spent per day on cycling or walking, shopping, walking the dog, gardening, and 
sports or exercise as reported previously [15].
Mediterranean diet score
Conformity with the MD was assessed using the alternate Mediterranean Diet Score (aMED) 
[16, 17], which is an adapted version of the traditional Mediterranean Diet Score created 
by Trichopoulou et al. [18, 19]. The aMED contains nine dietary components that are typical 
of the MD. To control for energy intake, the intake of each component was first adjusted 
to a daily intake of 2000 kcal [16, 17, 19]. For each of the presumed beneficial food items 
(vegetables (without potatoes), legumes, fruits, nuts, whole grains, fish, and the ratio of 
monounsaturated to saturated fatty acid intake (MUFA:SFA)), 1 point was given when the 
intake was at least the sex-specific median intake, and 0 otherwise. For red and processed 
meat, 1 point was given (and 0 otherwise) when the intake was below the sex-specific 
median intake. In the full aMED, 1 additional point is normally given when alcohol intake is 
between 5-25 g/day, and 0 otherwise [17]. However, since alcohol is a risk factor for breast 
cancer [8], we excluded alcohol from the score in the present analysis. The reduced sum 
score (aMEDr) ranged from 0 to 8 points (minimal to maximal conformity). MD adherence 
was also assessed using the modified Mediterranean Diet Score by Trichopoulou et al. [20], 
abbreviated as mMED. Apart from alcohol, this score differs from aMED as follows: fruits 
and nuts are combined in one component; dairy is considered as component; cereals are 
considered as component instead of whole grains; total meat is used instead of red and 
processed meat; and for fatty acids the ratio of unsaturated (MUFA + polyunsaturated fatty 
acids (PUFA)) fatty acids to SFA is used. 
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Statistical analysis 
The reduced scores (aMEDr and mMEDr) were categorized in three categories: 0-3, 4-5, and 
6-8 points. The distribution of the subcohort members by aMEDr-score, mMEDr-score and 
various characteristics was examined by cross-tabulations and summary statistics.
The relationship between MD adherence and breast cancer risk was evaluated using Cox 
proportional hazards models. It was verified that the proportional hazards assumption was 
not violated using scaled Schoenfeld residuals [21] and -ln(-ln) survival plots. Standard errors 
were estimated using the robust Huber–White sandwich estimator to account for additional 
variance introduced by the subcohort sampling [22]. We conducted age- and multivariable-
adjusted survival analyses in which aMEDr and mMEDr were tested on categorical and 
continuous scales. In the multivariable analyses, hazard ratios (HRs) were corrected for 
potential confounding by age at baseline (55-59, 60-64, 65-69 years), cigarette smoking 
(status (never, former, current), frequency (number of cigarettes per day; continuous, 
centered), duration (number of years; continuous, centered)), body height (continuous, 
cm), body mass index (BMI; <18.5, 18.5-<25, 25-<30, ≥30 kg/m2), non-occupational physical 
activity (≤30, >30-60, >60-90, >90 min/day), highest level of education (primary school 
or lower vocational, secondary school or medium vocational, and higher vocational or 
university), family history of breast cancer in mother or sisters (no, yes), history of benign 
breast disease (no, yes), age at menarche (≤12, 13-14, 15-16, ≥17 years), parity (nulliparous, 
1-2, ≥3 children), age at first birth (<25, ≥25 years), age at menopause (<45, 45-49, 50-54, 
≥55 years), oral contraceptive use (never, ever), postmenopausal hormone replacement 
therapy (never, ever), energy intake (continuous, kcal/day), and, depending on the analysis, 
alcohol intake (0, 0.1-<5, 5-<15, 15-<30, ≥30 g/day).
Tests for trends were assessed by fitting ordinal exposure variables as continuous terms.
The Akaike Information Criterion (AIC) [23] was used to compare performance of models 
with aMEDr- and mMEDr-scores. We also analyzed associations with the full aMED- and 
mMED-scores (including alcohol) to compare these with models using aMEDr and mMEDr, 
using the AIC. Besides overall postmenopausal breast cancer, we conducted these analyses 
for subtypes defined by hormone receptor status: ER+, ER-, PR+, PR-, ER+PR+, and ER-PR-. 
Differences in associations with MD-scores between breast cancer subtypes were tested 
using a heterogeneity test [24], in which the standard error for the observed difference 
in rate ratios was estimated using a bootstrapping method developed for the case-cohort 
design [25]. To evaluate potential residual confounding by breast cancer risk factors, and 
effect modification, analyses of MD-scores and breast cancer were also conducted within 
strata of age at baseline, smoking status, alcohol intake, BMI, physical activity, and family 
history of breast cancer. Interactions with these factors were tested using Wald tests and 
cross-product terms. In sensitivity analyses, we repeated analyses after excluding cancers 
(and person-years) occurring in the first two years of follow-up, and we also split the follow-
up period in three periods. 
Population attributable fractions (PAFs) were calculated [26] to estimate the potentially 
avoidable proportion of cancer if all participants would shift towards the highest MD-score 
category. As a more realistic scenario, preventable proportions were also calculated to 
estimate the preventable proportion of cancer if all participants in the lowest two categories 
of MD-scores would shift their pattern one category upward [27, 28]. The Stata-command 
“punafcc” was used to calculate the PAFs and 95% confidence intervals (95% CIs) [29].
56
Chapter 3
To investigate possible dominance of certain components of the MD-scores [30], we ran 
analyses in which all components were entered simultaneously as dichotomous variables 
in Cox regression models. We then alternately subtracted one component at a time from 
the original 9-point sum score (thus reducing it to an 8-point score), and estimated HRs per 
2-point increment in the reduced score (corrected by 8/9 before exponentiating them to 
preserve comparability), as in Trichopoulou et al. [30].
The MD-scores are relative measures, using cohort-specific medians as cut-offs. We 
compared the MD-score findings with a score that uses absolute cut-offs, based on the dietary 
part of the cancer prevention recommendations issued by World Cancer Research Fund/
American Institute for Cancer Research (WCRF/AICR) [1]. We operationalized their dietary 
recommendations by using the same absolute cut-offs per recommendation (sometimes 
subrecommendations) as in the European Prospective Investigation into Cancer and Nutrition 
(EPIC) cohort [31, 32], using scores of 1 if the recommendation was met, 0.5 if half met, and 
0 if not met. This concerned intake of energy-dense foods (≤125, >125-<175, ≥175 kcal/100 
g per day) and sugary drinks (0, ≤250, >250 g/day); vegetables and fruits (≥400, 200-<400, 
<200 g/day), and dietary fiber (≥25, 12.5-<25, <12.5 g/day); red and processed meat (red & 
processed meat <500 g/week and processed meat <3 g/day, red & processed meat <500 g/
week and processed meat 3-<50 g/day, red & processed meat ≥500 g/week or processed 
meat ≥50 g/day); and alcohol (<10, 10-20, >20 g/day). We additionally operationalized the 
WCRF/AICR-recommendation on salt intake by categorizing the calculated [33] total salt 
intake (from food and salt added during cooking or consumption) into <6, 6-<9, 9+ g/day 
with scores 1, 0.5, and 0, respectively (based on Dutch dietary guidelines 2015 [34]). The 
resulting sum score (ranging from 0 to 5) was used in survival analyses; an additional sum 
score without alcohol was also made. The AIC was used to compare the fit of models with 
these sum scores to models with MD-scores.
Meta-analyses
Using PubMed with search terms Mediterranean diet, and breast cancer/neoplasm/tumor, 
or mammary carcinoma/tumors, cohort studies of the association between MD adherence 
(a priori defined) and breast cancer were identified up to August 2016. Six articles on breast 
cancer (ER/PR subtypes) were identified [7, 35-39]. Because Buckland et al. [37] presented 
EPIC-wide results, the results from specific EPIC countries [35, 39] were not included in the 
meta-analysis to avoid overlap. In addition to EPIC-results, the publication by Pot et al. [39] 
also included results of Cade et al. [36]. Data on total postmenopausal breast cancer and 
subtypes of the remaining four cohorts (Nurses’ Health Study (NHS), UK Women’s Cohort 
Study (UKWCS), EPIC, and Women’s Lifestyle and Health (WLH)) were combined with NLCS-
data in the meta-analysis. HRs for the contrast between highest versus lowest category 
of MD adherence from each study were pooled using random-effects models. In these 
analyses, the HR-estimate for each study was weighted by the inverse of the variance of 
the log HR to calculate the summary HR and its 95% CI. Heterogeneity between studies was 
estimated using the Cochran’s Q test and I2 (the proportion of variation in HRs attributable 
to heterogeneity [40]). Publication bias was assessed by the Begg test [41]. Analyses were 
performed using Stata version 12; presented p-values are two-sided, with p<0.05 considered 
as statistically significant.
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Results
The mean (SD) score of aMEDr among subcohort members was 4.0 (1.6), and for mMEDr 
4.0 (1.5). Table 3.1 summarizes several baseline characteristics according to adherence to 
aMEDr and mMEDr. Conformity with the MD was lower in older women, in nulliparous 
women, current smokers, and in those with a positive family history of breast cancer (for 
aMEDr). MD adherence was higher in physically active women, higher educated women, 
and ever oral contraceptive users. Alcohol intake was somewhat higher in those scoring 
higher on aMEDr, but this was reversed for mMEDr. Women with a high score on mMEDr 
more often reported a history of benign breast disease. 
Table 3.2 shows results of the age-adjusted and multivariable-adjusted analyses of the 
associations of MD-scores with total breast cancer risk. While the aMEDr-score was 
significantly inversely associated with breast cancer risk in age-adjusted analyses, in 
multivariable-adjusted continuous analyses, the HR per 2-point increment was 0.92 (95% 
CI: 0.84, 1.01). In multivariable-adjusted categorical analyses, only the medium category 
showed a significantly decreased risk with a HR of 0.82 (95% CI: 0.70, 0.96), compared to 
low adherence scores, and there was no clear decreasing trend across categories (p-trend 
=0.066). The AIC of the model using aMEDr was smaller compared to the mMEDr-model, 
indicating a better fit using aMED-scoring. For comparison, the table also shows associations 
when using the full aMED and mMED including alcohol. The AIC-values indicated a worse 
fit for both aMED and mMED when alcohol was included in the scores (Table 3.2). Based 
on this, ensuing analyses were conducted primarily with aMEDr; at several places we also 
present results for mMEDr for reasons of comparison.
Table 3.3 shows age- and multivariable-adjusted associations between aMEDr and risk of 
ER and PR subtypes of breast cancer. There was a stronger inverse association with aMEDr 
for ER- breast cancer than for ER+ breast cancer, with HRs when comparing high versus low 
adherence of 0.60 (95% CI: 0.39, 0.93), p-trend=0.032 for ER-, and 0.87 (95% CI: 0.69, 1.10), 
p-trend=0.101 for ER+, respectively. The same pattern was seen for PR subtypes, albeit 
somewhat less strongly inverse in PR- than ER- subtypes. Similarly, ER-PR- breast cancer 
was significantly inversely related to MD adherence (p-trend=0.047) with a HR per 2-point 
increment of 0.75 (95% CI: 0.60, 0.94), while the ER+PR+ subtype showed no significant 
association. Heterogeneity tests across subtypes using bootstrapping were not significant. 
The analyses in Table 3.3 were also conducted with mMEDr. When mMEDr was used, the 
HRs per 2-point increment were 0.95 (95% CI: 0.85, 1.07) for ER+, 0.85 (0.71, 1.03) for ER-, 
0.95 (0.83, 1.08) for PR+, 0.90 (0.76, 1.07) for PR-, 0.94 (0.83, 1.08) for ER+PR+, and 0.79 
(0.63, 0.99) for ER-PR- breast cancer, i.e., all somewhat weaker associated than with aMEDr.
Estimation of the PAFs indicated that 2.3% (95% CI: -13.1%, 15.5%) of total breast cancer 
could be avoided if all participants would shift towards the highest aMEDr category. The 
estimated PAF for ER+ breast cancer was 2.3% (95% CI: -16.4%, 18.0%), and 32.4% (95% CI: 
4.1%, 52.3%) for ER- breast cancer. If participants would shift their pattern one category 
upward, the estimated preventable proportions were 4.8% for total breast cancer, 5.2% for 
ER+, and 20.0% for ER- breast cancer.
Supplementary Table S3.1 shows the HR of breast cancer associated with each of the 
components of aMEDr, dichotomized at the median intakes, when they were simultaneously 
entered in the model. Nut intake was significantly inversely associated with ER- breast cancer; 
other components were mostly weakly inversely associated with breast cancer (subtypes), 
but not statistically significantly. Table 3.4 shows the HR of breast cancer associated with a 
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2-point increment in aMEDr, and how this HR changed after alternate removal of each of 
its eight components; the percentage reduction in the size of the HR is also presented. For 
example, when vegetables were excluded from the score, the HR of 0.938 indicated the 
apparent beneficial effect was reduced by 23.8%, compared to HR=0.919 for the full score. 
These analyses are presented for total breast cancer and ER subtypes. Table 3.4 shows that 
whole grain intake contributed most to the inverse association for total and ER+ breast 
cancer, but for ER- breast cancer nut intake seemed most dominant. For total breast cancer, 
the second and third most dominant components were vegetables and fruit, for ER+ these 
were vegetables and fish, and for ER- breast cancer these were fruit and the MUFA:SFA ratio. 
Excluding red and processed meat, and legumes showed opposite effects on HRs for breast 
cancer, i.e., somewhat stronger HRs.
In Figure 3.1, associations between a 2-point increment in aMEDr and breast cancer are 
presented, in subgroups of potential effect modifiers: age at baseline, smoking status, alcohol 
intake, BMI, physical activity, and family history of breast cancer. Inverse associations were 
seen in most subgroups, and there was no significant interaction. Similarly, associations 
were essentially similar when the follow-up period was split in 0-2, 2-10, and 10-20 years 
(Figure 3.1). The corresponding interaction analyses for the ER subtypes of breast cancer are 
also presented in Figure 3.1. Only for ER- breast cancer, statistically significant interactions 
were seen with age at baseline and alcohol intake. While aMEDr showed a stronger inverse 
association with ER- breast cancer in women drinking 15 g/day of alcohol or more, the 
inverse association was also more apparent in younger women.
To enable comparison of HR-estimates using aMED-scores with models using the WCRF/
AICR-score for dietary recommendations, the scores were assessed as continuous variables 
with 1 SD as increment. This was done for the scores including and excluding alcohol. For 
comparability, models for aMED-scores were rerun with the same participants as in the 
WCRF/AICR-score models because the inclusion of salt data introduced some additional 
missing values. The results in Table 3.5 show that the model performance was better 
(as judged by lower AIC) when using the aMED-scores (excluding or including alcohol), 
compared to the dietary WCRF/AICR-scores, for total breast cancer and the ER subtypes. 
The analyses in Table 3.5 were also conducted with mMED. For comparison, when mMED 
(including alcohol) was used, the HR per 1-SD increment was 0.96 (95% CI: 0.90, 1.03). When 
mMEDr was used, the HRs per 1-SD increment were 0.95 (95% CI: 0.88, 1.02) in total breast 
cancer, 0.95 (0.88, 1.04) in ER+, and 0.89 (0.77, 1.02) in ER- breast cancer, i.e., all somewhat 
weaker associated than with aMEDr.
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Table 3.3  Hazard ratios of breast cancer subtypes, according to adherence to Mediterranean diet (aMEDr) in 
multivariable-adjusteda analyses, the Netherlands Cohort Study
aMEDr
 0-3 pts  4-5 pts  6-8 pts P trend AIC Cont, per 2 pts
Total breast cancer
No. of cases 928 987 406
Person-years in subcohort 10438 13016 5478
Age-adjusted HR 1 0.85 0.83 0.023 0.91
(95% CI) (0.74 - 0.98) (0.69 - 1.00) (0.84 - 0.99)
Multivariable-adjusted HR 1 0.82 0.87 0.066 33363 0.92
(95% CI) (0.70 - 0.96) (0.72 - 1.06) (0.84 - 1.01)
ER+ breast cancer
No. of cases 460 466 195
Age-adjusted HR 1 0.82 0.80 0.022 0.89
(95% CI) (0.69 - 0.97) (0.64 - 1.00) (0.81 - 0.99)
Multivariable-adjusted HR 1 0.81 0.87 0.101 16119 0.91
(95% CI) (0.68 - 0.97) (0.69 - 1.10) (0.82 - 1.02)
ER- breast cancer
No. of cases 100 116 32
Age-adjusted HR 1 0.93 0.59 0.024 0.81
(95% CI) (0.69 - 1.24) (0.39 - 0.91) (0.69 - 0.97)
Multivariable-adjusted HR 1 0.92 0.60 0.032 3623 0.81
(95% CI) (0.67 - 1.25) (0.39 - 0.93) (0.67 - 0.96)
PR+ breast cancer
No. of cases 276 305 122
Age-adjusted HR 1 0.89 0.83 0.139 0.93
(95% CI) (0.73 - 1.09) (0.64 - 1.08) (0.82 - 1.04)
Multivariable-adjusted HR 1 0.90 0.90 0.378 10101 0.94
(95% CI) (0.73 - 1.11) (0.69 - 1.19) (0.83 - 1.07)
PR- breast cancer
No. of cases 158 157 60
Age-adjusted HR 1 0.79 0.69 0.017 0.80
(95% CI) (0.61 - 1.01) (0.48 - 0.96) (0.69 - 0.93)
Multivariable-adjusted HR 1 0.76 0.72 0.047 5422 0.81
(95% CI) (0.59 - 1.00) (0.52 - 1.05) (0.69 - 0.96)
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Table 3.3  (continued)
aMEDr
 0-3 pts  4-5 pts  6-8 pts P trend AIC Cont, per 2 pts
ER+PR+ breast cancer
No. of cases 270 295 120
Age-adjusted HR 1 0.88 0.84 0.146 0.93
(95% CI) (0.72 - 1.08) (0.65 - 1.09) (0.83 - 1.04)
Multivariable-adjusted HR 1 0.89 0.91 0.400 9838 0.95
(95% CI) (0.71 - 1.10) (0.69 - 1.21) (0.83 - 1.08)
ER-PR- breast cancer
No. of cases 71 75 24
Age-adjusted HR 1 0.83 0.61 0.042 0.77
(95% CI) (0.59 - 1.18) (0.37 - 0.99) (0.63 - 0.95)
Multivariable-adjusted HR 1 0.79 0.61 0.047 2483 0.75
(95% CI) (0.55 - 1.14) (0.36 - 1.01) (0.60 - 0.94)
a Multivariable analyses were adjusted for: age at baseline (55-59, 60-64, 65-69 years), cigarette smoking (status 
(never, former, current), frequency (number of cigarettes per day; continuous, centered), duration (number of 
years; continuous, centered)), body height (continuous, cm), body mass index (<18.5, 18.5-<25, 25-<30, ≥30 kg/
m2), non-occupational physical activity (≤30, >30-60, >60-90, >90 min/day), highest level of education (primary 
school or lower vocational, secondary school or medium vocational, and higher vocational or university), 
family history of breast cancer in mother or sisters (no, yes), history of benign breast disease (no, yes), age 
at menarche (≤12, 13-14, 15-16, ≥17 years), parity (nulliparous, 1-2, ≥3 children), age at first birth (<25, ≥25 
years), age at menopause (<45, 45-49, 50-54, ≥55 years), oral contraceptive use (never, ever), postmenopausal 
hormone replacement therapy (never, ever), energy intake (continuous, kcal/day), and alcohol intake (0, 0.1-<5, 
5-<15, 15-<30, ≥30 g/day).
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Table 3.5  Hazard ratios of breast cancer associated with 1-SD increment in WCRF-diet score compared to 
aMED, including or excluding alcohol, in multivariable-adjusteda analyses, the Netherlands Cohort Study
Score HR (95% CI) AIC
Scores including alcohol
Breast cancer total (2289 cases)
WCRFdietalcb c 1.01 (0.93 - 1.08) 32853
aMEDb 0.95 (0.89 - 1.02) 32848
Scores excluding alcohol
Breast cancer total (2289 cases)
WCRFdietd 1.02 (0.94 - 1.09) 32844
aMEDr 0.94 (0.87 - 1.01) 32837
Breast cancer ER+ (1108 cases)
WCRFdietd 0.99 (0.90 - 1.08) 15826
aMEDr 0.92 (0.85 - 1.01) 15820
Breast cancer ER- (244 cases)
WCRFdietd 1.00 (0.86 - 1.16) 3532
aMEDr 0.84 (0.73 - 0.97) 3525
a Multivariable analyses were adjusted for: age at baseline (55-59, 60-64, 65-69 years), cigarette smoking 
(status (never, former, current), frequency (number of cigarettes per day; continuous, centered), duration 
(number of years; continuous, centered)), body height (continuous, cm), body mass index (<18.5, 18.5-
<25, 25-<30, ≥30 kg/m2), non-occupational physical activity (≤30, >30-60, >60-90, >90 min/day), highest 
level of education (primary school or lower vocational, secondary school or medium vocational, and 
higher vocational or university), family history of breast cancer in mother or sisters (no, yes), history of 
benign breast disease (no, yes), age at menarche (≤12, 13-14, 15-16, ≥17 years), parity (nulliparous, 1-2, 
≥3 children), age at first birth (<25, ≥25 years), age at menopause (<45, 45-49, 50-54, ≥55 years), oral 
contraceptive use (never, ever), postmenopausal hormone replacement therapy (never, ever), energy 
intake (continuous, kcal/day), and alcohol intake (0, 0.1-<5, 5-<15, 15-<30, ≥30 g/day). 
b Model excluding alcohol as covariate. 
c WCRF/AICR dietary recommendations including alcohol. 
d WCRF/AICR dietary recommendations excluding alcohol.
Mediterranean diet and breast cancer risk
3
65
Fi
gu
re
 3
.1
  H
az
ar
d 
ra
tio
s o
f b
re
as
t c
an
ce
r a
ss
oc
ia
te
d 
w
ith
 a
 2
-p
oi
nt
 in
cr
em
en
t i
n 
aM
ED
r, 
in
 su
bg
ro
up
s  
M
ul
tiv
ar
ia
bl
e 
an
al
ys
es
 w
er
e 
ad
ju
st
ed
 fo
r: 
ag
e 
at
 b
as
el
in
e 
(5
5-
59
, 6
0-
64
, 6
5-
69
 y
ea
rs
), 
ci
ga
re
tte
 sm
ok
in
g 
(s
ta
tu
s (
ne
ve
r, 
fo
rm
er
, c
ur
re
nt
), 
fr
eq
ue
nc
y 
(n
um
be
r o
f c
ig
ar
ett
es
 p
er
 
da
y;
 c
on
tin
uo
us
, c
en
te
re
d)
, d
ur
ati
on
 (n
um
be
r o
f y
ea
rs
; c
on
tin
uo
us
, c
en
te
re
d)
), 
bo
dy
 h
ei
gh
t (
co
nti
nu
ou
s,
 c
m
), 
bo
dy
 m
as
s i
nd
ex
 (<
18
.5
, 1
8.
5-
<2
5,
 2
5-
<3
0,
 ≥
30
 k
g/
m
2 ),
 n
on
-
oc
cu
pa
tio
na
l p
hy
sic
al
 a
cti
vi
ty
 (≤
30
, >
30
-6
0,
 >
60
-9
0,
 >
90
 m
in
/d
ay
), 
hi
gh
es
t l
ev
el
 o
f e
du
ca
tio
n 
(p
rim
ar
y 
sc
ho
ol
 o
r l
ow
er
 v
oc
ati
on
al
, s
ec
on
da
ry
 sc
ho
ol
 o
r m
ed
iu
m
 v
oc
ati
on
al
, 
an
d 
hi
gh
er
 v
oc
ati
on
al
 o
r u
ni
ve
rs
ity
), 
fa
m
ily
 h
ist
or
y 
of
 b
re
as
t c
an
ce
r i
n 
m
ot
he
r o
r s
ist
er
s (
no
, y
es
), 
hi
st
or
y 
of
 b
en
ig
n 
br
ea
st
 d
ise
as
e 
(n
o,
 y
es
), 
ag
e 
at
 m
en
ar
ch
e 
(≤
12
, 1
3-
14
, 1
5-
16
, ≥
17
 y
ea
rs
), 
pa
rit
y 
(n
ul
lip
ar
ou
s,
 1
-2
, ≥
3 
ch
ild
re
n)
, a
ge
 a
t fi
rs
t b
irt
h 
(<
25
, ≥
25
 y
ea
rs
), 
ag
e 
at
 m
en
op
au
se
 (<
45
, 4
5-
49
, 5
0-
54
, ≥
55
 y
ea
rs
), 
or
al
 c
on
tr
ac
ep
tiv
e 
us
e 
(n
ev
er
, e
ve
r)
, 
po
st
m
en
op
au
sa
l h
or
m
on
e 
re
pl
ac
em
en
t t
he
ra
py
 (n
ev
er
, e
ve
r)
, e
ne
rg
y 
in
ta
ke
 (c
on
tin
uo
us
, k
ca
l/d
ay
), 
an
d 
al
co
ho
l i
nt
ak
e 
(0
, 0
.1
-<
5,
 5
-<
15
, 1
5-
<3
0,
 ≥
30
 g
/d
ay
).
66
Chapter 3
Meta-analyses
The forest plots and summary estimates for highest versus lowest MD adherence category 
are presented in Figure 3.2, for total postmenopausal breast cancer and subtypes, when 
at least two studies were available. For total breast cancer, the summary HR (95% CI) was 
0.94 (0.88, 1.01), with no evidence of between-study heterogeneity (p=0.330). While there 
was no evidence for an association with ER+ breast cancer, the common HRs (95% CI) for 
ER- and ER-PR- breast cancer (each based on two cohorts) were 0.73 (0.57, 0.93) and 0.77 
(0.63, 0.94), respectively, with no evidence of between-study heterogeneity. As a further 
sensitivity analysis, Supplementary Figure S3.2 shows results of meta-analyses of studies on 
total postmenopausal breast cancer that included or excluded alcohol from the MD-score, 
respectively. When alcohol was excluded, the summary HR (95% CI) was 0.92 (0.87, 0.98), 
while there was no association when alcohol was included. 
Figure 3.2  Forest plots of postmenopausal breast cancer hazard ratios (HRs) and 95% confidence intervals (95% 
CIs) comparing highest versus lowest category of adherence to MD, from random-effects meta-analyses 
Separate plots are presented for total postmenopausal breast cancer and subtypes. Studies are referred to by first 
author, year of publication, and cohort abbreviation (EPIC: European Prospective Investigation into Cancer and 
Nutrition; NHS: Nurses’ Health Study; NLCS: Netherlands Cohort Study; UKWCS: UK Women’s Cohort Study; WLH: 
Women’s Lifestyle and Health). In addition, it is indicated whether or not alcohol was included in the MD-score. 
Studies are weighted according to the inverse of the variance of the log HR estimate. The HRs are represented by 
the squares (the size is proportional to the weights used in the meta-analysis) and 95% CIs are represented by the 
error bars. Diamonds represent the summary HR estimates and 95% CIs per endpoint.
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Discussion 
In this large prospective study, we found a statistically significant inverse association 
between adherence to MD and risk of ER- postmenopausal breast cancer, with a HR of 0.60 
for high versus low adherence to MD. There were no significant inverse associations with 
ER+ or total breast cancer risk. The model fit was better when alcohol was excluded from the 
aMED-score, and the aMED performed better than the mMED in our cohort. We found no 
association between breast cancer and adherence to WCRF/AICR-dietary recommendations. 
In meta-analyses, summary HRs for high versus low MD adherence were 0.94 for total 
postmenopausal breast cancer, 0.98 for ER+, 0.73 for ER-, and 0.77 for ER-PR- breast cancer. 
When alcohol was excluded from MD-scores, the summary HR (95% CI) was 0.92 (0.87, 0.98) 
for total breast cancer, while there was no association when alcohol was included. 
Several cohort studies have investigated the association between an a priori defined MD-
pattern and overall breast cancer risk, or subtypes. In the NHS-cohort, no association was 
found with total or ER+ postmenopausal breast cancer risk [7], but for ER- breast cancer, the 
HR comparing highest to lowest quintiles of aMED (including alcohol) was 0.79 (p-trend= 
0.03). In EPIC-overall, high versus low rMED-score (variant of mMED) (excluding alcohol) 
was related to reduced postmenopausal breast cancer risk (HR=0.93), especially with ER-/
PR- tumors (HR=0.80), and not with premenopausal breast cancer [37]. Thus, our findings 
are in accordance with these cohorts. In a Swedish cohort study, high versus low mMED-
score (including alcohol) was non-significantly inversely associated with postmenopausal 
breast cancer (HR=0.59), but no association was observed in continuous analyses [38]. Apart 
from overall EPIC-results, there are also some country-specific reports. MD adherence was 
inversely associated with overall postmenopausal breast cancer in EPIC-Greece (HR=0.78 
per 2-point increment) [35]. A UK Cohort consortium which included EPIC-Oxford and EPIC-
Norfolk reported no association between MD adherence and breast cancer [39], but no 
information was available on ER/PR status. In EPIC-France, an inverse association was found 
between an a posteriori defined “healthy/Mediterranean” diet and postmenopausal breast 
cancer, particularly in ER+/PR- tumors, but not in ER- tumors [42]. 
Our meta-analysis of cohort studies did not show a significant inverse association between 
overall postmenopausal breast cancer and high versus low MD adherence, although the 
HR-estimate of 0.94 was marginally significant, with no obvious heterogeneity. However, in 
contrast to ER+, our meta-analysis showed inverse associations with ER- or ER-PR- breast 
cancer subtypes, with significant HRs of 0.73 and 0.77, respectively. Although still based 
on few cohort studies, these subtype findings may be of particular importance because 
identification of preventive factors for ER- breast cancers may help to reduce the burden of 
breast cancer since these tumors respond less well to treatment and have lower five-year 
survival rates than ER+ tumors. As has been suggested before [7, 37], any potential influence 
of dietary factors may be difficult to detect in ER+ tumors given the strong influence of 
hormonal factors. In ER- tumors, other risk factors, including diet, may exert a relatively 
larger influence and be more easily detectable [7]. 
Interestingly, a recent secondary analysis of a RCT on primary prevention of cardiovascular 
diseases (PREDIMED) indicated a strong protective effect of MD versus low-fat diet on 
the risk of postmenopausal breast cancer in Spain, with a HR of 0.43 (95% CI: 0.21, 0.88). 
The effect was stronger in those randomized to the MD supplemented with extra-virgin 
olive oil than with nuts, but in both MD-intervention groups the effect was significant [6]. 
Nevertheless, because the trial had only 35 incident breast cancer cases as outcome, this 
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needs to be confirmed in larger trials, preferably also with analyses per receptor subtype.
Consistent with evidence on alcohol and breast cancer [8], our model fit was also worse 
when moderate alcohol was included in the scores. This was also confirmed in our meta-
analysis of MD-scores excluding and including alcohol. In our study, the performance of 
models with aMED-scores was better than with mMED-scores. This may possibly be due to 
the fact that the cereal group in mMED aggregates refined and whole grain cereals, while 
aMED uses whole grain cereals; both cereal types may have distinct effects on breast cancer 
risk [37, 43]. In our analysis with aMED-components, whole grain intake contributed most 
to the inverse association for total and ER+ breast cancer, whereas nut intake seemed most 
dominant for associations with ER- breast cancer. Such an analysis of dominant components 
has only been done before with total mortality using mMED [30], which makes it difficult 
to compare with our results. We did not specifically use a MD-score that included olive oil 
as component. Olive oil was infrequently used in the NLCS population in 1986, as in many 
non-Mediterranean countries. Therefore, the mMED was developed [20] in which fatty acid 
intake is assessed by calculating the ratio of unsaturated (MUFA + PUFA) fatty acids to SFA, to 
allow for the low consumption of olive oil-derived MUFA in non-Mediterranean countries.
The potential beneficial effects of the MD on cancer risk have been attributed to high 
amounts of fiber, antioxidants including polyphenols, and vitamins, and may be mediated 
through several biological mechanisms such as chronic inflammation and oxidative stress 
[44], and associated DNA oxidative damage [45], and through body weight regulation 
[46]. The evidence of the cancer protective effect of the MD-pattern is generally stronger 
than the evidence for individual foods, food groups, or nutrients and cancer risk [1]. Some 
possible explanations of this could be that interactions and synergisms exist between the 
components; individual components could also have health effects that are undetectable 
alone but when integrated with other foods or nutrients in a dietary index, the health 
benefits become more pronounced [19]. In addition, dietary indexes can overcome the 
issues of collinearity or confounding between components in the score, and dietary pattern 
indexes evaluate only the extremes of cumulative exposure, limiting the background noise 
of individual components [47]. 
According to a recent review [48], six cohort studies [31, 49-53] investigated the association 
between adherence to WCRF/AICR-cancer prevention guidelines and breast cancer 
incidence. These guidelines contain a dietary part (including alcohol) and a nondietary part 
(body fatness, physical activity, breastfeeding). Most, but not all [52], studies found a lower 
breast cancer risk for high versus low adherence to these guidelines. We compared the 
performance of the dietary part of these guidelines with MD adherence (+/- alcohol), and 
found that models with the MD-score performed better in our population. We found no 
association between breast cancer and adherence to WCRF/AICR-dietary recommendations. 
This might seem in contrast with the inverse associations in the earlier cohort studies, but 
these primarily investigated dietary and nondietary recommendations combined (i.e., 
including overweight and physical activity (and lactation)). It might be that these nondietary 
factors were dominating the inverse associations reported earlier. For example, Nomura 
et al. [51] found no effect of dietary recommendations beyond BMI and alcohol, but such 
dominance was not reported by Catsburg et al. [53]. When comparing our results with those 
of Romaguera et al. [31], whose operationalization of the dietary guidelines we followed 
(except salt), they reported a HR of 0.95 per 1-point increment in their 7-component score. 
However, their score also included nondietary recommendations; further research on this 
is needed. A recent pooled analysis of seven cohort studies also showed no association 
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between WCRF/AICR-dietary recommendations and breast cancer risk [54].
The prospective design and high completeness of follow-up of the NLCS make information 
bias and selection bias unlikely. A potential weakness is the moderate proportion of 
breast cancer cases for whom ER/PR status was known. Breast cancer cases with known 
and unknown receptor status did not differ importantly according to baseline and tumor 
characteristics, making selection bias of the cases unlikely (data not shown). Although many 
possible confounders were taken into account, the possibility of confounding by unmeasured 
factors remains. The validation study of the food frequency questionnaire has shown that it 
performs relatively well [13], but measurement error may still have attenuated associations. 
The lack of possibilities to update dietary intake or other lifestyle data during follow-up may 
have resulted in some attenuated associations too.
In conclusion, our cohort study showed, in accordance with major cohort studies as the NHS 
and EPIC, that MD adherence showed moderately strong inverse associations with risk of ER- 
(40% reduction), and ER-PR- (39% reduction) breast cancers, and weak inverse associations 
with ER+ and total postmenopausal breast cancer. Assuming causality, we estimated that 
32.4% of ER- breast cancer, and 2.3% of total and ER+ breast cancer could be avoided if the 
population would shift intake towards the highest MD category. 
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Supplementary materials
Netherlands Cohort Study on diet and cancer (N=62573 female participants)
↓ ↓
Random subcohort 20.3 yr Cancer incidence follow-up: number of cases
↓ ↓
2589 Breast cancer
Exclusion of prevalent cancer cases at baseline
↓ ↓
2438 3354
Exclusion of non-epithelial and borderline invasive cancer
↓ ↓ ↓ ↓ ↓
Breast cancer ER+ ER- PR+ PR-
3339 1618 364 1008 556
Exclusion of participants with incomplete or inconsistent dietary data
↓ ↓ ↓ ↓ ↓ ↓
2248 3081 1439 324 900 499
Exclusion of participants with inconsistent vegetable data and missing alcohol data
↓ ↓ ↓ ↓ ↓ ↓
2027 2818 1381 303 864 468
Exclusion of participants with missing values on covariates
↓ ↓ ↓ ↓ ↓ ↓
1665 2321 1121 248 703 375
Supplementary Figure S3.1  Flow diagram of the number of subcohort members and breast cancer cases on 
which analyses are based, the Netherlands Cohort Study
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Supplementary Figure S3.2  Forest plots of postmenopausal breast cancer hazard ratios (HRs) and 95% 
confidence intervals (95% CIs) comparing highest versus lowest category of adherence to MD, from random-
effects meta-analyses  
Separate plots are presented for studies that included alcohol in the MD-score, and those that excluded alcohol. 
Studies are referred to by first author, year of publication, and cohort abbreviation (EPIC: European Prospective 
Investigation into Cancer and Nutrition; NHS: Nurses’ Health Study; NLCS: Netherlands Cohort Study; UKWCS: 
UK Women’s Cohort Study; WLH: Women’s Lifestyle and Health). Studies are weighted according to the inverse 
of the variance of the log HR estimate. The HRs are represented by the squares (the size is proportional to the 
weights used in the meta-analysis) and 95% CIs are represented by the error bars. Diamonds represent the 
summary HR estimates and 95% CIs per endpoint.
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Abstract 
Background
Mediterranean diet (MD) adherence has been associated with reduced risks of esophageal 
and gastric cancer (subtypes) in a limited number of studies. We prospectively investigated 
associations between MD adherence and risks of esophageal squamous cell carcinoma 
(ESCC), esophageal adenocarcinoma (EAC), gastric cardia adenocarcinoma (GCA) and gastric 
non-cardia adenocarcinoma (GNCA) in a Dutch cohort.   
Methods
Analyses were conducted using data from the 120852 participants of the Netherlands 
Cohort Study (NLCS), who were aged between 55 and 69 years at enrollment. Various MD 
scores, with and without alcohol, were calculated to estimate MD adherence. Using 20.3 
years of follow-up, 133 ESCC, 200 EAC, 191 GCA and 586 GNCA cases could be included in 
multivariable Cox regression analyses. 
Results
Of the investigated scores, the alternate Mediterranean diet score without alcohol (aMEDr) 
performed best. aMEDr was inversely associated with risks of GCA and GNCA in men and 
women. However, statistical significance was only reached in men [ptrend: 0.019 (GCA), 0.016 
(GNCA)]. Furthermore, higher aMEDr values were significantly associated with a reduced 
ESCC risk in men [HRper two-point increment (95% CI)=0.57 (0.41 – 0.80), ptrend=0.013], but not in 
women (pheterogeneity=0.008). There was no evidence of an association between aMEDr and 
EAC risk. Educational level was a significant effect modifier for the association between 
aMEDr and GNCA risk (pheterogeneity=0.0073).
Conclusions
Higher MD adherence was associated with reduced risks of ESCC, GCA and GNCA in the 
NLCS. However, the decreased ESCC risk might be limited to men. 
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Introduction 
Cancers of the esophagus (sixth place) and stomach (third place) were amongst the most 
common causes of cancer-related death in the world in 2012 [1]. Two histologic types of 
esophageal cancer can be distinguished, namely esophageal squamous cell carcinoma 
(ESCC) and esophageal adenocarcinoma (EAC) [2]. Based on anatomic location, gastric 
cancers are subdivided into gastric cardia adenocarcinomas (GCA) and gastric non-cardia 
adenocarcinomas (GNCA) [3]. Different etiologies have been suggested for these subtypes 
[2, 3]. In the past decades, incidence rates of EAC and GCA have been rising in many European 
countries and the United States (US) [4, 5].
The traditional Mediterranean diet (MD) is characterized by a high consumption of 
vegetables, fruits, whole grains and other plant foods, with olive oil as the principal source 
of fat. Foods from animal origin are consumed in low amounts in the MD, whereas alcohol 
intake is moderate [6-8]. The relation between a priori defined MD adherence and the 
incidence of esophageal and/or gastric cancer (subtypes) has been the topic of a limited 
number of studies [9-13]. In these studies, higher MD adherence has been associated with 
reduced risks of ESCC, GCA, GNCA and total gastric cancer (GC), but results were not always 
significant and sometimes inconsistent, primarily with respect to the gastric cancer subtypes 
[9-13]. 
Information bias due to reversed causation is a major concern when investigating relations 
between dietary factors and gastrointestinal cancer risk, because preclinical disease 
symptoms may cause patients with gastrointestinal tumors to alter their dietary habits 
already before clinical diagnosis. Another concern is recall bias, which could particularly 
be a problem in case-control studies. For these reasons, effects of dietary factors on 
gastrointestinal cancers should be investigated prospectively, if possible. So far, associations 
between MD adherence and risks of esophageal and/or gastric cancer subtypes have been 
prospectively investigated in only two cohort studies [10, 11]. Therefore, more prospective 
evidence on this topic is desired.   
This study prospectively investigated the association of MD adherence with the risk of 
esophageal and gastric cancer subtypes (ESCC, EAC, GCA and GNCA) in the Netherlands 
Cohort Study (NLCS). We assessed MD adherence using various a priori defined MD scores, 
with and without alcohol, and examined associations for men and women separately. 
Methods 
Study population and cancer follow-up
The NLCS is a Dutch population-based cohort study, which has been described in detail 
previously [14-17]. In summary, the NLCS comprises 58279 men and 62573 women, aged 55 
to 69 years, from 204 Dutch municipalities, who completed a self-administered questionnaire 
on diet and other cancer risk factors at baseline in September 1986. A case-cohort design 
was used to allow for efficient processing and analysis of the data. Therefore, a subcohort 
(N=5000) was randomly sampled immediately after baseline to estimate the number of 
person-years at risk. Cases were obtained from the total cohort. Vital status information for 
subcohort members was acquired biennially using municipal population registries [14, 17, 
18]. Approval for the NLCS was obtained from the institutional review boards of Maastricht 
University and the Netherlands Organization for Applied Scientific Research. All cohort 
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members agreed to participate by filling out the questionnaire. 
Follow-up for cancer incidence was carried out annually by record linkage with the 
Netherlands Cancer Registry and the Dutch Pathology Registry (PALGA) [15]. The NLCS cohort 
was followed up for 20.3 years until December 31st 2006. To be eligible for inclusion in the 
present study, esophageal and gastric cancer cases had to be incident and microscopically 
confirmed with known tumor histology and topography. Based on the International 
Classification of Diseases for Oncology, Third Edition, esophageal and gastric cancers were 
classified into ESCC (C15, histology codes: 8050-8076), EAC (C15, histology codes: 8140, 
8141, 8190-8231, 8260-8263, 8310, 8430, 8480-8490, 8560 and 8570-8572), GCA (C16.0) 
and GNCA (C16.1-C16.9). Subjects were excluded if they had prevalent cancer at baseline 
(except any type of skin cancer) and/or incomplete or inconsistent data on diet, alcohol 
or MD adherence. In total, 143 ESCC, 224 EAC, 218 GCA and 642 GNCA cases and 4084 
subcohort members could be included in the analyses (Figure 4.1). 
Exposure assessment 
A self-administered, 150-item, semi-quantitative food frequency questionnaire (FFQ) was 
utilized to assess the participant’s habitual diet during the year preceding baseline. The 
validity and reproducibility of this FFQ have been described previously [16, 19]. Mean daily 
nutrient intakes were calculated using the Dutch food composition table of the year 1986 
[20]. 
Mediterranean diet adherence 
MD adherence was measured using two variants of the traditional Mediterranean diet 
score (tMED) created by Trichopoulou et al., namely the alternate Mediterranean diet score 
(aMED) and the modified Mediterranean diet score (mMED) [21-25]. Differences in daily 
energy intakes were taken into account in the calculation of the MD scores by standardizing 
daily food intakes to 2000 (women) and 2500 (men) kilocalories [21, 25]. aMED assesses 
relative MD adherence based on the mean daily intakes of nine dietary components [24, 
25]. Each component is scored by 0 or 1 points with the maximum score of 9 representing 
the highest level of MD adherence. Subjects receive 1 point for intakes at or above the sex-
specific median of vegetables (excluding potatoes), legumes, fruits, nuts, whole grains, fish 
and the ratio of monounsaturated to saturated fatty acids (MUFA:SFA ratio). The intake of 
red and processed meats is scored inversely. Additionally, 1 point is assigned to a moderate 
alcohol intake [5-25 grams per day (g/day) for both sexes] [24, 25]. mMED is calculated in 
a similar way as aMED, but includes slightly different dietary components [23]. In mMED, 
intakes of fruits and nuts are grouped together and total cereal and meat intake is scored. 
Additionally, 1 point is obtained for a dairy intake below the sex-specific median. To improve 
the usage of mMED in non-Mediterranean populations, the fatty acid quality is measured 
by the ratio of unsaturated fatty acids (MUFA + polyunsaturated fatty acids) to SFA. Finally, 
a moderate alcohol intake is defined differently for men (10-50 g/day) and women (5-25 g/
day) [23]. (Heavy) alcohol consumption has been associated with an increased risk of ESCC 
and probably GC [26]. Therefore, MD adherence was also assessed using aMED and mMED 
variants without alcohol (aMEDr and mMEDr, respectively), which had maximum scores of 
8 points. 
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Statistical analyses
All analyses were performed separately for men and women, unless otherwise specified. 
Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for associations of MD 
adherence with incidence of esophageal and gastric cancer subtypes were estimated using 
Cox proportional hazards models with follow-up duration as time variable. Person-years at 
risk for subcohort members were calculated from baseline until diagnosis of esophageal 
or gastric cancer, death, emigration, loss to follow-up or end of follow-up, whichever came 
first. Standard errors were estimated using the Huber-White sandwich estimator to account 
for the increased variance because of subcohort sampling [27]. To verify that all variables 
met the proportional hazards assumption, scaled Schoenfeld residuals tests and –ln(-ln) 
survival plots were used [28]. A time-varying covariate was included in the model when a 
potential confounder violated the proportional hazards assumption and inclusion of a time-
varying covariate altered the HR of the MD score. 
MD scores were included as categorical [low: 0-3, middle: 4-5, high: 6-8(9)] and continuous 
(per two-point increment) terms in age-adjusted and fully adjusted analyses [23, 25]. Tests for 
trends were performed by assigning sex-specific median values among subcohort members 
to the MD score categories and fitting these as continuous terms in the Cox regression 
models. To correct for potential confounding, the following set of literature-selected 
variables was included in fully adjusted Cox models: age at baseline, sex (except for sex-
specific models), cigarette smoking status, cigarette smoking frequency, cigarette smoking 
duration, body mass index (BMI), total daily energy intake, alcohol consumption (except for 
models containing original MD scores including alcohol), highest level of education, non-
occupational physical activity and family history of esophageal cancer (for ESCC and EAC) or 
gastric cancer (for GCA and GNCA). 
Akaike’s Information Criterion (AIC) was used to compare performances of models 
containing aMEDr and mMEDr [29]. Furthermore, it was evaluated if inclusion of alcohol 
in the MD scores affected the model fits. Considering that (heavy) alcohol consumption 
has been associated with an increased risk of ESCC and probably GC, MD scores without 
alcohol are prioritized in the Results section of this article and subsequent analyses were 
only performed using aMEDr [26]. Moreover, we prefer the use of aMEDr to assess MD 
adherence, because aMEDr-containing models had similar or better performances than 
mMEDr-containing models in the NLCS, both in the present and earlier analyses [30, 31].    
The relative importance of the individual aMEDr components was investigated in two ways. 
First, all aMEDr components were entered simultaneously as dichotomous variables into 
fully adjusted Cox models. Second, HRs per two-point increment were estimated upon 
alternate removal of each aMEDr component from the sum score, one at a time, using the 
method described by Trichopoulou et al. [32].  In addition, analyses stratified by cigarette 
smoking status, alcohol consumption, BMI and educational level were performed. The 
statistical significance of possible differences across strata was tested by including interaction 
terms between aMEDr and the potential effect modifiers. Finally, sensitivity analyses were 
performed in which the first two years of follow-up were excluded. Men and women were 
combined in the stratified and sensitivity analyses to increase the power. All statistical 
analyses were conducted using Stata version 15 (StataCorp LLC, College Station, TX, USA). 
Reported p-values are two-sided and p-values below 0.05 were considered statistically 
significant.
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Results 
Sex-specific baseline characteristics of cases and subcohort members are presented in Table 
4.1. Male ESCC, GCA, and GNCA cases had lower MD adherence than subcohort members. 
No clear differences in MD adherence were observed between female cases and subcohort 
members. Concerning potential confounding factors, cases were older (except for male ESCC 
and EAC cases) and less often never smokers (except for female EAC cases) than subcohort 
members. In addition, alcohol consumption was higher in ESCC and GCA (men only) cases, 
but lower in EAC cases (women only). Finally, the mean BMI was lower in ESCC cases, but 
higher in EAC and GCA cases.  
Tables 4.2 (men) and 4.3 (women) show fully adjusted associations between MD adherence, 
assessed using various MD scores, and the risk of esophageal and gastric cancer subtypes. 
Not all eligible study participants could be included in the Cox models because of missing 
values in covariates. Results of the age-adjusted analyses are presented in Supplementary 
Table S4.1. 
High MD adherence according to aMEDr was associated with significantly reduced risks of 
ESCC, GCA and GNCA in men [HRhigh vs. low (95% CI): ESCC=0.35 (0.14 – 0.89), GCA=0.48 (0.26 – 
0.89), GNCA=0.65 (0.45 – 0.94)] with significant tests for trends. In women, associations of 
aMEDr with GCA and GNCA risk were also inverse, but did not reach statistical significance 
[HRper two-point increment (95% CI): GCA=0.82 (0.51 – 1.33), GNCA=0.83 (0.67 – 1.01)]. In contrast to 
men, aMEDr was not inversely associated with ESCC risk in women. EAC risk was not associated 
with aMEDr in both sexes. Heterogeneity tests showed that the association of aMEDr with 
ESCC risk differed significantly between the sexes (pheterogeneity=0.008). Associations of similar 
directions were observed when MD adherence was assessed using mMEDr in men, whereas 
we did not observe associations with any of the subtypes in women using mMEDr. 
Overall, vegetable and fruit intakes were strong contributors to the inverse associations 
observed in male NLCS participants. High nut intake was associated with a significantly 
reduced GNCA risk (p=0.008) in men, but did not contribute to the inverse association with 
ESCC risk. Furthermore, a low intake of red and processed meats contributed considerably 
to the inverse association with ESCC risk in men. Concerning the non-significant inverse 
associations with GCA and GNCA risk observed in women, intakes of nuts, whole grains, fish 
and the MUFA:SFA ratio particularly contributed. In women, a high fish intake was associated 
with a significantly reduced GCA risk (p=0.046) (data not shown). 
Based on AIC values, models containing aMEDr performed similarly or better than mMEDr-
containing models for all esophageal and gastric cancer subtypes considered. Inclusion of 
alcohol in aMED resulted in a clearly worse model fit when considering ESCC risk. Similar 
model performances were observed when aMED variants with and without alcohol were 
compared for EAC, GCA and GNCA risk.  
In the stratified analyses (Table 4.4), men and women were combined to increase the 
statistical power. Associations of aMEDr with all esophageal and gastric cancer subtypes 
were similar across strata of cigarette smoking status, alcohol consumption and BMI. A 
significant interaction between aMEDr and level of education was observed for GNCA risk 
(pheterogeneity=0.0073) with a significant inverse association only being present in the lowest 
category. Inverse associations were also most apparent among those in the lowest education 
category when considering ESCC and GCA, but interaction tests were not significant for these 
subtypes. Finally, exclusion of the first two years of follow-up did not relevantly change the 
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results (data not shown).
Discussion 
In the NLCS, higher aMEDr values were associated with significantly reduced risks of ESCC, 
GCA and GNCA in men. In women, we observed non-significant inverse associations between 
aMEDr and risks of GCA and GNCA, but not ESCC. MD adherence was not associated with 
EAC risk. Associations of aMEDr with ESCC risk significantly differed between the sexes. 
Compared to mMEDr-containing models, aMEDr-containing models had similar or better 
performances. Model performances were generally comparable for aMED variants with and 
without alcohol, except for ESCC, were models containing aMED (including alcohol) clearly 
fitted worse.   
Results of previously conducted prospective cohort studies [10, 11] investigating the 
association of a priori defined MD adherence with the risk of esophageal and/or gastric 
cancer subtypes were partially in accordance with our observations in the NLCS. In the 
US National Institutes of Health-American Association of Retired Persons Diet and Health 
study, high MD adherence (aMED) was associated with a significantly reduced risk of ESCC, 
but not EAC, GCA and GNCA [11]. Although not statistically significant, the association with 
GNCA was also inverse. In the European Prospective Investigation into Cancer and Nutrition, 
inverse associations with MD adherence (relative Mediterranean diet score including 
alcohol, rMED) were suggested for total GC, GCA and GNCA, but only reached statistical 
significance for total GC and GCA [10]. In accordance with the cohort evidence, an Italian 
case-control study also observed a significant inverse association between a priori defined 
MD adherence and ESCC risk [9]. Case-control studies focusing on gastric cancer risk found 
higher MD adherence (a priori defined) to be associated with significantly reduced risks of 
GCA, GNCA and total GC [12, 13]. Finally, adherence to an a posteriori defined MD pattern 
was inversely associated with total GC risk in a Spanish case-control study [33]. Subtype-
specific analyses showed that the inverse association was only statistically significant for 
GNCA. Combining male and female participants in the present study, HRs (95% CI) per two-
point increment in aMEDr were 0.77 (0.61 – 0.98) for ESCC, 1.14 (0.94 – 1.37) for EAC, 0.86 
(0.71 – 1.04) for GCA and 0.83 (0.73 – 0.93) for GNCA. 
For ESCC, associations with aMEDr significantly differed between male and female NLCS 
participants. Prior studies by Bosetti et al. [9] and Li et al. [11] did not observe a significant 
interaction between sex and MD adherence for ESCC risk. However, the inverse association 
in the latter study also seemed to be restricted to men [11]. Residual confounding by 
smoking behavior could potentially have caused the inverse association between aMEDr 
and ESCC risk that we observed in men. Tobacco smoking is strongly associated with an 
increased risk of ESCC [2, 34]. In our study, subjects in the highest aMEDr category were less 
likely to be current smokers. Since, male participants were more likely to smoke than female 
participants, the effect of residual confounding by smoking behavior would be larger in men. 
This could potentially explain why we only observed an inverse association between aMEDr 
and ESCC risk in men. However, additional subgroup analyses for smoking status restricted 
to men showed that the inverse association between aMEDr and ESCC risk was strongest 
in men who had never smoked (data not shown), making it less likely that the observed 
differences between men and women in the NLCS were solely due to residual confounding 
by smoking behavior. Therefore, potential male-female differences in the association of MD 
adherence with ESCC risk deserve attention in future studies. For EAC, GCA, GNCA and total 
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GC there was no evidence of heterogeneity between the sexes in neither the present study 
nor the literature [10-13]. 
In the present study, inverse associations between aMEDr and ESCC, GCA and GNCA risk were 
most pronounced in subjects in the lowest education category with a significant interaction 
being observed for GNCA. Similarly, Li et al. [11] reported that aMED was only significantly 
inversely associated with EAC risk in the lowest education category (pinteraction=0.02). 
However, there was no evidence of effect modification by educational level in the study by 
Praud et al. [12]. Although the interaction between aMEDr and educational level that we 
observed might be a chance finding due to the large number of tests performed, it should 
be investigated in future studies. 
In their Third Expert Report, the World Cancer Research Fund/American Institute for Cancer 
Research suggested that high intakes of vegetables and fruits, and low intakes of processed 
meat and grilled (broiled) or barbecued (charbroiled) meat and fish might be associated with 
reduced risks of ESCC, EAC and/or GC [26]. This is in correspondence with our observations 
that high intakes of vegetables, fruits and nuts, and a low intake of red and processed meats 
(ESCC only) particularly contributed to the inverse associations with ESCC, GCA and GNCA 
risk in men in the NLCS. In women, nuts, whole grains, fish and the MUFA:SFA ratio were 
important aMEDr components contributing to the non-significant inverse associations 
observed for GCA and GNCA risk. Inverse associations (not all significant) between 
esophageal and/or gastric cancer subtypes and intakes of nuts (ESCC and GNCA), vegetables 
(ESCC and EAC) and fruits (ESCC) were also documented in previous NLCS analyses [35, 36]. 
Additionally, high intakes of red (non-significant) and processed meats were associated with 
an increased ESCC risk in men [37]. Although the abovementioned aMEDr components were 
important contributors to the inverse associations that we observed in the present analysis, 
none of the individual components seemed to be the sole driver. This supports our pattern-
based approach, which accounts for synergistic and antagonistic interactions between 
dietary components and solves collinearity and confounding issues associated with the 
evaluation of individual components. Moreover, weak effects of single dietary components 
may only emerge when combined in dietary patterns [22, 38, 39].  
Different etiologies have been suggested for the subtypes of esophageal and gastric cancer 
based on differences in risk factors and incidence trends [2, 3, 34, 40]. This stresses the 
importance of considering ESCC, EAC, GCA and GNCA as separate outcomes as we did in 
this study. ESCC and EAC were clearly differently associated with MD adherence in our 
analysis. While MD adherence was significantly inversely associated with ESCC risk in men, 
no association was observed with EAC risk. In contrast to the esophageal cancer subtypes, 
GCA and GNCA seemed to have roughly comparable associations with MD adherence. 
MD adherence might reduce cancer risk by decreasing oxidative stress, reactive oxygen 
species-induced DNA damage and inflammation [39, 41]. The MD is rich in antioxidants (e.g., 
vitamins and polyphenols) from plant foods and olive oil, and has been associated with higher 
total antioxidant capacity and lower levels of oxidized low-density lipoprotein cholesterol 
[26, 39, 41, 42]. Moreover, polyphenols (e.g., flavonoids) may reduce inflammation and MD 
adherence has been inversely associated with inflammatory biomarker concentrations [24, 
43]. Finally, dietary fiber possibly acts as a nitrite scavenger, counteracting the carcinogenic 
effects of N-nitroso compounds [39, 44]. Low meat intake may also contribute to the cancer-
protective effects of the MD. Nitrates and nitrites in processed meat can form N-nitroso 
compounds in the stomach. Besides, haem iron in red meat also stimulates the endogenous 
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formation of N-nitroso compounds and causes oxidative stress and DNA damage. Finally, 
carcinogenic heterocyclic amines and polycyclic aromatic hydrocarbons are formed during 
high-temperature cooking of meat [26]. 
The use of data from a large prospective cohort with a long duration of follow-up 
enabled us to perform subtype- and sex-specific analyses. However, case numbers for 
the individual subtypes were low, necessitating us to combine men and women in the 
stratified and sensitivity analyses to increase the statistical power. Another strength of 
our study was the availability of high quality dietary data. The NLCS-FFQ was validated 
using nine-day dietary records completed over three different seasons, showing an 
adequate performance [16]. Furthermore, a reproducibility study demonstrated that the 
single baseline measurement of this FFQ performed relatively well in ranking subjects 
according to their nutrient intake for over at least five years [19]. Nonetheless, changes in 
dietary habits and potential confounders during follow-up might still have attenuated the 
observed associations. Instead of using self-reporting based methods (e.g., FFQs, dietary 
records), dietary intake could be assessed by measurement of biomarker concentrations 
in blood. However, there are currently no biomarkers available that assess adherence 
to all aspects of the MD. Furthermore, biomarker levels in blood are also influenced 
by, e.g., absorption and excretion rates and reflect only short term dietary intake. 
Despite the fact that we adjusted for a large number of potential confounders, residual 
confounding by unmeasured factors may still exist. For example, we did not obtain data 
regarding Helicobacter pylori infection, which might have confounded our results in 
particular for GNCA. Furthermore, we cannot exclude the possibility of errors in the 
outcome measurements. However, it was reported that the histology and topography 
information from the Netherlands Cancer Registry, which we used to define the tumor 
subtypes, is of high accuracy [45]. Reversed causation due to the presence of preclinical 
disease symptoms in cases is another concern, particularly when investigating relations 
between dietary factors and gastrointestinal cancers, as we discussed previously [46]. 
Prospective cohort studies are less sensitive to this type of bias than case-control 
designs and we obtained similar results when excluding the first two years of follow-up. 
Data on the reliability of a priori scores used in the assessment of MD adherence are limited 
[47]. The reliability of ten indexes measuring MD adherence, including mMED and rMED, 
has been evaluated by assessing correlations with a hidden common factor (obtained by 
factor analysis) understood as “MD adherence” [48]. Both mMED and rMED were amongst 
the four indexes that showed high correlations with the “MD adherence” factor (mMED: 
0.83, rMED: 0.80) [48]. Regarding the validity of the MD scores used, subjects with higher 
MD score values in our study consumed, as expected, more plant foods (e.g., vegetables, 
legumes, fruits and nuts) and less foods from animal origin (e.g., meat and dairy products). A 
similar pattern was previously observed for tMED [22]. However, the validity of tMED and its 
variants has mainly been established by showing inverse associations with various adverse 
health outcomes including all-cause mortality and risks of and mortality from cardiovascular 
diseases and cancer, e.g., [22, 23, 25, 49, 50]. Several studies have compared associations 
between various index-based dietary patterns, including tMED (variants), and cancer risk. 
A review published in 2018 showed that 3 out of 4 studies investigating the association 
of tMED (variants) with postmenopausal estrogen receptor-negative breast cancer risk 
observed a significant inverse relation. However, associations were inconsistent for other 
dietary pattern scores [e.g., Dietary Inflammatory Index (DII), Healthy Eating Index (HEI) 
and Alternate Healthy Eating Index (AHEI)] [51]. Considering prostate cancer risk, tMED 
(variants) and DII showed relatively consistent associations across studies, whereas the 
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evidence was inconsistent and/or insufficient for other indexes [52]. Furthermore, healthier 
diets according to tMED (variants), HEI/AHEI and DII have all been associated with lower 
risks of colorectal cancer [53]. More studies evaluating associations of various index-based 
dietary patterns with cancer risk are required in order to identify the preferred dietary 
pattern(s) in the perspective of cancer prevention. A final limitation of our study was the 
population-dependent assignment of scores in the assessment of MD adherence, which we 
have elaborately discussed previously [46].
In conclusion, high MD adherence was associated with reduced risks of ESCC, GCA and GNCA 
in the NLCS. However, the inverse association with ESCC risk seemed to be restricted to men. 
So far, results for esophageal cancer generally were consistent with high MD adherence 
being associated with a reduced risk of ESCC, but not EAC. Findings concerning GCA and 
GNCA were more diverse, but generally, inverse associations (not always significant) were 
observed for at least one of the subtypes. The potential differences in associations between 
men and women, particularly for ESCC, require further attention.  
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Abstract
Studies investigating the association of Mediterranean diet (MD) adherence with pancreatic 
cancer risk are limited and had inconsistent results. We examined the association between 
MD adherence and pancreatic cancer incidence by pooling data from the Netherlands 
Cohort Study (NLCS, 120852 subjects) and the Dutch cohort of the European Prospective 
Investigation into Cancer and Nutrition (EPIC-NL, 40011 subjects). MD adherence was 
assessed using alternate and modified Mediterranean diet scores (aMED and mMED, 
respectively), including and excluding alcohol. After median follow-ups of 20.3 (NLCS) and 
19.2 (EPIC-NL) years, 449 microscopically confirmed pancreatic cancer (MCPC) cases were 
included in study-specific multivariable Cox models. Study-specific estimates were pooled 
using a random-effects model. MD adherence was not significantly associated with MCPC 
risk in pooled and study-specific analyses, regardless of sex and MD score. Pooled hazard 
ratios (95% confidence interval) for high (6-8) compared to low (0-3) values of mMED 
excluding alcohol were 0.66 (0.40 – 1.10) in men and 0.94 (0.63 – 1.40) in women. In 
never smokers, mMED excluding alcohol seemed to be inversely associated with MCPC risk 
(non-significant). However, no association was observed in ever smokers (pheterogeneity=0.03). 
Hazard ratios were consistent across strata of other potential effect modifiers. Considering 
MD scores excluding alcohol, mMED-containing models generally fitted better than aMED-
containing models, particularly in men. Although associations somewhat differed when all 
pancreatic cancers were considered instead of MCPC, the overall conclusion was similar. 
In conclusion, MD adherence was not associated with pancreatic cancer risk in a pooled 
analysis of two Dutch cohorts. 
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Introduction 
Despite its relatively low incidence, pancreatic cancer was ranked as the third most common 
cause of cancer death in the US based on 2010-2014 data [1]. Because the early disease 
stages are usually asymptomatic, pancreatic cancer is generally diagnosed in advanced 
disease stages resulting in a poor prognosis; five-year survival rates of pancreatic cancer 
in the US (2007-2013) were only 8.2% for all stages and 2.7% for distant stages [2, 3]. Diet 
could be a modifiable target for the primary prevention of pancreatic cancer. However, the 
World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) judged in 
their 2012 report on pancreatic cancer that the evidence supporting an association between 
dietary factors and pancreatic cancer is limited [2]. Only body fatness (convincing evidence) 
and greater childhood growth (probable evidence) were reported to be associated with an 
increased pancreatic cancer risk [2]. 
The plant-based traditional Mediterranean dietary pattern (MD) is characterized by a high 
intake of vegetables, legumes, fruits, nuts, whole grains, olive oil (rich in monounsaturated 
fatty acids (MUFA)) and fish. In contrast, high-fat dairy products, red and processed 
meats, refined grains and sweets are consumed in small amounts. Alcohol consumption 
is considered moderate in the MD [4-6]. High adherence to the MD has been shown to 
reduce cardiovascular disease incidence and mortality, as well as all-cause mortality [7-9]. 
Recently, researchers have taken an increasing interest in the potentially beneficial effect of 
MD adherence on cancer risk [10]. 
Up until now, the association between a priori defined MD adherence and the 
incidence of pancreatic cancer has been investigated in three studies (1 case-control, 2 
prospective cohorts), with inconsistent results [11-13]. An Italian hospital-based case-
control study showed a statistically significantly decreased risk of pancreatic cancer 
with higher MD adherence [12]. On the other hand, the reduced pancreatic cancer risk 
associated with higher MD adherence was not significant in a US prospective cohort 
study [11] and there was no evidence of an association in the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort [13]. In addition to the results 
concerning pancreatic cancer incidence, a significant decrease in pancreatic cancer 
mortality was associated with higher MD adherence in Swedish subjects [14]. 
It has previously been shown that associations of factors with pancreatic cancer risk depend 
on the microscopic confirmation status of the cases [15, 16]. The most valid results are 
obtained by restricting analyses to microscopically confirmed pancreatic cancer (MCPC) 
cases, which minimizes misclassification of disease status [15, 16]. Results for this subgroup 
of cases have only been reported in EPIC before [13]. 
The aim of the present analysis was to prospectively investigate the association of MD 
adherence with pancreatic cancer risk, using various a priori defined MD scores with and 
without alcohol. Analyses were performed considering all pancreatic cancer cases and 
MCPC cases specifically. We investigated these aims by pooling results of the Netherlands 
Cohort Study (NLCS) and the Dutch EPIC cohort (EPIC-NL) to increase the statistical power. 
106
Chapter 5
Materials and methods 
Study population and pancreatic cancer follow-up
A pooled analysis was conducted including individual participant data from the NLCS and EPIC-
NL cohorts. Detailed descriptions of both cohorts have been published previously [17-23]. In 
short, the NLCS is a nationwide population-based cohort study among 58279 men and 62573 
women from 204 Dutch municipalities, who were aged between 55 and 69 years at enrollment 
[17]. At baseline in September 1986, participants completed a self-administered questionnaire 
on diet and other cancer risk factors. For efficiency, data were processed and analyzed using 
the nested case-cohort design. Therefore, cases were derived from the entire NLCS cohort, 
whereas the number of person-years at risk was estimated based on a subcohort (N=5000). 
Subcohort members were randomly sampled immediately after baseline and were followed 
up biennially for vital status information using municipal population registries [17, 20, 24]. 
The EPIC-NL cohort comprises 40011 subjects, who were included in the EPIC-Prospect 
(17357 women, aged 49-70 years) or EPIC-MORGEN (10260 men and 12394 women, 
aged 20-65 years) cohorts [21-23]. Cohort members of EPIC-Prospect were participants 
of a breast cancer screening program in the region of Utrecht between 1993 and 1997, 
whereas EPIC-MORGEN was composed by selecting random population samples of three 
Dutch towns (Amsterdam, Maastricht and Doetinchem) in the same time period. Baseline 
measurements were performed using a general questionnaire and a food frequency 
questionnaire (FFQ). In addition, physical examinations, including measurements of height, 
weight and blood pressure, were carried out at baseline. Vital status information of EPIC-
NL participants was retrieved via linkage with the municipal population registries [21-23]. 
The NLCS and EPIC-NL cohorts were approved by the internal review boards of the institutions 
involved. All study participants consented to participation by completing the questionnaire 
(NLCS) or signing an informed consent form (EPIC-NL).
Incident cases of pancreatic cancer (International Classification of Diseases for Oncology, 
Third Edition (ICD-O-3), code C25) were identified by annual record linkage with the 
Netherlands Cancer Registry and PALGA, the nationwide Dutch Pathology Registry [18, 23]. 
Cases with endocrine pancreatic cancer, defined by ICD-O-3 code C25.4 or an endocrine 
tumor type, were excluded and censored at their date of diagnosis. Pancreatic cancer 
cases were considered to have MCPC, when they were diagnosed based on hematological, 
cytological or histological confirmation. Subjects were excluded from the analyses if they 
met one of the following criteria: prevalent cancer at baseline, except non-melanoma skin 
cancer (EPIC-NL) or any type of skin cancer (NLCS), or missing; incomplete, inconsistent or 
missing (dietary) questionnaires; a ratio of energy intake to basal metabolic rate in the lowest 
or highest 0.5% (EPIC-NL only); or incomplete data on alcohol consumption and variables 
necessary to calculate MD adherence. In total, 4084 of the NLCS subcohort members were 
eligible for inclusion in the analyses. In the EPIC-NL cohort, 35459 subjects met the eligibility 
criteria. Using 20.3 years of follow-up, 651 cases of exocrine pancreatic cancer (391 MCPC) 
were diagnosed in the NLCS. In the EPIC-NL cohort, 142 cases (104 MCPC) were detected 
during a median follow-up of 19.2 years. Observations were censored at December 31st 
2006 (NLCS) and December 31st 2014 (EPIC-NL). The selection process of subjects eligible 
for inclusion in the analyses is visualized in the flow diagrams in Supplementary Figure S5.1 
(NLCS) and Supplementary Figure S5.2 (EPIC-NL).  
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Exposure assessment
The habitual dietary intake over the year preceding enrollment was assessed by study-
specific, self-administered, semi-quantitative FFQs, of which the validity and reproducibility 
have been evaluated [19, 25-27]. Dutch food composition (NEVO) tables from the years 
1986 (NLCS) and 1998 (EPIC-NL) were utilized to calculate mean daily nutrient intakes [28].
Mediterranean diet adherence
Relative MD adherence was assessed using the alternate and modified Mediterranean diet 
scores (aMED and mMED, respectively), which are two variants of the original traditional 
Mediterranean diet score (tMED) developed by Trichopoulou et al. [29-33]. Before 
calculation of the MD scores, food intakes were adjusted to total energy intakes of 2000 
(women) and 2500 (men) kilocalories (kcal) per day to correct for differences in daily energy 
intakes [29, 33]. aMED is calculated based on the daily intakes of nine dietary components, 
which are each scored by 0 or 1 points, resulting in a sum score ranging from 0 (minimal 
MD adherence) to 9 (maximal MD adherence) [32, 33]. A score of 1 is assigned to: high 
intakes (≥ sex-specific median) of vegetables (excluding potatoes), legumes, fruits, nuts, 
whole grains, and fish; a high (≥ sex-specific median) ratio of MUFA to saturated fatty acids 
(SFA); a low intake (< sex-specific median) of red and processed meats; and a moderate 
alcohol intake (5-25 grams per day (g/day) for both sexes) [32, 33]. aMED is calculated in 
a similar way as tMED, but differs from the original score with respect to the composition 
of the dietary components. In tMED [29, 30], fruits and nuts are combined, total intakes of 
cereals and meats are considered, and consumption of dairy products is included (1 point if 
< sex-specific median). Besides, moderate alcohol consumption is defined differently in men 
(10-50 g/day) and women (5-25 g/day) [29, 30]. mMED [31] was specifically developed for 
usage in non-Mediterranean populations and differs from tMED with respect to the fatty 
acid ratio included. In mMED, the ratio of unsaturated fatty acids (polyunsaturated fatty 
acids (PUFA) + MUFA) to SFA replaces the MUFA:SFA ratio [31]. Sex-specific median intakes 
of dietary components were calculated separately for the NLCS and EPIC-NL cohorts. We 
also created reduced variants of aMED and mMED without alcohol (aMEDr and mMEDr, 
respectively), because moderate/heavy alcohol consumption (>3 drinks per day) might 
increase pancreatic cancer risk [2, 34]. aMEDr and mMEDr ranged from 0 to 8 points. Based 
on their MD score, subjects were categorized as having low (0-3), middle (4-5), or high (6-
8(9)) levels of MD adherence [31, 33]. Additionally, MD scores were included as continuous 
terms to obtain effect estimates per two-point increment in score.
Statistical analyses
All analyses were performed separately for men and women unless otherwise specified. As 
a general approach, we first determined study-specific (NLCS and EPIC-NL) estimates, which 
were pooled in a later stage.  
Cox proportional hazards models with follow-up as time variable were run to estimate study-
specific hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the relation between 
MD adherence and pancreatic cancer incidence. (Sub)cohort members were considered to 
be at risk from baseline until pancreatic cancer diagnosis, death, emigration, loss to follow-
up or end of follow-up, whichever came first. Since the case-cohort design introduces 
additional variance, the Huber-White sandwich estimator was used to estimate standard 
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errors of the HRs in the NLCS cohort [35]. Scaled Schoenfeld residuals tests and –ln(-ln) 
survival plots were used to evaluate the proportional hazards (PH) assumption [36]. In case 
of potential violations of the PH assumption for covariates, it was checked whether inclusion 
of a time-varying covariate altered the effect estimates of the exposures of interest.  
aMEDr and mMEDr were modelled as both categorical and continuous variables. In 
order to perform tests for trends across the MD adherence categories, study- and sex-
specific median values among (sub)cohort members were assigned to the MD adherence 
categories. Next, the created variable was fitted as a continuous term in the Cox model and 
statistical significance of the regression coefficient was assessed by the Wald test. Based 
on the literature, the following potential confounders were included in multivariable Cox 
models: age at baseline, sex (except for sex-specific analyses), cigarette smoking status, 
cigarette smoking frequency, cigarette smoking duration, body mass index (BMI), total daily 
energy intake, alcohol consumption (except for models containing the original MD scores 
including alcohol), history of (type 2) diabetes, level of education, and (non-occupational) 
physical activity. Cigarette smoking frequency and duration were combined into pack-years 
of smoking in the EPIC-NL cohort. Models based on NLCS data were additionally adjusted for 
family history of pancreatic cancer (not available for EPIC-NL), whereas the EPIC-NL models 
were also adjusted for cohort (EPIC-Prospect or EPIC-MORGEN). 
Study-specific HRs were combined using a DerSimonian and Laird random-effects model to 
obtain pooled effect estimates for the association between MD adherence and pancreatic 
cancer risk. Weights were assigned to the study-specific estimates based on the inverse of 
their variances [37, 38].  
The fits of aMEDr- and mMEDr-containing models (study-specific) were compared using 
Akaike’s Information Criterion (AIC) [39]. In addition, AIC was used to compare performances 
of study-specific models containing MD score variants with and without alcohol. To evaluate 
whether the relation between MD adherence and pancreatic cancer risk is influenced by 
the microscopic confirmation status of the cases, we also restricted the analyses to MCPC 
cases. This article will mainly focus on results obtained among MCPC cases, as the most 
valid results are obtained in this case group [15, 16]. Because moderate/heavy alcohol 
consumption might increase the risk of pancreatic cancer, we give priority to the use of MD 
scores without alcohol [2, 34]. 
Furthermore, it was evaluated whether the relation between MD adherence and pancreatic 
cancer risk varied across strata of potential effect modifiers. HRs for strata of cigarette 
smoking status, BMI, alcohol consumption and history of diabetes were retrieved by pooling 
study-specific effect estimates. Similarly, pooled regression coefficients were obtained for 
interaction terms between the MD scores and the potential effect modifiers and significance 
of the interactions was tested. Finally, because preclinical disease could potentially alter a 
subject’s diet and therefore influence the observed association between MD adherence and 
pancreatic cancer risk, sensitivity analyses excluding the first two years of follow-up were 
performed on the individual study level. Statistical analyses were performed using Stata15 
(StataCorp LLC, College Station, TX, USA). All presented p-values are two-sided. Statistical 
significance was defined as a p-value below 0.05. 
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Results 
After median follow-up times of 20.3 (NLCS) and 19.2 (EPIC-NL) years, 793 (men: 378; 
women: 415) eligible cases of exocrine pancreatic cancer were diagnosed in the total study 
population of whom 495 (men: 245; women: 250) were microscopically confirmed. 
Study-specific baseline characteristics of the included cohorts are presented in Table 5.1 
and Table 5.2. As expected, mean MD score values in the cohorts were similar. In contrast, 
noteworthy age differences were observed between the cohorts, with a substantially higher 
median age in the NLCS. Within the EPIC-NL cohort, women were older than men. Compared 
to EPIC-NL participants, NLCS participants were less often current smokers (women only), 
lower educated, less physically active, had lower daily intakes of energy and alcohol, had 
a lower BMI and were more likely to have a history of diabetes. The described differences 
between the cohorts might (partly) be attributed to variations in age and other study 
characteristics, such as participant recruitment criteria, time period of study, measurement 
methods and variable definitions. 
As is shown in Table 5.1 and Table 5.2, mean MD score values were similar for MCPC cases 
and (sub)cohort members, except for aMEDr in EPIC-NL. Compared to (sub)cohort members, 
MCPC cases were older (EPIC-NL only), consumed more alcohol, had a higher BMI and were 
more likely to have a history of diabetes. MCPC cases were also more often current smokers. 
However, this did not apply for female MCPC cases in EPIC-NL, who were less often current 
smokers. 
Table 5.3 and Table 5.4 present pooled and study-specific results of the multivariable 
Cox proportional hazards analyses evaluating sex-specific associations of MD adherence, 
measured by various MD scores, with MCPC risk. Due to missing values in covariates, 46 
(9.3%) MCPC cases (NLCS: 43 (11.0%); EPIC-NL: 3 (2.9%)) and 1307 (3.3%) (sub)cohort 
members (NLCS: 364 (8.9%); EPIC-NL: 943 (2.7%)) could not be included in the multivariable 
Cox proportional hazards analyses. 
MD adherence was not statistically significantly associated with MCPC risk among men 
in the pooled multivariable analyses (Table 5.3). Pooled HRs (95% CI) comparing high to 
low MD adherence were 0.70 (0.44 – 1.12) and 0.66 (0.40 – 1.10) for aMEDr and mMEDr, 
respectively. Although the HR was not significant, middle mMEDr values seemed to be 
associated with an increased risk of MCPC. There was also no evidence of an association 
between MD adherence and MCPC risk when HRs were estimated per two-point increment 
in MD score (aMEDr=0.96, 95% CI: 0.80 – 1.16; mMEDr=0.99, 95% CI: 0.83 – 1.18). The 
observed associations were consistent among the individual cohorts (Table 5.3). The –ln(-
ln) survival plots indicated a potential violation of the PH assumption for the MD scores in 
men in the EPIC-NL cohort. However, PH assumption tests were not statistically significant. 
Furthermore, results generally similar to those for MCPC were obtained when all pancreatic 
cancer cases were included in the analyses (Supplementary Table S5.1). 
As in men, we observed no association between MD adherence and MCPC risk among 
women in the pooled multivariable analyses (Table 5.4). Pooled HRs (95% CI) per two-point 
increment in score were 1.07 (0.89 – 1.27) and 1.01 (0.84 – 1.21) for aMEDr and mMEDr, 
respectively. Associations seemed to differ between the individual cohorts, particularly when 
MD adherence was expressed using mMEDr categories. Overall, mMEDr was not associated 
with MCPC risk in the NLCS, though a non-significantly reduced MCPC risk seemed to be 
associated with middle mMEDr values (HRmiddle vs. low=0.71, 95% CI: 0.49 – 1.01). In contrast 
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Chapter 5
to the NLCS findings, associations between the categorical mMEDr and MCPC risk were 
absent or slightly positive in EPIC-NL. There was also no evidence of an association between 
MD adherence and pancreatic cancer risk in women when all pancreatic cancer cases were 
included in the analyses (Supplementary Table S5.2). 
Study-specific tests for heterogeneity between the sexes were mostly not statistically 
significant, except when MD adherence was assessed by mMEDr categories in the NLCS. 
Comparing study-specific AIC values, we found that mMEDr-containing models generally 
fitted better than models containing aMEDr, particularly in men. In women, this pattern was 
unclear. Also, no consistent pattern was observed when performances of models containing 
MD scores with and without alcohol were compared. 
Table 5.5 shows pooled associations between MD adherence and the risk of MCPC within 
strata of potential effect modifiers. Since study-specific tests for heterogeneity between the 
sexes were not statistically significant when MD adherence was modelled using continuous 
MD scores, study-specific subgroup results based on both sexes were pooled to increase 
the statistical power. The association between mMEDr and MCPC risk differed statistically 
significantly across the strata of cigarette smoking status (pheterogeneity=0.03). Although not 
significant, mMEDr seemed to be inversely associated with MCPC risk in never smokers, 
whereas there was no evidence of an inverse association in ever smokers. A similar, but 
weaker and non-significant, pattern was noticed when MD adherence was assessed 
using aMEDr. No differences in associations were observed across strata of BMI, alcohol 
consumption and history of diabetes. Finally, exclusion of the first two years of follow-up 
did not alter the study-specific results. However, in the NLCS, we did note a non-significant 
inverse association between MD adherence and MCPC risk when focusing on the first two 
years of follow-up. In EPIC-NL, too few cases were available to perform this analysis.
Discussion 
MD adherence was not significantly associated with MCPC risk in pooled multivariable 
analyses, including NLCS and EPIC-NL data, as well as study-specific multivariable analyses, 
regardless of sex and MD score used. The model fit was generally better for mMEDr-
containing models compared to aMEDr-containing models, especially in men. Comparison 
of performances of models containing MD scores with and without alcohol did not show 
a consistent pattern. Stratified analyses indicated an inverse association between mMEDr 
and MCPC risk in never smokers (non-significant), but not in ever smokers (pheterogeneity=0.03). 
There was no evidence for effect modification by BMI, alcohol consumption or history of 
diabetes. 
Results of our pooled analysis are in line with those obtained in previous prospective 
cohort studies [11, 13] that did also not find a statistically significant inverse association 
between MD adherence and pancreatic cancer incidence. In diabetes-free participants 
of the National Institutes of Health-American Association of Retired Persons (NIH-AARP) 
Diet and Health Study, a HR of 0.92 (95% CI: 0.81 – 1.05) was observed when comparing 
high (aMEDr: 5-8) to low (0-4) MD adherence [11]. In the same study, a non-significantly 
reduced pancreatic cancer risk was found when scores of 7-8 were compared to scores of 
0-1 (p=0.06). Furthermore, there was no indication for an inverse association between MD 
adherence, assessed by a variant of the relative Mediterranean diet score excluding alcohol, 
and pancreatic cancer risk in the EPIC cohort (HRhigh vs. low=0.99, 95% CI: 0.77 – 1.26) [13]. 
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Table 5.5  Pooled results for fully adjusted associationsa of aMEDr and mMEDr with microscopically confirmed 
pancreatic cancer risk for various subgroups
aMEDr (per two-point increment) mMEDr (per two-point increment)
Subgroup Cases HRpooled
b (95% CI) Pheterogeneity
c HRpooled
b (95% CI) Pheterogeneity
c
Overall 449 1.03 (0.90 - 1.16) 1.01 (0.89 - 1.15)
Cigarette smoking statusd 
Never smokers 137 0.89 (0.71 - 1.13) 0.81 (0.65 - 1.02)
Ever smokers 312 1.08 (0.93 - 1.25) 0.230 1.11 (0.94 - 1.31) 0.034
Body mass indexe
≥18.5 - <25.0 kg/m2 203 1.03 (0.85 - 1.25) 1.01 (0.84 - 1.21)
≥25.0 kg/m2 245 1.04 (0.87 - 1.24) 0.742 1.03 (0.86 - 1.24) 0.926
Alcohol consumptionf g
>0 - <15.0 g/day 244 1.09 (0.92 - 1.28) 1.07 (0.90 - 1.26)
≥15.0 g/day 139 0.89 (0.69 - 1.14) 0.215 0.91 (0.72 - 1.15) 0.264
History of diabetesh
No 423 1.02 (0.89 - 1.16) 1.02 (0.89 - 1.16)
Yes 26 1.48 (0.62 - 3.49) 0.634 0.80 (0.37 - 1.74) 0.672
Abbreviations: aMEDr, alternate Mediterranean diet score without the alcohol component; mMEDr, modified 
Mediterranean diet score without the alcohol component; NLCS, Netherlands Cohort Study; EPIC-NL, the 
Dutch cohort of the European Prospective Investigation into Cancer and Nutrition; EPIC, European Prospective 
Investigation into Cancer and Nutrition; CPAI, Cambridge Physical Activity Index 
 
a The fully adjusted analyses in the NLCS cohort were adjusted for age at baseline (years), sex (men, women), 
cigarette smoking status (never, former, current), cigarette smoking frequency (cigarettes smoked per day, 
centered), cigarette smoking duration (years, centered), body mass index (kg/m2), daily energy intake (kcal), 
alcohol consumption (g/day), history of diabetes (no, yes), family history of pancreatic cancer (no, yes), 
highest level of education (primary school or lower vocational, secondary school or medium vocational, higher 
vocational or university), and non-occupational physical activity (≤30, >30-≤60, >60-≤90, >90 min/day). 
The fully adjusted analyses in the EPIC-NL cohort were adjusted for age at baseline (years), sex (men, women), 
cohort (EPIC-Prospect, EPIC-MORGEN), cigarette smoking status (never, former, current), pack-years of cigarette 
smoking (pack-years, centered), body mass index (kg/m2), daily energy intake (kcal), alcohol consumption 
(g/day), history of type 2 diabetes (no, yes), highest level of education (primary school or lower vocational, 
secondary school or medium vocational, higher vocational or university), and total physical activity (CPAI, 
missings imputed: inactive, moderately inactive, moderately active, active). 
b Study-specific effect estimates were pooled using the DerSimonian and Laird random-effects model.    
c P-values for heterogeneity between subgroups were obtained by testing the statistical significance of pooled 
interaction terms between aMEDr/mMEDr and the potential effect modifiers.  
d Not adjusted for cigarette smoking status. 
e Not adjusted for body mass index. 
f No pooled HRs could be obtained for non-consumers of alcohol, because no microscopically confirmed cases of 
pancreatic cancer were diagnosed in this subgroup in the EPIC-NL cohort. 
g Not adjusted for alcohol consumption. 
h Not adjusted for history of (type 2) diabetes.  
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In contrast, an Italian hospital-based case-control study did show a statistically significant 
inverse association between MD adherence (revised tMED including alcohol) and pancreatic 
cancer incidence (odds ratio≥6 vs. <3=0.48, 95% CI: 0.35 – 0.67) [12]. Additionally, higher MD 
adherence according to an adapted version of mMED including alcohol was associated 
with a significant decrease in pancreatic cancer mortality in the prospective Västerbotten 
Intervention Program with a HR of 0.82 (95% CI: 0.72 – 0.94) per one-point increment in 
score [14]. However, the results of the latter study were based on only 92 pancreatic cancer 
deaths and might have been distorted by selection bias, as excluded participants were 
characterized by a higher mortality risk. 
The main results of the present study were based on analyses that were restricted to MCPC 
cases. Restricting the analyses to MCPC cases minimizes misclassification of disease status 
and therefore renders the most valid results [15, 16]. Non-MCPC cases may present with 
different subtypes of pancreatic cancer or non-pancreatic cancer. This could affect the 
observed association when these subtypes or non-pancreatic cancers are differentially 
related to the exposure of interest compared with MCPC [16]. Although we observed some 
differences between associations determined among all pancreatic cancer cases and MCPC 
cases in the present analysis, the overall conclusion was similar for both case sets. Of the 
previously conducted studies concerning MD adherence and pancreatic cancer risk, only 
the EPIC study by Molina-Montes et al. [13] reported results in MCPC cases specifically and 
concluded that exclusion of non-MCPC cases did not alter the effect estimates. 
Dietary habits may be influenced by the presence of preclinical disease, in particular in case 
of gastrointestinal cancers. Preclinical disease symptoms may result in reduced intakes of 
Mediterranean foods, such as vegetables, fruits and nuts, by cases. This could cause case-
control studies to find a protective effect, whereas in fact there is no association. With regard 
to MD adherence and pancreatic cancer incidence, only the case-control study by Bosetti et 
al. [12] observed a statistically significant inverse association. Moreover, in the NLCS cohort, 
we noted that higher MD adherence was associated with a non-significantly reduced MCPC 
risk when we only included the first two years of follow-up, whereas there was no evidence 
for a relation in later follow-up periods. This indicates that indeed the presence of preclinical 
disease could cause us to find an inverse association in the absence of a true effect. 
Study-specific tests for heterogeneity showed that the association of MD adherence with 
MCPC risk did not significantly differ between the sexes in the NLCS and EPIC-NL, except 
when MD adherence was assessed by mMEDr categories in the NLCS. Likewise, previously 
conducted studies on the topic did also not observe clear differences in associations between 
men and women [11-14]. In our pooled analysis, the association of mMEDr, but not aMEDr, 
with MCPC risk differed statistically significantly across the strata of smoking status. Higher 
mMEDr values seemed to be associated with a decreased MCPC risk in never smokers 
(non-significant), but not in ever smokers. In contrast, previous studies did not observe 
an interaction with smoking status [12-14]. Future studies should further investigate the 
potential effect modifying role of smoking status in the association between MD adherence 
and pancreatic cancer risk. HRs were consistent across strata of the other potential effect 
modifiers that we evaluated, including history of diabetes. Similarly, there was no evidence 
for an interaction with diabetes status in the study by Molina-Montes et al. [13]. In contrast, 
the significant inverse association between MD adherence and pancreatic cancer risk 
observed in the study by Bosetti et al. [12] was restricted to non-diabetics (pheterogeneity=0.01). 
Comparing various MD score variants, we observed that mMEDr-containing models 
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performed better than aMEDr-containing models in men, whereas no clear pattern was 
present in women. In contrast, previous NLCS analyses concerning breast and lung cancer 
consistently showed a better performance for aMEDr-containing models [40, 41]. Because 
moderate/heavy alcohol consumption might be associated with an increased pancreatic 
cancer risk [2, 34], we also compared model performances of MD score variants including and 
excluding alcohol component, which showed no consistent pattern. Previously conducted 
studies evaluating the effect of considering alcohol as MD score component, found similar 
HRs for MD score variants with and without alcohol [12, 13].  
A major strength of our study is the pooling of data of two cohorts, which increased the 
statistical power. However, it should be noted that the relatively low number of male 
MCPC cases in the EPIC-NL cohort caused the pooled results for men to primarily reflect 
the associations observed in the NLCS cohort. Another strength with respect to the pooled 
analyses was the availability of individual participant data, which enabled us to standardize 
the statistical methods as well as the exposure, confounding and outcome variables, thereby 
minimizing between-study heterogeneity. Additionally, we had access to detailed dietary 
data retrieved via FFQs of which the validity and reproducibility have been evaluated [19, 
25-27]. Finally, the prospective designs and long durations of follow-up were other strengths 
of the included cohorts.
A potential weakness of the MD scores used, particularly in non-Mediterranean countries 
such as the Netherlands, is the population-dependent assignment of scores. Therefore, even 
though diets of subjects with higher MD scores in our study population can be considered to 
be more Mediterranean compared to those of subjects with lower MD scores, high MD scores 
do not necessarily reflect close adherence to a true MD. However, MD adherence was also 
not significantly associated with a reduced pancreatic cancer risk in the southern European 
countries of the EPIC cohort [13]. Olive oil is the principal source of fat in the traditional MD 
[4, 5]. However, tMED [29, 30] and many of its derivatives, including the MD scores that 
we used, do not incorporate olive oil consumption as a specific component. Instead, a fatty 
acid ratio is used to model the high levels of MUFA (mainly from olive oil) and low levels 
of SFA characteristic of the Greek MD [29]. The use of a fatty acid ratio to reflect the high 
olive oil intake in the traditional MD improves the usage of tMED and its derivatives in non-
Mediterranean countries in which the olive oil consumption is generally low, as was also 
the case in the Netherlands at the time of our baseline measurements. Another weakness 
of our analysis was the reliance on single baseline measurements for dietary habits and 
potential confounding factors. Hence, changes in diet and/or confounding factors during 
follow-up might have attenuated the associations. However, it has been shown that the 
reproducibility of the FFQs used was generally good [25-27]. The NLCS-FFQ had an average 
test-retest correlation of 0.66 for all nutrients. After five years, the correlation between the 
baseline and repeated measurement of the NLCS-FFQ had declined on average only 0.07 
[25]. The FFQ used in the EPIC-NL cohort had a median 12-month reproducibility for food 
groups of 0.71 for men and 0.77 for women [26]. Finally, errors in the measurements of 
dietary habits and residual confounding by unmeasured factors cannot fully be excluded. 
In conclusion, higher MD adherence was not associated with a decreased risk of pancreatic 
cancer in a pooled analysis of two Dutch cohorts. 
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EPIC-Prospect (N=17357) EPIC-MORGEN (N=22654)
↓ ↓
EPIC-NL (N=40011)
↓
4552 subjects were excluded:
- End of follow-up date that preceded the recruitment date (N=6)
- No permission for linkage with the municipal population registry (N=1044)
- No permission for linkage with the Netherlands Cancer Registry or missing (N=1246)
- Prevalent cancer at baseline or missing (N=1794)
- No food frequency questionnaire (N=128)
- Energy intake : BMR ratio in lowest or highest 0.5% (N=334)
- Missing alcohol data and/or MD adherence (N=0)
↓
Eligible study population (N=35459)
↓
Cancer follow-up (median: 19.2 years)
↓
Exocrine pancreatic cancer cases
(N=142)
Microscopic confirmation status
↓ ↓
All pancreatic Microscopically confirmed
 cancer cases  pancreatic cancer cases
(N=142) (N=104)
Supplementary Figure S5.2  Flow diagram of the number of EPIC-NL participants, who are eligible for inclusion 
in the analyses 
 
Abbreviations: EPIC, European Prospective Investigation into Cancer and Nutrition; EPIC-NL, the Dutch EPIC 
cohort; BMR, basal metabolic rate; MD, Mediterranean diet 
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Abstract 
Mediterranean diet (MD) adherence has been associated with a large variety of health 
benefits. However, prospective studies investigating the relation between MD adherence 
and colorectal cancer risk had inconsistent results. In this analysis of the Netherlands Cohort 
Study (NLCS), we evaluated sex- and subsite-specific associations of MD adherence with 
colorectal cancer risk. In 1986, 120852 subjects filled out the NLCS baseline questionnaire, 
which incorporated a 150-item food frequency questionnaire. MD adherence was estimated 
through alternate Mediterranean diet scores including and excluding alcohol (aMED and 
aMEDr, respectively). Using 20.3 year follow-up data, 1993 male and 1574 female colorectal 
cancer cases could be included in multivariable case-cohort analyses. aMEDr was not 
significantly associated with colorectal cancer risk, regardless of sex. Hazard ratios (95% 
confidence intervals) per two-point increment were 1.04 (0.95 – 1.13) for men and 0.97 (0.88 
– 1.07) for women. Additionally, there was no evidence of an inverse association with any of 
the colorectal cancer subsites (colon, proximal colon, distal colon, and rectum). In women, 
the association between aMEDr and colorectal cancer risk was significantly modified by 
smoking status (pinteraction=0.015). Comparable results were obtained for the original aMED 
including alcohol. In conclusion, higher MD adherence was not associated with a reduced 
risk of colorectal cancer or anatomical subsites in the context of a Dutch population. 
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Introduction 
Globally, colorectal cancer was an important contributor to the total cancer burden in 2018, 
ranking third and second in terms of incidence and mortality, respectively [1]. The global 
burden of colorectal cancer is expected to increase even further in the next decade. In 2030, 
over 2.2 million people are estimated to be diagnosed with colorectal cancer, whereas more 
than 1.1 million people are expected to die from this disease [2]. Colorectal cancer is a 
slow-growing disease [3], which offers the opportunity to intervene during the disease 
development process using preventive measures. These preventive strategies could for 
instance focus on maintenance of a healthy diet. 
The traditional Mediterranean diet (MD), typical for the olive-cultivating areas bordering the 
Mediterranean basin in the early 1960s, has been associated with a large variety of health 
benefits, including decreases in all-cause mortality as well as cardiovascular disease risk and 
mortality [4-8]. This dietary pattern is characterized by the consumption of large quantities 
of vegetables, legumes, fruits, nuts, whole grains, and olive oil (rich in monounsaturated 
fatty acids, MUFA). In contrast, intakes of foods from animal origin (e.g., dairy and meat) are 
low. Finally, wine is consumed in moderate amounts, particularly during meals [4, 5].   
The relation between a priori defined MD adherence and colorectal cancer risk has been 
evaluated in a number of prospective studies so far, with mixed results. Though some studies 
reported MD adherence to be associated with a significantly reduced colorectal cancer risk 
[9-12], inverse associations were absent or only observed in specific subgroups in others 
[13-20]. Additionally, heterogeneity of associations across the sexes and colorectal cancer 
subsites was indicated [9, 10, 12, 13, 16, 17, 20]. 
The colorectum can anatomically be divided in the proximal colon, distal colon, and 
rectum. Depending on the anatomical subsite, colorectal tumors may develop through 
distinct molecular pathways and show varying patterns of (epi)genetic changes [21, 22]. 
Furthermore, differences have been shown in subsite-specific incidence trends and survival 
[21, 22]. Because of their potentially distinct etiologies, cancers of the proximal colon, distal 
colon, and rectum should initially be considered as separate endpoints in epidemiological 
studies. 
In the present analysis, we aimed to investigate associations of MD adherence with risks of 
colorectal cancer and anatomical subsites (colon, proximal colon, distal colon, and rectum) 
in the prospective Netherlands Cohort Study (NLCS). The level of MD adherence was 
assessed using a priori defined MD scores with and without alcohol component. Moreover, 
associations were estimated separately for men and women.
Methods 
Study population and cancer follow-up 
The NLCS was conducted among 58279 men and 62573 women, who were aged 55 to 
69 years [23-26]. At baseline (September 1986), information on diet and other cancer 
risk factors was gathered via a self-administered questionnaire. Data were processed 
and analysed using the case-cohort method, in which cases are derived from the entire 
cohort and person-years at risk are estimated based on a subcohort. Therefore, a random 
subcohort (N=5000) was selected immediately after baseline and vital status information 
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of subcohort members was acquired biennially [23, 26, 27]. Follow-up for cancer incidence 
was accomplished via annual record linkage with the Netherlands Cancer Registry and the 
nationwide Dutch Pathology Registry (PALGA) [24]. The NLCS was approved by institutional 
review boards from Maastricht University and the Netherlands Organization for Applied 
Scientific Research.
After 20.3 years of follow-up, 4084 subcohort members and 3966 cases with incident and 
microscopically confirmed colorectal cancer (ICD-O-3 codes: C18-C20) were eligible for 
inclusion in the present analyses (Figure 6.1). Eligible study participants did not have a 
history of cancer at baseline (except skin cancer), had complete and consistent dietary data, 
and had data available on alcohol consumption and MD adherence.  
Exposure assessment
Habitual dietary intake during the year preceding baseline was assessed using a 150-item, 
semi-quantitative food frequency questionnaire (FFQ) [25, 28]. Previously, it has been 
shown that this FFQ performed adequately and that dietary habits were reproducible for 
over at least five years [25, 28]. The 1986 Dutch food composition (NEVO) table was used to 
calculate nutrient intakes from the FFQ data [29].
Mediterranean diet adherence
MD adherence was assessed using the alternate Mediterranean diet score (aMED), which 
is a variant of the traditional Mediterranean diet score (tMED) developed by Trichopoulou 
et al., that was adapted for usage in the United States [30-33]. aMED assesses relative 
MD adherence based on energy-adjusted mean daily intakes of nine food groups with 
typically high or low consumption in the MD [32, 33]. Each food group is scored by 0 or 
1 points, creating a sum score with a maximum value of 9 points (highest level of MD 
adherence). Subjects receive 1 point for: high intakes (≥ sex-specific median) of vegetables 
(excluding potatoes), legumes, fruits, nuts, whole grains, and fish; a high (≥ sex-specific 
median) MUFA to saturated fatty acids (SFA) ratio; a moderate alcohol intake (5-25 g/
day); and a low intake (< sex-specific median) of red and processed meats [32, 33]. 
Moderate and heavy alcohol consumption have been associated with an increased colorectal 
cancer risk [34, 35]. Therefore, MD adherence was also assessed using a reduced variant of 
aMED (aMEDr) that does not include alcohol and ranges from 0 to 8 points. Because of 
the positive association between alcohol consumption and colorectal cancer risk, we will 
concentrate on results obtained using aMEDr in this article. MD score values were grouped 
into three MD adherence categories [low (0-3), middle (4-5), and high (6-8(9))] and were 
continuously modelled per two-point increment [33]. 
Statistical analyses
Cox proportional hazards analyses were conducted to estimate hazard ratios (HRs) and 95% 
confidence intervals (95% CIs) for sex-specific associations of MD adherence with incidences 
of total colorectal cancer and anatomical subsites (colon, proximal colon, distal colon, 
and rectum). Duration of follow-up was used as time variable and person-years at risk of 
subcohort members were calculated from baseline until colorectal cancer diagnosis, death, 
emigration, loss to follow-up, or end of follow-up, whichever came first. To account for the 
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increased variance inherent to the case-cohort design, we estimated standard errors using 
the robust Huber–White sandwich estimator [36]. Scaled Schoenfeld residuals tests and –
ln(–ln) survival plots confirmed that it was appropriate to assume proportionality of hazards 
for the exposure variables [37].
MD scores were included as categorical and continuous terms in age- and multivariable-
adjusted Cox models. Based on the literature, we included the following predefined 
confounders in the multivariable-adjusted models: age at baseline, cigarette smoking 
behaviour (status, frequency, and duration), body mass index (BMI), alcohol consumption 
(except for models containing the original aMED including alcohol), total daily energy 
intake, highest level of education, non-occupational physical activity, and family history 
of colorectal cancer. Other covariates considered were height, history of diabetes, history 
of chronic bowel irritation, use of hormone replacement therapy (women only), and 
long-term use of non-steroidal anti-inflammatory drugs. These factors did not change 
the HR estimates of aMEDr ≥10% and were therefore not included in the final model. 
P-values for trends over the MD adherence categories were obtained by appointing sex-
specific median MD score values among subcohort members to each category and fitting 
these as continuous terms in Cox regression models. Performances of models including MD 
score variants with and without alcohol (aMED and aMEDr, respectively) were compared 
using Akaike’s Information Criterion (AIC) [38]. Statistical significance of differences in 
associations with aMEDr across the anatomical locations of colorectal cancer (colon, 
proximal colon, distal colon, and rectum) was tested using a competing risks procedure, 
by which standard errors were estimated using a bootstrapping method developed for the 
case-cohort design [39, 40].  
Stratified analyses were performed to evaluate associations of aMEDr with colorectal 
cancer risk across levels of cigarette smoking status, alcohol consumption, BMI, educational 
level, and family history of colorectal cancer. Interaction terms between aMEDr and these 
potential effect modifiers were added to the models to test the statistical significance of 
potential differences. To test the sensitivity of our results, analyses were repeated excluding 
the first two years of follow-up. Furthermore, the total follow-up time was divided into three 
periods (≤2, >2-≤10, and >10 years). 
As an additional sensitivity analysis, we compared the population-dependent aMED to 
the absolute WCRF/AICR diet score, which is based on the dietary recommendations for 
cancer prevention issued by the World Cancer Research Fund/American Institute for Cancer 
Research (WCRF/AICR) in 2007 [41]. Our WCRF/AICR diet score is based on the WCRF/AICR 
score developed in the European Prospective Investigation into Cancer and Nutrition (EPIC) 
cohort [42, 43] and operationalizes the recommendations concerning foods and drinks that 
promote weight gain, plant foods, red and processed meats, (alcohol), and salt. A detailed 
description of the calculation of the score has been published previously [44]. Score variants 
were created including and excluding the alcohol recommendation, resulting in sum scores 
ranging from 0 to 4 (or 5 when including alcohol) points with higher values reflecting closer 
adherence to the WCRF/AICR dietary recommendations. Cox regression analyses were 
performed to estimate multivariable-adjusted associations of the WCRF/AICR diet scores 
(per SD-increment) with risks of colorectal, colon, and rectal cancer. A similar approach was 
applied to the aMED indices to be able to compare model performances of both scores using 
AIC. Statistical analyses were conducted using Stata (version 15). Statistically significant 
results had a two-sided p-value below 0.05.  
Mediterranean diet and colorectal cancer risk
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Results 
Sex-specific median daily intakes of the aMEDr components among subcohort members are 
displayed in Table 6.1. As expected, median daily intakes of beneficial components increased 
with higher levels of MD adherence, whereas the opposite was observed for the intake of 
red and processed meats. Alcohol consumption was constant over the aMEDr categories 
in men, whereas in women slightly higher intakes were observed with closer adherence to 
the MD. Distributions of potential (colorectal) cancer risk factors (e.g., smoking status, BMI, 
and physical activity) over the aMEDr categories in the NLCS subcohort have been described 
in detail previously [45]. Comparing the highest to the lowest aMEDr category, subcohort 
members adhering more closely to the MD were less likely to smoke at baseline, had a lower 
BMI, and were more physically active. Generally, comparable levels of MD adherence were 
observed among colorectal cancer cases and subcohort members of both sexes, with mean 
aMEDr values of approximately 4 (Table 6.2). Considering other baseline characteristics, 
male and female colorectal cancer cases were more often former smokers compared to 
subcohort members, but less often current smokers (except female rectal cancer cases, Table 
6.2). Additionally, levels of physical activity and alcohol consumption were higher in male, 
but lower in female, colorectal cancer cases. Furthermore, colon cancer cases were more 
likely to be highly educated than subcohort members (men only), whereas the opposite 
was observed for rectal cancer cases. Finally, colorectal cancer cases of both sexes more 
frequently reported a family history of this disease. 
Table 6.3 presents sex-specific and multivariable-adjusted associations of aMED, including 
and excluding alcohol, with risks of colorectal cancer and anatomical subsites. Age-adjusted 
associations can be found in Supplementary Table S6.1. Not all eligible subjects could be 
included in the Cox models because of missing information on covariates.
In men, aMEDr was not significantly associated with colorectal cancer risk in categorical 
and continuous analyses [HRper two-point increment (95% CI): 1.04 (0.95 – 1.13)] (Table 6.3). Subsite-
specific HR estimates per two-point increment in aMEDr (all not statistically significant) 
ranged from 0.98 for distal colon cancer to 1.11 for rectal cancer and did not significantly 
differ [pheterogeneity: 0.566 (proximal vs. distal colon) and 0.518 (colon vs. rectum)]. Similar to 
men, no significant association was observed between aMEDr and colorectal cancer risk in 
women [HRper two-point increment (95% CI): 0.97 (0.88 – 1.07)] (Table 6.3). However, middle vs. low 
aMEDr values were associated with a borderline significantly reduced colorectal cancer risk 
[HR (95% CI): 0.86 (0.73 – 1.00)]. Though subsite-specific associations were all not statistically 
significant and there was no evidence of heterogeneity [pheterogeneity: 0.690 (proximal vs. distal 
colon) and 0.194 (colon vs. rectum)], results suggested a weak inverse association between 
aMEDr and rectal cancer risk in women [HRper two-point increment (95% CI): 0.91 (0.76 – 1.08)]. 
Comparable results were obtained for the original aMED including alcohol in both men and 
women (Table 6.3). For colorectal cancer risk, inclusion of alcohol in the MD score resulted 
in a worse model fit.
Associations of aMEDr with colorectal cancer risk in women differed statistically significantly 
across strata of smoking status (pinteraction=0.015, Table 6.4). In female ex-smokers, increasing 
aMEDr values were associated with a significantly reduced colorectal cancer risk [HRper two-
point increment (95% CI): 0.78 (0.63 – 0.98)]. In contrast, a positive association was suggested 
in female current smokers, with a significant positive trend over the aMEDr categories 
(ptrend=0.04, data not shown). Finally, there was no evidence of an association in women who 
had never smoked. No significant interactions were observed between aMEDr and other 
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potential colorectal cancer risk factors (alcohol consumption, BMI, educational level, and 
family history of colorectal cancer) in men and women, or smoking status in men (Table 6.4). 
Simultaneous inclusion of all aMEDr components as dichotomous variables in multivariable-
adjusted models showed that none of the individual components was significantly associated 
with colorectal cancer risk (data not shown). Associations were comparable after exclusion 
of the first two years of follow-up and did not significantly differ across the three follow-up 
periods (data not shown). 
Like the population-dependent aMED indices, the absolute WCRF/AICR diet scores (including 
and excluding alcohol) were not significantly associated with risks of colorectal, colon, and 
rectal cancer in men and women (Table 6.5). Performances of models containing aMED 
indices and WCRF/AICR diet scores were mostly comparable.  
Discussion 
In this prospective cohort study, a priori defined MD adherence, assessed by aMEDr, was 
not significantly associated with colorectal cancer risk. Associations were absent for all 
investigated anatomical subsites and in both men and women. The association between 
aMEDr and colorectal cancer risk in women was significantly modified by smoking status 
(pinteraction=0.015). A significant inverse association was observed in female ex-smokers, 
whereas a positive association was suggested in female current smokers. For colorectal 
cancer risk, the best model performance was obtained when alcohol intake was not included 
in the MD score. 
Various prospective cohorts have investigated the relation of a priori defined MD adherence 
with colorectal cancer risk and indicated disparate associations for men and women. In men, 
higher MD adherence has fairly consistently been associated with a reduced colorectal cancer 
risk (but not always significant) [9, 10, 13, 16, 17, 20]. For example, in male participants of 
the Multiethnic Cohort Study (MEC), the National Institutes of Health-American Association 
of Retired Persons (NIH-AARP) Diet and Health Study, and the Health Professionals Follow-
up Study (HPFS), statistically significant HR estimates of 0.84, 0.72, and 0.80, respectively, 
were obtained when comparing high to low aMED values [13, 16, 20]. Furthermore, high 
compared to low MD adherence (modified Mediterranean diet score) was associated with a 
non-significantly reduced colorectal cancer risk in the male part of the EPIC cohort [HR (95% 
CI): 0.89 (0.76 – 1.04)] [10]. With some exceptions [9, 12], studies in women did not support 
the presence of an inverse association between MD adherence and colorectal cancer risk 
[10, 13, 15-18, 20]. For comparison, non-significant HR estimates of 0.96 (MEC), 0.89 (NIH-
AARP), 0.99 (Nurses’ Health Study, NHS), and 0.88 (EPIC), were reported for high vs. low 
MD adherence in female participants of the abovementioned studies [10, 13, 16, 20]. In 
the present analysis of the NLCS, a priori defined MD adherence was not associated with 
a significantly decreased risk of colorectal cancer in both sexes. Similar to our analysis, the 
majority of the previously conducted studies used aMED (variants) to assess MD adherence. 
However, the particular food items included in the aMED components may have differed 
between studies, which could (partly) explain the contrasting results that we observed for 
men in our cohort. Additionally, the more homogenous nature of the NLCS study population 
may have resulted in relatively small contrasts in absolute food intakes between subjects in 
the highest and lowest adherence categories making it more difficult to detect potentially 
beneficial effects of the MD on health outcomes. Median daily intakes among male NLCS 
subcohort members in the highest and lowest aMEDr categories were for example 266 g and 
Mediterranean diet and colorectal cancer risk
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Table 6.4  Sex-specific and multivariable-adjusted associations of aMEDr (per two-point increment) with 
colorectal cancer risk for various subgroups in the Netherlands Cohort Study
Colorectal cancer
Men Women
Cases HR (95% CI)a b Cases HR (95% CI)a b 
Cigarette smoking statusc
Never 256 1.11 (0.87 - 1.41) 915 1.00 (0.88 - 1.13)
Former 1184 1.03 (0.92 - 1.15) 350 0.78 (0.63 - 0.98)
Current 553 1.02 (0.85 - 1.22) 309 1.21 (0.96 - 1.51)
Pinteraction
d 0.714 0.015
Alcohol consumptione
0 g/day 235 1.14 (0.90 - 1.46) 489 1.04 (0.86 - 1.25)
>0 - <15.0 g/day 934 1.05 (0.92 - 1.19) 865 0.97 (0.86 - 1.10)
≥15.0 g/day 824 0.98 (0.85 - 1.13) 220 0.88 (0.66 - 1.17)
Pinteraction
d 0.731 0.539
Body mass indexf
≥18.5 - <25.0 kg/m2 970 1.04 (0.92 - 1.17) 848 1.03 (0.90 - 1.17)
≥25.0 kg/m2 1018 1.05 (0.92 - 1.19) 707 0.90 (0.78 - 1.04)
Pinteraction
d 0.876 0.232
Highest level of educationg
Primary school or lower vocational 863 0.97 (0.84 - 1.12) 841 0.95 (0.84 - 1.08)
Secondary school or medium vocational 706 1.04 (0.90 - 1.19) 579 1.00 (0.84 - 1.19)
Higher vocational or university 424 1.21 (0.98 - 1.50) 154 1.08 (0.79 - 1.47)
Pinteraction
d 0.133 0.920
Family history of colorectal cancerh
No 1811 1.06 (0.97 - 1.16) 1412 0.99 (0.89 - 1.09)
Yes 182 0.82 (0.55 - 1.23) 162 0.90 (0.59 - 1.39)
Pinteraction
d 0.204 0.423
Abbreviation: aMEDr, alternate Mediterranean diet score without the alcohol component 
 
a All HRs were estimated per two-point increment in aMEDr. 
b Adjusted for age at baseline (years), cigarette smoking status (never, former, current), cigarette smoking 
frequency (cigarettes smoked per day, centered), cigarette smoking duration (years, centered), body mass index 
(kg/m2), alcohol consumption (0, >0-<5, ≥5-<15, ≥15-<30, ≥30 g/day), daily energy intake (kcal), highest level 
of education (primary school or lower vocational, secondary school or medium vocational, higher vocational 
or university), non-occupational physical activity (≤30, >30-≤60, >60-≤90, >90 min/day), and family history of 
colorectal cancer (no, yes). 
c Not adjusted for cigarette smoking status. 
d P-values for interaction were obtained by testing the statistical significance of interaction terms between 
aMEDr and the stratifying covariates in multivariable-adjusted models. 
e Not adjusted for alcohol consumption. 
f Not adjusted for body mass index. 
g Not adjusted for highest level of education.  
h Not adjusted for family history of colorectal cancer. 
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177 g for vegetables, 230 g and 120 g for fruits, and 101 g and 139 g for red and processed 
meats, respectively. In male participants of the HPFS [20], the mean numbers of servings 
per day in the highest and lowest aMED quintiles were 4.9 and 2.0 for vegetables, 2.6 and 
0.8 for fruits, and 0.7 and 1.2 for red and processed meats. We calculated ratios comparing 
median/mean intakes in the highest and lowest MD categories. The ratios showed clearly 
higher contrasts in intakes of vegetables and fruits in the HPFS [vegetables: 1.5 (NLCS) vs. 
2.5 (HPFS), fruits: 1.9 (NLCS) vs. 3.3 (HPFS)]. The contrast in the intake of red and processed 
meats was comparable in both cohorts [0.7 (NLCS) vs. 0.6 (HPFS)]. We were forced to 
compare median daily intakes in the NLCS with mean numbers of servings per day in the 
HPFS, because there were no other data available. Despite our relatively homogeneous 
study population, we previously detected significant inverse associations between aMEDr 
and risks of esophageal squamous cell carcinoma, gastric cardia adenocarcinoma (GCA), and 
gastric non-cardia adenocarcinoma (GNCA) in men in the NLCS [46], suggesting sufficient 
contrast. In female NLCS participants, associations of aMEDr with risks of GCA and GNCA 
were also inverse, but did not reach statistical significance. 
None of the aMEDr components was individually associated with colorectal cancer risk in 
the present study. Possibly, the individual effects of the aMEDr components were too weak 
to be detected. Combining these components into a dietary pattern score increases the 
likelihood that the potentially weak individual effects are being detected. Furthermore, 
by investigating the effect of a dietary pattern, one allows for synergistic or antagonistic 
interactions between the dietary components, and solves confounding and collinearity 
problems associated with the analysis of single food groups. Finally, the contrast within 
the study population in terms of overall healthiness of the diet is possibly increased when 
considering the MD as a whole, which increases the chance of detecting true effects, if 
present [31, 47, 48].
The potentially distinct etiological backgrounds of tumors arising in the proximal colon, distal 
colon, and rectum and varying exposures to (carcinogens in) fecal matter across subsites 
may cause heterogeneous susceptibilities to (lifestyle) risk factors [21, 49]. Subsite-specific 
analyses in the NIH-AARP and HPFS cohorts demonstrated that the inverse association 
between MD adherence and colorectal cancer risk in men was particularly pronounced 
for distal colon cancer and rectal cancer [13, 20]. However, associations did not seem to 
differ across the subsites in men in our study. Additionally, there was no clear evidence for 
heterogeneity across the anatomical subsites in women, both in our cohort and in most 
previous studies [13, 15, 20]. 
In women in our cohort, associations between MD adherence and colorectal cancer risk 
significantly differed across strata of smoking status, with oppositely directed associations 
being observed in former smokers (inverse) and current smokers (positive). Smoking status 
did not significantly interact with MD adherence in female participants of the NHS [20]. 
However, this study did not differentiate between former and current smokers. A possible 
explanation for the interaction with smoking status that we observed is chance, considering 
the large number of tests performed. We recommend that the potentially modifying role 
of smoking status in the association between MD adherence and colorectal cancer risk, as 
well as underlying mechanisms, are investigated in future studies. Preferably, these studies 
should be performed separately for men and women, and distinguish between former and 
current smokers.
Colorectal cancers usually develop slowly over the course of 10 to 15 years [3], making 
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the prospective design and long duration of follow-up major strengths of the present 
study. The large number of cases diagnosed during follow-up facilitated the performance 
of sex-specific analyses for cancers of the colorectum, colon, proximal colon, distal colon, 
and rectum with acceptable statistical power, while adjusting for relevant confounders. 
Additionally, associations were estimated within strata of colorectal cancer risk factors, 
separately for men and women. Since the national population screening program for 
colorectal cancer in the Netherlands started after the end of follow-up of our study [50], it 
could not have influenced the results. Despite the high quality of the dietary information, 
possible measurement error may have attenuated associations. Another limitation is the 
single measurement of diet and lifestyle factors at baseline. Changes in diet and lifestyle 
factors during follow-up may have led to non-differential misclassification and attenuated 
associations. However, the baseline assessment of the NLCS-FFQ has been shown to be 
capable of ranking subjects according to their nutrient intakes relatively well for over at least 
five years [28]. Furthermore, associations between aMEDr and colorectal cancer risk were 
largely similar, and did not significantly differ, across the three periods of follow-up (≤2, >2-
≤10, and >10 years). Residual confounding by unmeasured factors also cannot be excluded. 
Lastly, aMEDr assesses the relative level of MD adherence using population-based cut-offs. 
Therefore, subjects with high scores do not necessarily adhere closely to a traditional MD, 
particularly in non-Mediterranean study populations. Comparison of diets of the Netherlands 
and Greece using previously reported intake data from the EPIC cohort [51] showed that 
mean daily intakes of food groups typically consumed in large amounts in the MD, such as 
vegetables, fruits, and legumes, were lower in participants of the Dutch EPIC cohorts (EPIC-
NL) compared to participants of the Greek EPIC cohort (EPIC-Greece). Mean daily intakes 
of vegetables, fruits, and legumes among men were 131 g, 156 g, and 6 g in EPIC-NL and 
269 g, 234 g, and 33 g in EPIC-Greece, respectively. Among female participants of EPIC-NL 
and EPIC-Greece, mean daily intakes were 128 g and 211 g for vegetables, 183 g and 218 g 
for fruits, and 4 g and 21 g for legumes, respectively. As expected, meat consumption was 
higher in Dutch subjects [EPIC-NL: 141 g (men) and 80 g (women), EPIC-Greece: 68 g (men) 
and 35 g (women)] [51]. Regardless of its use of population-based cut-offs, the model fit of 
aMEDr was generally comparable to that of the absolute WCRF/AICR diet score in our study. 
In conclusion, results of this large prospective cohort study do not support the hypothesis 
that higher MD adherence is associated with a reduced risk of colorectal cancer. MD 
adherence was not significantly associated with the risk of any of the colorectal cancer 
subsites in both men and women.
Mediterranean diet and colorectal cancer risk
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Abstract 
Background
Prostate and urinary bladder cancer are frequently occurring cancers with few risk factors 
identified. We examined the relation of Mediterranean diet (MD) adherence with risks of 
prostate and bladder cancer in the Netherlands Cohort Study (NLCS).
Methods
Data were available for 58279 men and 62573 women, who completed a baseline 
questionnaire on diet and other cancer risk factors. Multiple MD scores, including the 
alternate Mediterranean diet score without alcohol (aMEDr), were calculated to assess 
MD adherence. After 20.3 years of follow-up, 3868 prostate cancer cases (advanced: 1256) 
and 1884 bladder cancer cases could be included in multivariable Cox proportional hazards 
analyses.
Results
aMEDr was not associated with advanced prostate cancer risk [HRper two-point increment (95% 
CI)=1.06 (0.96 – 1.17)]. In contrast, higher aMEDr values were associated with a significantly 
increased risk of nonadvanced prostate cancer (ptrend=0.04). For bladder cancer risk, no 
association was observed with aMEDr [HRper two-point increment (95% CI)=1.00 (0.92 – 1.09)]. 
Absolute scores based on the WCRF/AICR dietary recommendations were not associated 
with prostate or bladder cancer risk.
Conclusions
MD adherence, measured by aMEDr or other MD scores, was not associated with decreased 
risks of advanced prostate cancer and bladder cancer in the NLCS. Higher levels of care-
seeking behavior, screening attendance and prostate cancer awareness in higher educated 
men with healthier lifestyles could potentially explain the positive associations that we 
observed for nonadvanced prostate cancer risk. 
Impact
MD adherence does not seem to reduce the risk of (advanced) prostate cancer or bladder 
cancer. 
Mediterranean diet and risk of prostate and bladder cancer
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Introduction 
Worldwide, cancers of the prostate and urinary bladder were estimated to be the second 
and tenth most commonly diagnosed cancer types in 2018 [1]. Together, these cancer types 
were responsible for over half a million deaths in this year [1]. So far, only advancing age, 
African-American race, family history of prostate cancer and genetic predisposition have 
been identified as established risk factors for prostate cancer [2, 3]. Tobacco smoking is 
the most important risk factor for bladder cancer [4]. Other bladder cancer risk factors 
include Schistosoma haematobium infection, environmental and occupational exposure to 
chemicals, and exposure to arsenic in drinking water [5]. The high incidences, slow disease 
development and progression (prostate cancer), and high recurrence rates (bladder cancer), 
make prostate and bladder cancer suitable targets for preventive approaches [6-8]. 
The traditional Mediterranean dietary pattern (MD) is mainly based on plant foods. Intakes 
of vegetables, legumes, fruits, nuts, whole grains, fish and monounsaturated fatty acids 
(MUFA, from olive oil) are high in the MD, whereas animal foods (e.g., meats and dairy 
products) are consumed in limited amounts. Typically, alcohol is consumed in moderation 
and usually in the form of wine during meals [9-11]. 
Prostate cancer is a disease with a heterogeneous nature. Advanced and more aggressive 
prostate tumors may etiologically differ from early, screening-detected forms that otherwise 
might never have become clinically relevant [2]. Risk factors for prostate cancer subtypes 
(defined by grade, stage or survival) may differ as they may exert their effect via different 
biological pathways [12]. Therefore, effects of potential risk factors on advanced prostate 
cancer risk are of primary interest. Up until now, two prospective cohort studies from 
the United States (US) have evaluated the relation of a priori defined MD adherence with 
advanced prostate cancer risk and did not observe an association [13, 14]. In contrast to the 
results for advanced prostate cancer, the prospective evidence suggests that MD adherence 
might be associated with a reduced risk of (invasive) bladder cancer/urothelial cell carcinoma 
(UCC) [15, 16]. However, the inverse associations were not statistically significant.  
In this analysis of the Netherlands Cohort Study (NLCS), we examined associations between 
a priori defined MD adherence and risks of prostate and urinary bladder cancer. Associations 
were compared for subtypes of the investigated cancer sites classified by stage at diagnosis 
(prostate cancer) or malignancy grade (bladder cancer). In addition, the effect of exclusion 
of alcohol from the MD scores was evaluated and performances of the relative MD scores 
were compared to those of absolute scores based on the dietary recommendations to 
prevent cancer issued by the World Cancer Research Fund/American Institute for Cancer 
Research (WCRF/AICR).  
Materials and methods
Study population and cancer follow-up
The prospective NLCS includes 58279 men and 62573 women, aged 55 to 69 years [17-
20]. Study participants consented to participate by completing a self-administered baseline 
questionnaire on diet and other cancer risk factors in September 1986. A case-cohort 
approach was applied to process and analyze the data efficiently [17, 20, 21]. A subcohort 
(N=5000) was randomly drawn just after baseline to estimate accumulated person-years at 
risk, whereas cases originated from the entire cohort. Subcohort members were followed 
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up biennially for vital status. The NLCS was approved by the institutional review boards from 
Maastricht University and the Netherlands Organization for Applied Scientific Research, and 
was conducted in accordance with the Declaration of Helsinki.  
Incident cancer cases were detected annually for 20.3 years of follow-up (baseline until 
31 December 2006) through record linkage with the Netherlands Cancer Registry and the 
nationwide Dutch Pathology Registry (PALGA) [18]. In total, 3978 prostate cancer cases 
(ICD-O-3 code C61), 2049 bladder cancer cases (ICD-O-3 code C67) and 4084 subcohort 
members (men: 2057, women: 2027) were eligible for inclusion in the present analyses 
(Supplementary Figures S7.1 and S7.2). Prostate cancer cases were classified as nonadvanced 
(N=2397, stages T1/T2, N0 and M0) or advanced (N=1294, stages T3/T4 or N+ or M1) 
at diagnosis, whereas bladder cancer cases were categorized in noninvasive (N=1053, 
malignancy grade 2) and invasive (N=996, malignancy grade 3) subtypes. All included cases 
were microscopically confirmed. Furthermore, eligible cases and subcohort members did 
not have prevalent cancer at baseline (except skin cancer), and had complete and consistent 
data available on diet, alcohol and MD adherence. 
Exposure assessment
At baseline, participants were asked about their usual dietary intake during the previous year 
via a validated, 150-item, semi-quantitative food frequency questionnaire (FFQ) [19, 22]. 
Nutrient intakes were derived from the FFQ data utilizing the 1986 Dutch food composition 
(NEVO) table [23].  
Mediterranean diet adherence
The alternate and modified Mediterranean diet scores (aMED and mMED, respectively) 
were calculated to estimate the relative level of MD adherence [24-26]. These scores are 
adaptations of the traditional Mediterranean diet score (tMED) created by Trichopoulou et 
al. [27, 28] and are each composed of nine dietary components. For aMED [24, 26], 1 point 
(and 0 otherwise) is assigned to mean daily intakes at or above the sex-specific median of 
vegetables (excluding potatoes), legumes, fruits, nuts, whole grains, fish and the ratio of 
MUFA to saturated fatty acids (SFA). Inverse scoring is applied to red and processed meats. 
Finally, 1 point can be obtained for a moderate alcohol consumption, defined as 5-25 g/day 
[24, 26]. mMED [25] differs from aMED as follows: fruits and nuts are combined, total intakes 
of cereal and meat are considered, dairy intake is included (1 point if below sex-specific 
median), and the ratio of unsaturated fatty acids (MUFA + polyunsaturated fatty acids) to 
SFA replaces the MUFA:SFA ratio. Furthermore, other cut-offs are used to define moderate 
alcohol consumption (men: 10-50 g/day, women: 5-25 g/day) [25]. Before calculation of 
the MD scores, food intakes were standardized to daily energy intakes of 2000 (women) 
and 2500 (men) kilocalories [26, 27]. aMED and mMED range from 0 to 9 points (lowest to 
highest MD adherence). Because alcohol consumption has been associated with increased 
risks of several types of cancer [29], we also created aMED and mMED variants without 
alcohol (aMEDr and mMEDr, respectively) ranging from 0 to 8 points. 
Mediterranean diet and risk of prostate and bladder cancer
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Statistical analyses
We evaluated relations between MD adherence and risks of prostate and bladder cancer 
(subtypes) using Cox proportional hazards models with duration of follow-up as time scale 
to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs). Person-years at risk 
in the subcohort were calculated from baseline until prostate or bladder cancer diagnosis, 
death, emigration, loss to follow-up or end of follow-up, whichever came first. Sampling 
from the cohort introduces additional variance. Therefore, standard errors were calculated 
using the Huber-White sandwich estimator [30]. The proportional hazards assumption was 
checked by scaled Schoenfeld residuals tests and visual inspection of –ln(-ln) survival plots 
[31]. 
We tested associations of MD adherence with risks of prostate and bladder cancer (subtypes) 
in age- (and sex-)adjusted and fully adjusted analyses, in which MD scores were modelled 
both categorically [low: 0-3, middle: 4-5, high: 6-8(9)] and continuously (per two-point 
increment) [25, 26]. Men and women were combined in the models for bladder cancer, 
because there was no statistically significant interaction by sex. The fully adjusted models 
concerning prostate cancer risk were adjusted for the following predefined confounders: 
age at baseline, body mass index (BMI), alcohol consumption (except for models containing 
MD scores including alcohol), total daily energy intake, highest level of education and family 
history of prostate cancer. For bladder cancer risk, sex and cigarette smoking behavior 
(status, frequency and duration) were also listed as predefined confounders. Additionally, 
these analyses were adjusted for family history of bladder cancer instead of prostate cancer. 
Other confounders considered, but not included (removal resulted in <10% change in the 
effect estimate of the MD score), were cigarette smoking status (prostate cancer only), 
non-occupational physical activity, history of diabetes, height (prostate cancer only), tea 
consumption and coffee consumption (bladder cancer only). Sex-specific median MD score 
values in the subcohort were appointed to each adherence category and fitted continuously 
in Cox regression models to perform trend tests. A competing risks procedure was applied to 
test for heterogeneity across the prostate and bladder cancer subtypes [32]. Standard errors 
for the observed differences were estimated using a bootstrapping method specifically 
designed for the case-cohort approach [33].   
Model fits of the various MD scores considered (aMEDr and mMEDr, with and without 
alcohol) were compared using Akaike’s Information Criterion (AIC) [34]. Because of the equal 
or better performance of aMEDr compared to mMEDr in both the current and previous 
NLCS analyses [35-37], the Results section of this article mainly focuses on associations 
with aMEDr and subgroup analyses were only performed using this score. We preferred 
the aMED variant without alcohol (aMEDr), because alcohol consumption is a risk factor for 
several types of cancer [29].  
Potential effect modification by sex (bladder cancer only), cigarette smoking status (bladder 
cancer only), alcohol consumption, BMI, educational level and family history of prostate/
bladder cancer was explored by testing the statistical significance of interaction terms 
between these factors and aMEDr. Additionally, HRs were estimated for strata of the potential 
effect modifying factors. For prostate cancer risk, we estimated associations with the MD 
scores within time periods before (1986-1994) and after (1995-2006) the introduction of 
prostate-specific antigen (PSA) testing in clinical practice in the Netherlands. Furthermore, 
the effect of excluding the first two years of follow-up was evaluated. 
Because of the use of cohort-specific cut-offs, the MD scores used measure relative levels 
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of MD adherence. Therefore, we also evaluated associations of prostate and bladder cancer 
(subtypes) with an absolute score based on the dietary part of the 2007 cancer prevention 
recommendations published by the WCRF/AICR [38]. The WCRF/AICR score used in the 
current study includes the recommendations concerning intakes of foods and drinks that 
promote weight gain, plant foods, red and processed meats, alcohol and salt. When possible, 
recommendations were operationalized as in the European Prospective Investigation into 
Cancer and Nutrition (EPIC) cohort [39, 40]. For a detailed description of the scoring method 
and the absolute cut-offs used we refer to a previous NLCS article [35]. The resulting sum 
score ranged from 0 to 5 points (lowest to highest adherence). Additionally, we created a 
variant of the WCRF/AICR score without the alcohol recommendation that ranged from 0 to 
4 points. Fully adjusted HRs and 95% CIs were estimated per standard deviation (SD) increase 
in WCRF/AICR score. For comparison, we also estimated HRs and 95% CIs per SD-increment 
for the aMED variables (with and without alcohol). Finally, AIC was used to compare model 
fits of the WCRF/AICR score and aMED variables. All analyses were performed using Stata 
version 15. Two-sided p-values < 0.05 were considered statistically significant.
Results 
Baseline characteristics NLCS subcohort and cases of prostate and bladder cancer
Table 7.1 compares baseline characteristics of subcohort members with those of prostate 
and bladder cancer cases. The mean level of MD adherence was similar for cases and 
subcohort members, except for the slightly lower mean aMEDr value in female noninvasive 
bladder cancer cases. Compared to subcohort members, prostate cancer cases were less 
often current smokers, higher educated (particularly nonadvanced prostate cancer), more 
physically active (particularly nonadvanced prostate cancer) and more likely to have a family 
history of prostate cancer. When comparing nonadvanced with advanced cases at diagnosis, 
nonadvanced cases more frequently had a high level of education and were slightly more 
active. Bladder cancer cases were more often current smokers, consumed higher amounts 
of alcohol and reported more commonly a family history of bladder cancer than subcohort 
members. Patterns were mostly comparable for noninvasive and invasive bladder cancer 
cases.        
Mediterranean diet adherence and risks of prostate and bladder cancer 
Fully adjusted associations of MD adherence with prostate and bladder cancer incidence are 
presented in Tables 7.2 and 7.3, respectively. For age- (and sex-)adjusted associations we 
refer to Supplementary Tables S7.1 (prostate) and S7.2 (bladder). The number of subjects 
included in the Cox models is slightly smaller than the number of eligible participants due to 
missing values in covariates. 
Prostate cancer
Higher MD adherence, measured by aMEDr, was associated with an increased risk of 
prostate cancer [HRper two-point increment (95% CI): 1.09 (1.01 – 1.17)] (Table 7.2). Though, this 
positive association was mainly present in nonadvanced cases. For nonadvanced prostate 
cancer risk, the HR (95% CI) comparing high to low aMEDr values was 1.22 (1.01 – 1.48) 
with a significant test for trend (p=0.04). However, aMEDr was not significantly associated 
Mediterranean diet and risk of prostate and bladder cancer
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with the risk of advanced prostate cancer [HRper two-point increment (95% CI): 1.06 (0.96 – 1.17)]. 
Despite this difference between the prostate cancer subtypes, tests for heterogeneity were 
not statistically significant. Associations of similar directions were observed when MD 
adherence was assessed using mMEDr and inclusion of alcohol in the MD scores did not 
notably change the results. Comparison of model performances showed equal or better 
(nonadvanced prostate cancer) fits for aMEDr compared to mMEDr (Table 7.2). Additionally, 
model fits were generally better for scores with alcohol than scores without alcohol.  
Associations of aMEDr with risks of nonadvanced and advanced prostate cancer did not 
significantly differ across strata of potential effect modifiers (Table 7.4). Nevertheless, 
increasing aMEDr was associated with a significantly increased risk of both prostate cancer 
subtypes among men in the highest education category, whereas there was no clear 
evidence of an association in the other education categories. Results were comparable 
after exclusion of the first two years of follow-up [HRper two-point increment in aMEDr: 1.09 (total), 1.13 
(nonadvanced), 1.06 (advanced)]. Additionally, the strength of the associations did not 
significantly differ before (1986-1994) and after (1995-2006) the introduction of PSA testing 
in clinical practice in the Netherlands (Table 7.4). However, the positive association between 
aMEDr and nonadvanced prostate cancer risk was only statistically significant in the late 
period (1995-2006). 
Bladder cancer
MD adherence was not significantly associated with bladder cancer risk, regardless of the 
MD score used (Table 7.3). HRs (95% CIs) per two-point increase in aMEDr were 1.00 (0.92 
– 1.09), 1.01 (0.92 – 1.12) and 0.99 (0.89 – 1.09) for total, noninvasive and invasive bladder 
cancer, respectively. In contrast to the fully adjusted analyses, inverse trends (not always 
significant) seemed to be present between MD adherence and risks of total and invasive 
bladder cancer in age- and sex-adjusted analyses (p=0.04 for mMED and invasive bladder 
cancer, Supplementary Table S7.2). Comparable performances were observed for models 
containing aMEDr and mMEDr (Table 7.3). Furthermore, MD scores without alcohol fitted 
equally or better than their equivalents including alcohol.  
There was no evidence of effect modification by sex, cigarette smoking status, alcohol 
consumption, educational level and family history of bladder cancer (Table 7.5). Higher 
aMEDr values seemed to be associated with a non-significantly decreased risk of bladder 
cancer in subjects with a normal BMI, but not in overweight or obese subjects [pinteraction: 
0.026 (total), 0.037 (noninvasive), 0.128 (invasive)]. Associations did not essentially change 
after exclusion of the first two years of follow-up [HRper two-point increment in aMEDr: 1.01 (total), 1.02 
(noninvasive), 1.00 (invasive)]. 
Dietary WCRF/AICR recommendations and risks of prostate and bladder cancer
Because values of aMED indices are population-dependent, we compared these indices 
to absolute WCRF/AICR scores (Table 7.6). The WCRF/AICR scores were not significantly 
associated with prostate and bladder cancer risk, but as with the aMED indices, associations 
with prostate cancer risk were in the positive direction. For prostate cancer risk, WCRF/AICR 
scores had worse model fits compared to aMED indices, particularly when considering the 
nonadvanced subtype (Supplementary Table S7.3). Comparable model performances were 
observed for bladder cancer risk (Supplementary Table S7.3).  
Mediterranean diet and risk of prostate and bladder cancer
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Discussion 
In the large prospective NLCS, a priori defined MD adherence (aMEDr) was associated with 
a significantly increased risk of nonadvanced prostate cancer. In contrast, no association 
was observed with advanced prostate cancer risk. MD adherence was not associated with 
risks of total, noninvasive and invasive bladder cancer. Model fits were equal or better for 
aMEDr compared to mMEDr. Additionally, inclusion of alcohol in the MD scores resulted in 
generally better model fits for prostate cancer risk, whereas the opposite was observed for 
bladder cancer risk. Finally, adherence to the dietary WCRF/AICR recommendations was not 
associated with risks of both prostate and bladder cancer. 
Previously conducted cohort studies in the US and Europe consistently found no association 
between a priori defined MD adherence and prostate cancer risk [13, 14, 41, 42]. Similar 
results were obtained when focusing on advanced cases of prostate cancer specifically [13, 
14]. Case-control studies showed less consistent results. One study observed a significant 
inverse association between a priori defined MD adherence and prostate cancer risk, whereas 
no relation was present in another study [43, 44]. The vulnerability of the case-control design 
to several types of bias, including recall and selection biases, could potentially explain this 
inconsistency. Furthermore, prospective cohort studies may also have some limitations. For 
example, reliance on a single assessment of dietary intake at baseline may lead to exposure 
misclassification and attenuated associations. Although exposure misclassification could 
have contributed to the null findings of the previously conducted cohort studies, some 
cohorts did have updated dietary information available during follow-up [14, 42].  
Results of the present study were partially in concordance with results of previous cohort 
studies. We found higher MD adherence to be significantly associated with an increased 
risk of nonadvanced prostate cancer, while there was no evidence of an association with 
advanced prostate cancer risk. Prostate cancer is a heterogeneous disease with potentially 
etiologically different subtypes that may differ in risk factors [2, 12, 45]. The subgroup of 
nonadvanced cancers at diagnosis mainly encompasses relatively nonaggressive forms 
of prostate cancer that progress slowly and might never have become clinically relevant. 
Approximately half of the diagnosed prostate cancers were estimated to not have caused any 
harm if they had remained undiagnosed and untreated [45]. The prevalence of undiagnosed 
prostate cancer in elderly men is high, in 47.3% of US White and European men above the 
age of 80 years incident prostate cancer was detected at autopsy [45]. Due to the often 
indolent nature of nonadvanced prostate cancers, advanced prostate cancer is the subtype 
of our primary interest. In this study, MD adherence was not significantly associated with 
advanced prostate cancer risk. 
The significant positive associations that we observed between MD adherence and 
nonadvanced prostate cancer risk could potentially be explained by differences in care-
seeking behavior, screening attendance and prostate cancer awareness related to education 
and lifestyle. Male NLCS subcohort members with higher MD adherence overall seemed to 
have a healthier lifestyle judged by lower levels of smoking and alcohol consumption, and 
higher levels of physical activity, and were higher educated [36]. Higher educated men with 
a more health-conscious lifestyle may be more aware of prostate cancer and more prone to 
seek care or attend screenings, resulting in a larger number of nonadvanced prostate cancer 
diagnoses in this group, part of which never would have become clinically relevant and 
otherwise would have remained undiagnosed. Nonadvanced prostate cancer cases in our 
study were more physically active and higher educated than advanced cases and subcohort 
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members, implying a healthier lifestyle. Furthermore, the positive association between 
MD adherence and nonadvanced prostate cancer risk was strongest and only statistically 
significant in the highest education category, which fits our hypothesis that nonadvanced 
prostate tumors are more likely to be detected in highly educated men. Finally, results of 
our stratified analyses by follow-up period showed that the positive association between 
MD adherence and nonadvanced prostate cancer risk only reached statistical significance 
in the period after the introduction of PSA testing in clinical practice in the Netherlands 
(1995-2006). 
Similar to our findings for bladder cancer risk, a priori defined MD adherence was not 
significantly associated with total UCC risk in the prospective EPIC and Melbourne 
Collaborative Cohort Study (MCCS) cohorts [15, 16]. Although not statistically significant, 
HR estimates for risks of total, nonaggressive and aggressive UCC in EPIC were suggestive of 
an inverse association with MD adherence [15]. Additionally, higher MD adherence seemed 
to be associated with a decreased risk of invasive UCC (p=0.06), but not superficial UCC, in 
the Australian MCCS [16]. HR estimates in our study were much closer to unity. Residual 
confounding by cigarette smoking, which is the most important bladder cancer risk factor 
[4], could (partially) explain the non-significant inverse associations between MD adherence 
and (invasive) UCC risk that were observed in the previously conducted prospective studies. 
The adjustment for cigarette smoking seemed to be less comprehensive in these studies 
compared to the present study and the inverse associations were restricted to (former 
and) current smokers. Besides, we also observed (non-significant) inverse associations with 
invasive bladder cancer risk when we only adjusted our models for age and sex. Very recently, 
a pooled analysis of 13 prospective cohorts showed that MD adherence was associated 
with a significantly decreased risk of total, non-muscle-invasive and muscle-invasive bladder 
cancer [46]. However, this study did not sufficiently adjust for smoking behavior. Finally, an 
Italian hospital-based case-control study found higher MD adherence to be associated with 
a significantly decreased UCC risk [47]. 
In this study, BMI significantly modified the association between MD adherence and 
risks of total and noninvasive bladder cancer, with non-significant inverse associations 
being observed among subjects with a normal BMI, but not among overweight or obese 
subjects. An inverse association has been suggested between BMI and levels of urinary 
8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, particularly in smokers [48]. 
Therefore, subjects with a normal BMI potentially benefit most from the high antioxidant 
content (e.g., vitamins and polyphenols) of the MD [49, 50]. However, this interaction could 
also be a chance finding. The interaction with BMI was not detected in the EPIC cohort [15] 
and requires attention in future research. The association of MD adherence with bladder 
cancer risk did not significantly differ across strata of other potential effect modifiers 
including sex and smoking status.
Major strengths of the NLCS are its prospective design and the nearly complete follow-up 
of 20.3 years. The large number of prostate and bladder cancer cases allowed subtype-
specific analyses based on tumor stage/invasiveness at diagnosis, extensive adjustment 
for confounding and stratified analyses for potential effect modifying factors. Despite 
the comprehensive adjustment for cigarette smoking habits in the analyses concerning 
bladder cancer risk, residual confounding by smoking (bladder cancer) or unmeasured 
factors (prostate and bladder cancer) could still have affected our results. For example, we 
had no information about PSA testing. Nevertheless, associations of MD adherence with 
prostate cancer risk did not statistically significantly differ in time periods before and after 
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the introduction of PSA testing in the Netherlands, making a relevant effect on our results 
unlikely. Moreover, we were not able to adjust the analyses concerning bladder cancer 
risk for environmental and occupational exposures to chemicals or exposure to arsenic in 
drinking water. A final strength of our study includes the high quality of the dietary data. 
The single baseline measurement of the NLCS-FFQ was shown to perform adequately when 
compared to nine-day dietary records and dietary habits were reproducible for over at 
least five years [19, 22]. However, changes in dietary habits and confounding factors after 
baseline as well as measurement errors may have attenuated associations. The population-
dependent assignment of scores is a weakness of the MD scores that we used to assess 
MD adherence. Therefore, high MD score values may not necessarily represent a truly 
Mediterranean way of eating, especially in the Netherlands and other non-Mediterranean 
countries. Nonetheless, largely similar results were obtained when we used absolute scores 
based on the WCRF/AICR dietary recommendations to prevent cancer. Additionally, aMED-
containing models performed equally well or better than models containing WCRF/AICR 
scores in our study population. 
In conclusion, high adherence to the MD was not associated with decreased risks of advanced 
prostate cancer as well as total, noninvasive and invasive bladder cancer in the NLCS. The 
positive associations that we observed between MD adherence and nonadvanced prostate 
cancer risk potentially resulted from higher levels of care-seeking behavior, screening 
attendance and prostate cancer awareness in higher educated men with healthier lifestyles, 
causing a larger number of nonadvanced prostate cancer diagnoses in this group. Therefore, 
we recommend that future studies on dietary factors and prostate cancer risk also report 
results specifically for advanced prostate cancer. 
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The principal aim of this thesis was to evaluate the association of Mediterranean diet (MD) 
adherence with risks of overall cancer and specific cancer types in the Netherlands in a 
prospective setting. This aim was primarily studied within the Netherlands Cohort Study 
on Diet and Cancer (NLCS). However, for pancreatic cancer, we additionally used data 
collected as part of the Dutch cohort of the European Prospective Investigation into Cancer 
and Nutrition (EPIC-NL). The relative level of MD adherence was assessed using two a 
priori defined MD scores: the alternate Mediterranean diet score (aMED) and the modified 
Mediterranean diet score (mMED). Although moderate consumption of wine during meals 
is considered beneficial in the traditional MD, alcohol consumption has been related to 
increased risks of several types of cancer. Therefore, we created score variants without the 
alcohol component (aMEDr and mMEDr, respectively) and compared these to the original 
scores (including alcohol component). Special attention was paid to potential heterogeneity 
of associations across the sexes and subtypes of specific cancer sites.
In this chapter, we will first provide a summary of the most important findings of this thesis. 
Subsequently, we will try to put these findings into perspective by relating them to previously 
published prospective research evaluating the effect of a priori defined MD adherence 
and discussing some methodological considerations. Furthermore, the implications of our 
findings for policymakers and the Dutch society will be addressed. We will end this chapter 
with our recommendations for future research.   
1. Summary of the main findings 
In this section, we will highlight the most important results of this thesis. For most cancer 
sites, equal or better model fits were observed when MD adherence was assessed using 
aMEDr as opposed to mMEDr. Therefore, we will focus on results obtained for aMEDr in the 
description and interpretation of our main findings. Additionally, we prefer the aMED variant 
without alcohol (aMEDr), because alcohol consumption is a well-established risk factor for 
multiple cancer types [1-3]. The most important findings of this thesis are summarized in 
Table 9.1. For associations between mMEDr and the investigated cancer sites, we refer to 
the corresponding chapters of this thesis. 
First, we investigated the association of MD adherence with lung cancer incidence (Chapter 
2), showing non-significant inverse associations when comparing the highest to the lowest 
aMEDr category in both men and women. The inverse associations appeared to be strongest 
in women and never smokers (pinteraction>0.05 in both cases). Although heterogeneity tests did 
not reach statistical significance, the strength of the associations seemed to vary somewhat 
across the histological lung cancer subtypes, especially in men.  
Furthermore, higher adherence to the MD was associated with a significantly reduced 
risk of estrogen receptor (ER) negative postmenopausal breast cancer in the NLCS, as we 
showed in Chapter 3. Weaker, and not statistically significant, inverse associations were 
observed for risks of total and ER positive postmenopausal breast cancer. Similar patterns 
were observed for progesterone receptor (PR) and combined ER/PR subtypes. Additionally, 
we performed meta-analyses including our results and those of previously published cohort 
studies. Results of these meta-analyses were consistent with the NLCS findings.
Different etiologies have been suggested for subtypes of esophageal and gastric cancer. 
Therefore, subtype-specific associations of these cancer sites with MD adherence were 
evaluated in Chapter 4. In both sexes, higher MD adherence was associated with decreased 
risks of gastric cancer subtypes [i.e., gastric cardia adenocarcinoma (GCA) and gastric non-
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cardia adenocarcinoma (GNCA)]. However, the inverse associations were only statistically 
significant in men. For esophageal squamous cell carcinoma (ESCC) risk, associations 
significantly differed between the sexes. A statistically significant inverse association was 
observed in men, whereas there was no evidence of an association in women. MD adherence 
was not associated with esophageal adenocarcinoma (EAC) risk in both men and women.  
In Chapter 5, the association between MD adherence and pancreatic cancer incidence was 
examined by pooling results of the NLCS and EPIC-NL. In these analyses, MD adherence was 
not significantly associated with risk of microscopically confirmed pancreatic cancer (MCPC) 
in both sexes. Our findings suggested that the association between MD adherence and MCPC 
risk might be modified by smoking status. Weak and non-significant inverse associations 
were observed in never smokers, but not in ever smokers. The overall conclusion was similar 
when we also included cases that were not microscopically confirmed in the analyses.
Similarly, we observed no significant association between MD adherence and colorectal 
cancer risk (Chapter 6). Associations were absent for all anatomical subsites (i.e., colon, 
proximal colon, distal colon, and rectum) in both men and women.
In Chapter 7, aMEDr was not associated with the risk of advanced prostate cancer. However, 
a statistically significant positive association was observed for nonadvanced prostate cancer 
risk. Possibly, nonadvanced prostate tumors have a higher chance of being detected in 
higher educated men with a more health-conscious lifestyle and greater adherence to the 
MD, who may be more aware of prostate cancer and more likely to seek care or attend 
screening programs. For bladder cancer risk (Chapter 7), we did not observe an association 
with MD adherence, regardless of the malignancy grade at diagnosis.
Finally, the association of MD adherence with overall cancer incidence was evaluated in 
Chapter 8. Although not statistically significant, increasing MD adherence seemed to be 
associated with a decreased risk of cancer in women. However, there was no evidence of 
an inverse association in men. In addition, we compared associations with MD adherence 
for subgroups of cancers related vs. not related to tobacco smoking, obesity, and alcohol 
consumption, and concluded that these did not relevantly differ, irrespective of sex. In men, 
heterogeneity tests were significant for all subgroup comparisons made, but differences 
were small and probably reached statistical significance because of the large number of 
cases. 
For the findings described above, MD adherence was assessed using aMEDr, which does 
not include alcohol. Largely similar results were obtained when we used the original aMED 
including alcohol component. Generally, inclusion of alcohol in the MD score either did not 
affect the model performance or resulted in a worse model fit. 
2. Interpretation of the main findings 
In our analyses conducted in the Dutch population, MD adherence seemed to be associated 
with (non-significantly) reduced risks of some cancer types (i.e., cancers of the lung and 
breast, ESCC, GCA, and GNCA). Many of these cancer (sub)types have a relatively poor 
prognosis, underlining the importance of the development of successful preventive 
strategies for these cancer sites.  
Closer adherence to an a priori defined MD has consistently been associated with a decreased 
lung cancer risk in prospective studies [4-7]. The largest cohort evaluating this relation was 
the National Institutes of Health-American Association of Retired Persons (NIH-AARP) Diet 
and Health Study (9272 incident lung cancer cases among 460770 eligible participants) [5], 
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Table 9.1  Summary of the main findings of this thesis with respect to the association between Mediterranean 
diet adherence and cancer risk in the Netherlandsa b
Men Women Chapter
- Alcohol + Alcohol - Alcohol + Alcohol
aMEDr aMED aMEDr aMED
Lung (-) (-) (-) (-) 2
- Adenocarcinoma 0 (-)
- Squamous cell carcinoma (-) (-)
- Small cell carcinoma (-) (-)
- Large cell carcinoma 0 0
Breast (postmenopausal)c (-) (-) 3
- ER+ (-)
- ER- -
Esophagus 4
- ESCC - - 0 0
- EAC 0 0 0 0
Stomach 4
- GCA - (-) (-) (-)
- GNCA - - (-) (-)
Pancreas (MCPC) 0 0 0 0 5
Colorectum 0 0 0 0 6
- Colon 0 0 0 0
- Rectum 0 0 0 0
Prostate + + 7
- Nonadvanced + +
- Advanced 0 0
Bladderd 0 0 0 0 7
- Noninvasive 0 0 0 0
- Invasive 0 0 0 0
Overall cancer 0 0 (-) (-) 8
Abbreviations: aMEDr, alternate Mediterranean diet score without the alcohol component; aMED, alternate 
Mediterranean diet score; ER+, estrogen receptor positive; ER-, estrogen receptor negative; ESCC, esophageal 
squamous cell carcinoma; EAC, esophageal adenocarcinoma; GCA, gastric cardia adenocarcinoma; GNCA, gastric 
non-cardia adenocarcinoma; MCPC, microscopically confirmed pancreatic cancer; NLCS, Netherlands Cohort 
Study; EPIC-NL, the Dutch cohort of the European Prospective Investigation into Cancer and Nutrition; PR+, 
progesterone receptor positive; PR-, progesterone receptor negative
a Associations were estimated within the NLCS for all cancer sites. For pancreatic cancer, the presented 
associations were obtained by pooling results from the NLCS and EPIC-NL.  
b - inverse association; (-) inverse association, not statistically significant; 0 null association; (+) positive 
association, not statistically significant; + positive association. 
c Patterns for the PR+/PR- and the combined ER/PR subtypes resembled the pattern that was observed for the 
ER+/ER- subtypes. 
d The presented associations for bladder cancer risk were determined in men and women combined.
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which showed that MD adherence was associated with a significantly reduced lung cancer risk 
in both sexes in the US. Subtype-specific analyses revealed that the inverse association was 
statistically significant for adenocarcinoma and squamous cell carcinoma, but not for small 
cell carcinoma. Likewise, the strength of the association with MD adherence also seemed 
to vary across the histological subtypes in this thesis. Additionally, our results indicated that 
the potentially beneficial effect of MD adherence on lung cancer risk might be slightly more 
pronounced in women compared to men. The small number of incident lung cancer cases in the 
other cohorts possibly hampered detailed evaluations of subtype- or sex-specific associations. 
Tobacco smoking is by far the strongest risk factor for lung cancer [1]. Because smoking often 
coincides with an unhealthy diet and lifestyle, residual confounding by tobacco smoking is 
a major concern in the analysis of dietary factors and lung cancer risk. It is unlikely that the 
non-significant inverse associations of MD adherence with lung cancer risk that we observed 
can fully be attributed to residual confounding by tobacco smoking. We adjusted extensively 
for potential confounding by cigarette smoking through the inclusion of smoking status, 
frequency, and duration in our multivariable models. Moreover, associations were also in 
the inverse direction when we only considered NLCS participants who had never smoked. 
Furthermore, our results suggested that MD adherence might reduce postmenopausal 
breast cancer risk, particularly of the ER negative subtype. The effect of a MD supplemented 
with either extra-virgin olive oil or mixed nuts compared to a low-fat control diet on 
postmenopausal breast cancer risk was evaluated in the randomized Prevención con Dieta 
Mediterránea trial [PREDIMED, 35 incident breast cancer cases diagnosed among 4282 
Spanish women with high cardiovascular disease (CVD) risk] [8]. After a median follow-
up of 4.8 years, incidence rates of postmenopausal breast cancer turned out to be (non-
significantly) lower in the MD groups. Additionally, the association between a priori defined 
MD adherence and breast cancer risk has been investigated in a number of cohort studies 
[7, 9-17]. For an elaborate discussion of the literature concerning MD adherence and breast 
cancer risk we refer to Chapter 3 of this thesis. Since we wrote this chapter, several additional 
prospective investigations have been published [7, 15-17], of which the study by Petimar et al. 
[17] is of particular interest. This study showed that MD adherence was inversely associated 
with breast cancer risk in US women with a family history of breast cancer. Although the 
inverse associations were not statistically significant for all hormone receptor subtypes, 
they seemed slightly more pronounced for ER negative breast cancers, with the strongest 
inverse relation being observed for triple-negative breast cancer [17]. Considering the 
prospective cohort evidence in its totality, one may conclude that the inverse association of 
MD adherence with breast cancer risk, if present, seems to be restricted to postmenopausal 
women. Genetic and early life factors may play a more important role in premenopausal 
disease [10, 12, 18, 19]. Despite some heterogeneity, findings for the hormone receptor 
subtypes indicated that the potentially protective effect of MD adherence might be more 
pronounced for ER negative breast cancers. Possibly, (weak) relations of dietary factors with 
ER negative breast cancers are easier to detect, because of the strong influence of hormonal 
factors on ER positive breast cancers [9, 12].  
For esophageal cancer, we found MD adherence to be significantly inversely associated with 
ESCC risk among men, whereas no association was observed with EAC risk, regardless of sex. 
The heterogeneous associations for ESCC and EAC risk were not unexpected, as varying risk 
factors and incidence trends suggest different etiological backgrounds [20, 21]. In line with 
this thesis, a similar pattern for the esophageal cancer subtypes was observed in the only 
other cohort study (NIH-AARP) conducted on this topic [22]. Additionally, the significantly 
reduced ESCC risk upon higher levels of MD adherence in the NIH-AARP cohort seemed to 
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be restricted to men as well. 
Concerning the gastric cancer subtypes, findings of prospective studies are inconclusive 
[22, 23]. In the NIH-AARP cohort [22], MD adherence was not significantly associated with 
a reduced risk of either subtype. Nonetheless, the results were indicative of a possible 
inverse association with GNCA risk. Although both gastric cancer subtypes were inversely 
associated with MD adherence in EPIC [23], statistical significance was only reached for 
GCA risk. The EPIC cohort involves centers from ten European countries of which three are 
located in the Mediterranean region (i.e., Greece, Italy, and Spain) [24]. In our analyses of 
the NLCS, the (non-significant) inverse associations with MD adherence seemed to be of 
roughly comparable strength for GCA and GNCA risk. Of note, neither our study nor the 
NIH-AARP and EPIC studies were able to correct for Helicobacter pylori infection, which is 
an important risk factor for GNCA [25] and could potentially have confounded the results.
When examining the relation between dietary patterns and (upper) gastrointestinal cancer 
risk, potential bias resulting from reversed causation should be carefully considered. Already 
before their diagnosis, dietary habits of cases may have been influenced by preclinical 
disease symptoms. When these symptoms would have led to a decreased consumption of 
Mediterranean foods (e.g., vegetables, fruits, or nuts), it may erroneously be concluded 
that MD adherence is protective against gastrointestinal cancers. Results of cohort studies 
are less likely to be affected by reversed causation than results of case-control studies. 
Because exclusion of the first two years of follow-up did not essentially alter our findings for 
esophageal and gastric cancer risk, the inverse associations that we observed probably have 
not resulted from reversed causation. Moreover, results of the NIH-AARP and EPIC cohorts 
were also largely comparable after excluding the first few years of follow-up in a lag analysis 
[22, 23].
MD adherence was not associated with a decreased incidence of cancers of the pancreas, 
colorectum (any subsite), prostate (advanced), and bladder in this thesis. However, 
previously published prospective studies did suggest a potentially beneficial effect of a priori 
defined MD adherence on colorectal and bladder cancer risk.
Even though overall findings for colorectal cancer risk have been mixed, greater MD 
adherence has rather consistently been associated with a reduced colorectal cancer risk 
in men [26-31]. For women, on the other hand, previous results have generally not been 
supportive of an inverse association [7, 26, 28-33]. Associations with MD adherence may 
differ between the anatomical subsites of colorectal cancer as well. Besides the potentially 
distinct etiological backgrounds of these tumors, exposures to (carcinogens in) fecal matter 
may vary across the length of the colorectum [34, 35]. Accordingly, in male participants of 
the US-based NIH-AARP [26] and Health Professionals Follow-up Study (HPFS, [31]) cohorts, 
inverse associations with MD adherence seemed strongest for tumors arising in the distal 
colon and rectum. In our analyses, we did not observe an inverse relation of MD adherence 
with any of the colorectal cancer subsites in both men and women. Perhaps, the relatively 
modest contrasts in absolute food intakes between participants with high and low MD 
adherence in the homogeneous NLCS study population did not suffice to enable detection 
of the rather weak inverse association of this dietary pattern with colorectal cancer risk 
that seems to be present in men. Nevertheless, MD adherence was associated with (non-)
significantly reduced risks of lung cancer, ESCC, GCA, and GNCA in male NLCS participants, 
as we have described above, which suggests adequate exposure contrast.        
Concerning bladder cancer, MD adherence was not significantly associated with urothelial 
cell carcinoma (UCC) risk in two initial cohort studies, which were conducted in Europe 
and Australia, respectively [36, 37]. However, effect estimates pointed towards an inverse 
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association, particularly for invasive UCC. A significant inverse association between MD 
adherence and bladder cancer risk was reported in a more recent analysis of 13 prospective 
cohort studies [38]. A limitation of all three previous analyses is the level of adjustment for 
cigarette smoking, i.e., the most important bladder cancer risk factor [39], which was not as 
comprehensive, and could potentially have accounted for the differential findings compared 
to our study. Moreover, the inverse associations were restricted to (former and) current 
smokers in two of the three studies [36, 37], and thus may have resulted from residual 
confounding by cigarette smoking.
The currently available prospective evidence does not point towards a strong beneficial 
influence of MD adherence on pancreatic and prostate cancer risk, which is in agreement 
with our analyses.
The relation between a priori defined MD adherence and pancreatic cancer incidence 
has been evaluated in three cohort studies (2 European, 1 US), all showing no significant 
association [7, 40, 41]. Comparable to the EPIC-wide result, MD adherence was also not 
associated with a significantly decreased pancreatic cancer risk in the southern European 
countries of the EPIC cohort in subgroup analyses [41]. Furthermore, the use of cohort-wide 
instead of country-specific tertiles in the assessment of MD adherence did not appreciably 
affect the associations [41]. 
Considering prostate cancer, advanced tumors at diagnosis comprise the most informative 
end point. In contrast to the advanced subtype, the subgroup of nonadvanced prostate 
cancers is predominated by less aggressive tumors that have low progression rates and may 
never reach a clinically relevant state. Distinct etiologies have been suggested and risk factor 
profiles of prostate tumors possibly vary depending on the stage at diagnosis [42-44]. MD 
adherence was not related to advanced prostate cancer risk in two US cohorts [45, 46]. 
In addition to the specific cancer types, overall cancer incidence is an interesting outcome 
to evaluate the potential of the MD as a dietary strategy to prevent cancer. So far, the 
cohort evidence on the association between MD adherence and overall cancer incidence 
has been inconclusive, with inverse relations being observed in some studies [47, 48], but 
not in others [7, 16, 49]. In this thesis, we showed that higher MD adherence was only 
associated with a non-significantly reduced cancer risk in women. In accordance with our 
findings, a stronger inverse association was observed in female participants of EPIC-Greece 
(pinteraction>0.05) [47]. However, sex-specific associations did not vary in the remainder of 
the studies [7, 48, 49]. When investigating the effect of dietary factors on overall cancer 
incidence, one should realize that contributions of individual cancer types to the total cancer 
incidence vary depending on the study population. For example, a large proportion of the 
cancers diagnosed in men and women is made up by sex-specific tumors (e.g., tumors of 
the prostate and breast). As MD adherence seems to be related differently to specific cancer 
types, this could, at least partly, explain discrepancies in associations with overall cancer risk 
across the sexes or cohorts.   
Integrating the findings of this thesis and other prospective studies, we may conclude that 
adherence to the MD possibly has a preventive effect on several cancer types, including 
cancers of the lung, postmenopausal breast, esophagus (ESCC in men), stomach, and 
colorectum (men only). It remains to be seen whether MD adherence is associated with 
a decreased risk of bladder cancer as well or that the observed inverse associations in the 
literature were the result of residual confounding by tobacco smoking. Heterogeneity of 
associations across the sexes and/or subtypes was indicated for cancers of the lung, breast, 
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esophagus, (stomach), and colorectum. Unfortunately, the number of cohort studies 
reporting subtype-specific associations in men and women is still limited for many cancer 
sites. Potential mechanisms underlying the possible cancer-protective effect of the MD have 
already been discussed in the introduction of this thesis (Chapter 1). 
3. Methodological considerations
3.1 Moderate alcohol consumption and the Mediterranean diet 
The inclusion of moderate alcohol consumption as a favorable component in the MD is 
controversial. Traditionally, moderate amounts of red wine were consumed with meals 
in many Mediterranean regions [50, 51]. Red wine is a source of antioxidant and anti-
inflammatory polyphenols, which may beneficially affect cardiovascular health [52]. It has 
been debated whether a light-to-moderate intake of red wine (and alcoholic beverages in 
general) exerts a cardioprotective effect [52]. Correspondingly, many MD scores consider a 
moderate alcohol intake beneficial. Alcohol consumption is generally not assumed to have 
a favorable effect on cancer risk at any level. Even at light or moderate intake levels, alcohol 
has been associated with elevated risks of cancers of the oral cavity and pharynx, larynx, 
esophagus (ESCC), colorectum, and female breast [2]. Therefore, in cancer prevention, a 
MD that does not allow any consumption of alcoholic drinks might be preferred. For this 
reason, we compared MD scores with and without an alcohol component, which has been 
done in other studies as well (e.g., [15, 22, 31, 38, 41]). For the majority of the cancer sites, 
an equal or better model fit was obtained for the MD score variant without alcohol (aMEDr). 
Furthermore, exclusion of the alcohol component did not seem to affect associations of 
MD adherence with cancer risk as was demonstrated by the essentially similar results 
for both score variants. Nevertheless, in our meta-analyses concerning postmenopausal 
breast cancer, higher MD adherence was only associated with a reduced risk when we 
combined results of studies that excluded alcohol from the MD score. Earlier cohort studies 
investigating breast cancer risk have reported virtually similar relations for MD scores with 
and without alcohol [12, 13, 15, 17]. Based on the above, we recommend that alcohol is 
excluded from the MD score in future studies, especially when relations with cancer risk 
are investigated. As an alternative, MD scores with and without alcohol component could 
be compared.  
3.2 Olive oil and the Mediterranean diet
The generous use of olive oil instead of other plant oils or animal fats characterizes the 
traditional MD [50, 51]. This is reflected in the fatty acid profile of the MD that is high in 
monounsaturated fatty acids (MUFA, from olive oil), but low in saturated fatty acids (SFA) 
[50, 51, 53]. Olive oil consumption is not specifically scored in the traditional Mediterranean 
diet score (tMED, [53, 54]) and many of its derivatives, including aMED [55, 56] and mMED 
[57]. Alternatively, the favorable fatty acid profile of the MD is taken into account through 
the inclusion of a fatty acid ratio (originally MUFA:SFA) in the score. By using the fatty acid 
ratio as a proxy for the high olive oil consumption in the MD, tMED and variants are also 
easy to apply in non-Mediterranean populations, where olive oil is typically less commonly 
used in the preparation of meals. At the time of the baseline measurements of the NLCS 
and EPIC-NL, the use of olive oil as the main dietary fat was rather uncommon in the 
Netherlands as well and olive oil consumption was therefore not specifically included as 
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an item in the food frequency questionnaires (FFQs). In mMED [57], the fatty acid ratio was 
adapted to the dietary habits of non-Mediterranean populations by including both MUFA 
and polyunsaturated fatty acids (PUFA). The inclusion of PUFA in the fatty acid ratio was 
desired, because PUFA constitute the largest proportion of unsaturated fatty acids in these 
populations and are suggested to have beneficial health effects themselves. Additionally, 
meat (and not olive oil) is an important source of MUFA in non-Mediterranean countries.
In several analyses of the EPIC cohort (e.g., focusing on breast, pancreatic, and bladder 
cancer) similar associations were observed for MD scores that included the MUFA(+ 
PUFA):SFA ratio and scores that directly incorporated olive oil intake [10, 12, 36, 41]. This 
may indicate that the fatty acid ratio is a suitable way to model the high olive oil consumption 
that characterizes the MD.
3.3 Dietary pattern analysis
Human beings do not consume isolated foods and nutrients. Instead, dietary components are 
consumed in certain combinations and collectively compose an individual’s dietary pattern. 
Synergistic or antagonistic interactions between dietary components may modify health 
effects of single foods or nutrients [54, 58, 59]. Therefore, in our attempt to gain insight into the 
possible cancer-protective effects of the MD and the potential of this diet in cancer prevention, 
dietary pattern analysis seemed to be the most fruitful approach. Besides acknowledging 
interactions between dietary components, dietary pattern analysis has some additional 
advantages. Firstly, the capability to reveal true health benefits of the MD is increased, 
because effects of singular components may be small and for that reason undetectable unless 
integrated into a pattern. Moreover, by considering the combined effect of all aspects of the 
MD, extremes of cumulative exposures are evaluated. Finally, collinearity and confounding 
issues arising from the high correlations between food groups are avoided [54, 58, 59]. 
Results of our analyses underlined the usefulness of the pattern-based approach. Although 
higher MD scores were associated with (non-significantly) reduced risks of cancers of the 
lung, breast (postmenopausal), esophagus (ESCC in men), and stomach (GCA and GNCA), 
associations for individual score components were sometimes absent or in unexpected 
directions. Additionally, inverse associations with these cancer types did not seem to be 
dominated by a single MD component.  
3.4 The use of cohort-specific cut-offs in the assessment of Mediterranean diet adherence
3.4.1 Dietary habits of the Dutch population in the 1990s 
A potential weakness of the MD scores that we applied in this thesis is the use of population 
medians as cut-offs to separate subjects with high and low intakes of the individual dietary 
components. Therefore, MD scores of individuals with identical dietary habits may vary 
depending on the diet of the remainder of the population. For example, a subject with a 
high MD score in the Dutch EPIC cohort may be classified as having an intermediate or low 
level of MD adherence in one of the southern European EPIC cohorts. The use of population-
based cut-offs in the assessment of MD adherence may particularly have consequences in 
non-Mediterranean populations where the overall level of MD adherence is generally low.   
To get an idea about the extent to which the dietary habits of NLCS and EPIC-NL study 
participants resembled the traditional MD, we can compare mean daily intakes of typically 
(non-)Mediterranean food groups between the Dutch and Greek EPIC cohorts (EPIC-NL and 
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EPIC-Greece, respectively). Between 1995 and 2000, single 24-hour dietary recalls were 
collected from random samples of the EPIC cohorts to estimate mean daily intakes of 22 
food groups, adjusted for age, day of the week, and season [60]. Among men, mean daily 
intakes of vegetables, fruits (including nuts), and legumes were clearly lower in EPIC-NL, 
while the opposite was observed for meat intake (vegetables: 131 vs. 269 g/day; fruits: 
156 vs. 234 g/day; legumes: 6 vs. 33 g/day; meat: 141 vs. 68 g/day). A similar pattern was 
reported when comparing female participants of the Dutch and Greek EPIC cohorts, with 
average daily intakes of 128 vs. 211 g for vegetables, 183 vs. 218 g for fruits, 4 vs. 21 g for 
legumes, and 80 vs. 35 g for meat, respectively.  
Thus, appreciable differences existed between the dietary patterns of Dutch and Greek EPIC 
participants. The diet of the non-Mediterranean EPIC-NL cohort was characterized by a lower 
intake of plant foods and a higher intake of meat. Therefore, it seems likely that the diet of 
most individuals assigned to the highest MD adherence category in our analyses did not 
truly resemble a traditional MD. Nevertheless, these individuals may still experience lower 
cancer risks than subjects whose dietary habits deviated more from the MD as reflected by 
their lower MD scores. The MD is essentially an example of a plant-based dietary pattern, 
as there are several other index-based dietary patterns that are plant-based, such as the 
Healthy Eating Index-2015 (HEI-2015, [61]), the Alternative Healthy Eating Index-2010 
(AHEI-2010, [62]), and the Dietary Approaches to Stop Hypertension (DASH, [63]) score, and 
does not necessarily have to be confined to the Mediterranean region.
3.4.2 The absolute WCRF/AICR diet score for cancer prevention 
In this paragraph, we will focus on the likelihood that the population-based scoring in our 
assessment of MD adherence has affected our findings by comparing the relative aMED to 
absolute scores based on the dietary part of the cancer prevention guidelines developed 
by the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) 
in 2007 [64]. 
With the aim to prevent cancer, the WCRF/AICR published a list of recommendations in 2007 
[64], of which six focused on diet and supplement use. In short, these dietary guidelines 
encouraged the consumption of plant foods, while stating that the intake of foods and drinks 
that promote weight gain, animal foods, alcoholic drinks, salt, and dietary supplements 
should be limited or avoided. In order to create an absolute WCRF/AICR diet score, we 
operationalized the recommendations concerning foods and drinks that promote weight 
gain, plant foods, red and processed meats, alcohol, and salt, using the same absolute cut-
offs as earlier applied in the EPIC cohort [65, 66], whenever possible. Analogous to aMED, 
an additional score was made that did not incorporate the alcohol recommendation. For a 
detailed description of the calculation of the score, we refer to Chapter 3 of this thesis. 
Focusing on scores that did not contain alcohol, we may conclude that the absolute WCRF/
AICR diet score did not outperform the cohort-specific aMEDr in our study population. 
Compared to aMEDr, model performances of the WCRF/AICR diet score were roughly similar 
(cancers of the lung, colorectum, and bladder) or worse (cancers of the breast and prostate). 
Additionally, associations per SD-increment in both scores pointed in the same direction for 
most of the investigated cancer sites. Unlike aMEDr, a SD-increase in the WCRF/AICR diet 
score was not inversely associated with breast cancer risk.  
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3.5 Strengths and limitations of the NLCS and EPIC-NL cohorts
The prospective designs and long durations of follow-up are major strengths of the included 
cohorts that minimized the potential for information and selection biases. Furthermore, 
the large number of cancer diagnoses during follow-up for most cancer sites (particularly 
in the NLCS) allowed us to perform sex- and subtype-specific analyses with adequate 
statistical power and to evaluate the presence of effect modification by smoking status and 
other important cancer risk factors. However, case numbers for pancreatic cancer (MCPC) 
and subtypes of esophageal and gastric cancer were generally relatively small. Detailed 
dietary information of NLCS and EPIC-NL cohort members was retrieved via validated FFQs 
at baseline [67-69], but the possibility of errors in the dietary assessment cannot fully be 
excluded. A limitation of both cohorts is the absence of repeated dietary measurements 
during follow-up to update the baseline information. Therefore, we were not able to take 
possible changes in dietary habits or confounding factors after baseline into account in our 
analyses, which may have resulted in non-differential measurement error and attenuated 
associations. However, the reproducibility has been tested for both the NLCS and the 
EPIC-NL FFQ and was shown to be generally good [68-70]. Finally, residual confounding 
by unmeasured or imperfectly measured factors may have affected our results. Because 
we corrected our multivariable analyses for a large number of potential confounders, this 
influence is not likely to be strong.
Whenever possible, the abovementioned limitations should be addressed in future studies. 
We particularly encourage the repeated assessment of dietary habits at regular time 
intervals during follow-up. 
4. Implications for public health 
As we have already stated in Chapter 1 of this thesis, the cancer burden in the Netherlands 
is high [71-73]. A further increase is anticipated in the coming decades due to the ageing 
population and increasing life expectancy [74]. It has been estimated that about 10% of 
the incident cancer cases in the Dutch population in 2010 could have been prevented if 
everyone had adhered to a healthy diet [75]. According to this thesis, MD adherence may be 
associated with decreased risks of cancers of the lung, breast, esophagus (ESCC in men), and 
stomach in the Netherlands. Cancers of the lung, esophagus, and stomach have a relatively 
poor prognosis and are therefore particularly in need of successful preventive strategies. The 
literature has indicated an additional beneficial effect of MD adherence on the incidence of 
colorectal cancer (men only), as we have described earlier in this chapter. 
So, is the current scientific evidence sufficient to promote the traditional MD specifically as 
a dietary strategy for cancer prevention? In our opinion, probably not.
Although the relation between MD adherence and cancer risk has been the topic of a 
considerable number of publications in the past few years, the cohort evidence is still limited, 
especially for some cancer (sub)sites. Additional prospective studies reporting sex-specific 
associations of MD adherence with incidence of cancer subsites may help to answer the 
remaining questions and to solve the inconsistencies. Randomized controlled trials (RCTs) 
that evaluate the effect of a MD intervention on cancer risk might be particularly helpful. As 
far as we know, no sizeable RCTs with this primary aim have been conducted yet. Our study 
adds to the currently available evidence, but does not suffice to enable the formulation of 
definitive conclusions concerning the cancer-protective effect of the MD in the Netherlands. 
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Instead of promoting the traditional MD specifically with the aim to prevent cancer, 
policymakers in the Netherlands could use the MD as a basis to formulate a healthy plant-
based dietary pattern for the prevention of chronic disease in general. Besides its potentially 
beneficial effect on cancer risk, higher MD adherence may be associated with reduced risks 
of several other chronic diseases (including CVD) and all-cause mortality (e.g., [76-80], see 
also Chapter 1), which enables the formulation of an unambiguous message to the Dutch 
population.
The MD is generally considered to be a delicious and versatile dietary pattern and MD-
style meals can be prepared rather quickly and easily if desired [81]. The tastiness of the 
MD as well as the absence of constraints to energy intake (though energy balance should 
be maintained) may improve the willingness of the Dutch people to adopt a more plant-
oriented diet. Murphy et al. [81] suggested that the versatility and palatability of the MD 
contributed to the high and long-term compliance that has been observed in MD intervention 
studies in Australia, which investigated effects of the MD on CVD risk factors and cognitive 
performance in elderly people and mental health in adults suffering from depression [81-
85].
Another advantage of the MD is its low impact on the environment compared to more 
Western dietary patterns [86-89]. The MD has been associated with a favorable water 
footprint and lower greenhouse gas emissions, because of its plant-based nature and the 
low consumption of animal foods [86-91]. After examining health effects, environmental 
footprints, and monetary costs of the Mediterranean, Provegetarian, and Western dietary 
patterns simultaneously, the MD appeared to be the most sustainable option [92].  
In the previous paragraph, we discussed that the stimulation of a healthy plant-based 
dietary pattern, which incorporates some of the aspects of the traditional MD, may be an 
interesting approach in the prevention of chronic disease in the Netherlands. The following 
comments can be made regarding the constituents of this suggested MD-derived dietary 
pattern. In line with the MD, plant foods should play a central role in the promoted dietary 
pattern, which also encompasses the regular use of olive oil as the main culinary fat. Of 
note, the recommended dietary pattern does not need to be exclusively vegetarian and 
may allow the consumption of small and moderate amounts of meat and fish, respectively. 
Alcohol consumption, on the other hand, should be completely discouraged because of its 
carcinogenic effect in humans [1, 2]. Perhaps, a suitable dietary pattern can be defined by 
adapting the MD to the local food availability as well as specific needs and preferences of 
the Dutch population [81]. Stimulation of the consumption of locally grown and seasonal 
foods, which also constitutes a core characteristic of the MD, may improve the sustainability 
of the dietary pattern even further [93, 94]. Moreover, by allowing the consumption of, e.g., 
low-fat dairy products, the dietary pattern may better accommodate the preferences of the 
Dutch population, potentially improving the attitude of the general public to the proposed 
guidelines. With an average consumption of 352 g per day between 2012 and 2016, dairy 
products compose a substantial part of the present diet in the Netherlands [95]. For the 
suggested intake levels, we refer to the Dutch dietary guidelines 2015, which were issued 
by the Health Council of the Netherlands and were based on the latest scientific evidence 
concerning chronic disease risk [96]. The MD shows many similarities with these guidelines: 
both recommend an eating pattern that is abundant in plant foods, but limited in foods 
from animal origin. According to the Dutch dietary guidelines 2015, people should consume 
several servings of dairy each day, including milk or yoghurt. 
Supportive measures, e.g., by policymakers and governmental institutions, are most likely 
required to successfully implement a healthy and more sustainable plant-based diet in the 
214
Chapter 9
Dutch population [81]. The formulation of clear guidelines and the provision of recipes 
or meal plans could be very helpful to the public, facilitating an easier transition to a diet 
primarily based on plant foods [81]. Furthermore, efforts should be made to make plant 
foods accessible and affordable to all social classes. In this respect, one could think of 
guaranteeing the availability of a large variety of plant foods at local stores and reducing 
the tax on vegetables, fruits, and other foods of plant origin. Oppositely, the tax on meat 
and other unhealthy foods could be increased to make these foods more expensive and 
therefore less appealing to the general public.     
With adequate governmental actions, clear guidelines, and support, the Dutch population 
should theoretically be able to change their present dietary behaviors for the better and to 
adopt a healthy plant-based dietary pattern. Besides promoting a healthy diet, it is of utmost 
importance in the prevention of cancer and other chronic diseases in the Netherlands to 
keep stimulating the public to quit smoking, to maintain a healthy body weight, and to be 
physically active. At the population level, adoption of a healthier lifestyle by the Dutch people 
might reduce the incidence of chronic diseases. However, it is challenging, if not impossible, 
to predict who will get ill at the individual level. Some men and women who adhere to a 
healthy lifestyle might still suffer from chronic disease in the future as a consequence of 
other exposures, genetics, or merely bad luck. 
5. Future recommendations 
The field of nutrition-related research is continuously evolving and future research on the 
MD could take a wide array of directions. In both this chapter and previous chapters of 
this thesis, we have already briefly pinpointed some areas in which additional research is 
warranted. In this section, we would like to highlight some of our recommendations for 
future research.
Firstly, the relation between MD adherence and cancer risk has primarily been investigated 
in studies with observational designs. However, evidence for causal relationships can only 
be obtained from well-designed RCTs [97]. To our knowledge, no well-designed, adequately-
sized RCTs with a long duration of follow-up have been conducted thus far with the principal 
aim to evaluate the effect of a MD-like dietary intervention on cancer risk. Such studies 
are desired, in both Mediterranean and non-Mediterranean countries, and may enable the 
formulation of definitive conclusions concerning the potentially cancer-protective effect of 
the MD.
A disadvantage of large and long-term dietary intervention trials is that they are costly, 
labor-intensive, and not always feasible [97-99]. Provided that the obtained results are 
consistent, large and well-designed cohort studies may still produce convincing evidence 
that suffices for the establishment of dietary guidelines [98-100]. In order to add to the 
currently available evidence, future cohort studies evaluating the relation of MD adherence 
with cancer risk should meet at least one of the following requirements: 
•	 Subtype-specific associations between MD adherence and cancer incidence are 
evaluated separately for men and women. 
•	 Improved methods are utilized for the measurement of dietary intake. These could 
be based on new technologies, such as apps or barcode scanners. Preferably, 
dietary information is updated at regular time intervals during follow-up.
•	 The absolute level of MD adherence is assessed using an evidence-based score. 
Up until now, the large majority of the studies measured the relative level of MD 
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adherence using tMED or one of its many derivatives. An example of an evidence-
based score that assesses the absolute level of MD adherence is the literature-
based adherence score to the Mediterranean diet (MEDI-LITE) developed by Sofi 
et al. [77, 101]. In order to define absolute cut-off values for the included food 
groups, median (or mean) consumption levels were retrieved from all cohort 
studies evaluating the health effects of the MD and subsequently combined. 
Thus far, a large variety of a priori defined MD indexes has been created to assess MD 
adherence. These MD indexes were reported to differ in respect to multiple facets, including 
the number and types (e.g., food groups, nutrients etc.) of components, the scoring method, 
and, if applicable, the specific dietary components incorporated [102]. Moreover, disparities 
were noted in the definition and/or assessment of the dietary components [102]. These 
differences may have contributed to the generally rather weak correlations between a 
priori defined MD indexes [103]. Therefore, homogeneity regarding the dietary components 
included in the MD indexes and the scoring criteria used has been advocated [103].
Besides the MD, several other a priori index-based dietary patterns exist, like the HEI-
2015 [61], the AHEI-2010 [62], and the DASH score [63]. All these index-based dietary 
patterns (including the MD) have in common that their scores increase with a more plant-
oriented diet. Various studies have compared associations of multiple index-based dietary 
patterns (including the MD) with mortality in a prospective setting, among others as part 
of the Dietary Patterns Methods Project [104-107]. However, comparable studies for risk of 
cancer in general or the majority of the individual cancer types have been performed less 
frequently, while these could be very useful in the identification of the most effective plant-
based dietary pattern(s) for cancer prevention. Therefore, we recommend that such studies 
will be conducted in the future. Research aiming to unravel the underlying mechanisms may 
also be helpful in this regard. 
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Summary
With its high incidence and mortality, cancer negatively affects many lives. According to 
estimations, about a tenth of the cancers diagnosed in the Netherlands in 2010 would have 
been preventable by the adoption of a healthy diet. The traditional Mediterranean diet 
(MD) can be defined as the dietary pattern typical of the olive-cultivating areas bordering 
the Mediterranean Sea in the late 1950s and the early 1960s, which was primarily based on 
plant foods (Chapter 1). The MD was characterized by a high consumption of vegetables, 
fruits, legumes, nuts, whole grains, and olive oil (rich in monounsaturated fatty acids). In 
contrast, the intake of meat and dairy products was low. Alcohol was consumed in moderate 
amounts and usually during meals. Adherence to the MD has been associated with numerous 
health benefits, including reduced all-cause mortality, and cardiovascular disease incidence 
and mortality. Despite the increasing interest in the potential cancer-protective effect of MD 
adherence in recent years, the evidence is still limited for most cancer sites. Additionally, 
results of conducted studies were not always consistent and had often been obtained 
using case-control designs, which are prone to bias. Moreover, potential heterogeneity 
of associations with MD adherence across the sexes or subtypes of specific cancer sites 
has been suggested, but has rarely been evaluated in prospective studies. Therefore, the 
principal aim of this thesis was to prospectively evaluate the association of MD adherence 
with incidence of specific cancer sites (i.e., lung, breast, esophagus, stomach, pancreas, 
colorectum, prostate, and bladder) as well as overall cancer incidence in the Netherlands. 
Specific attention was paid to possible differences in associations between men and women, 
and across subtypes of the investigated cancer sites. The relative level of MD adherence was 
assessed using two a priori defined MD scores, namely the alternate Mediterranean diet 
score (aMED) and the modified Mediterranean diet score (mMED). Alcohol consumption 
may increase the risk of multiple types of cancer even at low or moderate intake levels. 
Therefore, reduced variants of aMED and mMED were created that did not include the 
alcohol component (aMEDr and mMEDr, respectively) and models containing MD score 
variants with and without alcohol were compared in terms of performance. In order to 
investigate our aims, we primarily used data collected from the 120852 participants of the 
population-based Netherlands Cohort Study on Diet and Cancer (NLCS), who were between 
the ages of 55 and 69 years at baseline in September 1986. To increase statistical power, the 
association between MD adherence and pancreatic cancer risk was evaluated by pooling 
results from the NLCS and the Dutch cohort of the European Prospective Investigation into 
Cancer and Nutrition (EPIC-NL). The EPIC-NL cohort includes 40011 men and women, who 
were aged 20 to 70 years at enrolment between 1993 and 1997. NLCS participants were 
followed up for cancer incidence for a maximum of 20.3 years, whereas the median follow-
up in EPIC-NL was 19.2 years. 
For the majority of the cancer sites, aMEDr-containing models had an equal or better 
performance than mMEDr-containing models. Therefore, aMEDr was considered our 
principal measure of MD adherence. Furthermore, the score variant without alcohol 
component was preferred, because of the carcinogenic effect of alcohol in humans. 
Higher MD adherence (aMEDr) was associated with a non-significantly reduced lung cancer 
risk in men and women (Chapter 2). Subgroup analyses suggested that the non-significant 
inverse association was most pronounced in women and those who never smoked, but 
the interaction tests did not reach statistical significance. When comparing associations 
with aMEDr across the histological lung cancer subtypes, some variations in strength were 
observed, especially in men.
Increasing levels of MD adherence were also associated with a non-significantly reduced 
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incidence of postmenopausal breast cancer in female NLCS participants (Chapter 3). 
Stratification by estrogen receptor (ER) status showed that the inverse association was 
strongest and only statistically significant for the ER negative subtype. Similar findings were 
obtained when we evaluated progesterone receptor (PR) and combined ER/PR subtypes. 
Finally, we combined our results of the NLCS and results of previously published cohort 
studies in random-effects meta-analyses. Results of these meta-analyses were in line 
with the NLCS observations, showing inverse associations between MD adherence and 
postmenopausal breast cancer risk, particularly of the ER negative subtype. 
For esophageal and gastric cancer (Chapter 4), associations with MD adherence were 
evaluated separately for subtypes defined by histology and anatomic location, respectively, 
which were suggested to have distinct etiological backgrounds. A significantly decreased risk 
of esophageal squamous cell carcinoma (ESCC) was observed among men with higher levels 
of MD adherence. In contrast, MD adherence was not associated with ESCC risk in women 
or risk of esophageal adenocarcinoma (EAC) in both men and women. Although statistical 
significance was only reached in men, MD adherence was inversely associated with risks 
of gastric cardia adenocarcinoma (GCA) and gastric non-cardia adenocarcinoma (GNCA) in 
both sexes. 
Using data of both the NLCS and EPIC-NL cohorts, the relation of MD adherence with 
pancreatic cancer incidence was investigated in Chapter 5. MD adherence was not 
significantly associated with the risk of microscopically confirmed pancreatic cancer (MCPC) 
in pooled and cohort-specific analyses, irrespective of sex. Potential effect modification by 
smoking status was indicated. MD adherence was weakly and non-significantly inversely 
associated with MCPC risk in never smokers, but not in ever smokers. The overall conclusion 
did not change when we also included cases who were not microscopically confirmed in the 
analyses.       
Furthermore, MD adherence was not significantly associated with colorectal cancer risk in 
men and women, regardless of the anatomical subsite (i.e., colon, proximal colon, distal 
colon, and rectum) evaluated (Chapter 6).   
Associations of MD adherence with risks of prostate and bladder cancer were examined in 
Chapter 7. For prostate cancer, associations were estimated separately for advanced and 
nonadvanced tumors at diagnosis, because differences in etiology and risk factor profiles 
have been suggested. The subgroup of nonadvanced prostate cancers at diagnosis mainly 
encompasses less aggressive tumors, which progress slowly and might never become 
clinically relevant. Therefore, we considered advanced prostate cancer risk to be the most 
interesting outcome. MD adherence was not associated with advanced prostate cancer 
risk in our analyses. For nonadvanced prostate cancer risk, a statistically significant positive 
association was observed. The prostate cancer awareness, likelihood to seek care, and 
screening attendance may be higher among well-educated men with healthier lifestyles and 
higher MD adherence. Consequently, nonadvanced prostate tumors may more commonly be 
diagnosed in this part of the population. Additionally, we evaluated the association between 
MD adherence and bladder cancer risk combining male and female NLCS participants, and 
showed that there was no evidence of a relation, irrespective of the malignancy grade at 
diagnosis.    
The association of MD adherence with overall cancer incidence was the focus of Chapter 
8. Higher MD adherence was associated with a non-significantly reduced cancer risk in 
women, but not in men. In women, similar associations with MD adherence were observed 
for subgroups of cancers related vs. not related to tobacco smoking, obesity, and alcohol 
consumption. Even though differences across the subgroups seemed small and irrelevant 
in men as well, heterogeneity tests in men were significant for all subgroup comparisons 
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made, possibly because of the high statistical power.   
As was described above, our primary measure of MD adherence was aMEDr, which does not 
include the alcohol component. Largely similar results were obtained when MD adherence 
was assessed using the original aMED including the alcohol component. However, in most 
cases an equal or better model performance was observed for the MD score variant without 
alcohol. 
In Chapter 9, the findings of this thesis were put into perspective by relating them to results 
of previously published studies and discussing methodological considerations. Moreover, 
implications for public health and recommendations for future research were addressed. 
This thesis shows that higher MD adherence might be associated with a reduced risk of 
several cancer (sub)types in the Netherlands. Therefore, the MD could potentially be an 
interesting dietary approach in the prevention of cancer in the Dutch population. However, 
when looking at the totality of the evidence, no final conclusions regarding the cancer-
preventive properties of the MD can be drawn at this time. Inverse associations in our 
analyses did not always reach statistical significance and the number of prospective cohort 
studies is still small for some cancer (sub)sites. In agreement with our findings, it has been 
suggested that associations with MD adherence might differ between the sexes and/or 
depend on the cancer subsite evaluated, but unfortunately, it is not common practice yet 
to report sex- and subtype-specific results. Accordingly, in future, well-designed cohort 
studies and randomized controlled trials are warranted, which might provide the additional 
evidence required to justify the promotion of the MD with the specific aim to prevent cancer. 
Until this is the case, policymakers in the Netherlands could consider using the MD as a 
framework to develop a healthy plant-based dietary strategy for the prevention of chronic 
diseases in general. 
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Samenvatting 
De ziekte kanker heeft vanwege haar hoge incidentie en sterfte een nadelige invloed op het 
leven van veel mensen. Naar schatting had ongeveer tien procent van de gediagnosticeerde 
kankers in Nederland in 2010 voorkomen kunnen worden door gezonde voeding. Het 
traditionele mediterraan dieet (MD) kan worden gedefinieerd als het voedingspatroon 
dat eind jaren ’50, begin jaren ’60 van de vorige eeuw kenmerkend was voor gebieden 
grenzend aan de Middellandse Zee waar olijven werden geteeld (Hoofdstuk 1). Het MD 
was een plantaardig dieet dat werd gekarakteriseerd door een hoge inname van groenten, 
fruit, peulvruchten, noten, volkoren graanproducten en olijfolie (een bron van enkelvoudig 
onverzadigde vetzuren). De inname van vlees en zuivelproducten was daarentegen laag. 
Alcohol werd geconsumeerd in matige hoeveelheden, met name gedurende de maaltijd. 
Er zijn meerdere gezondheidsvoordelen toegeschreven aan het MD, waaronder een 
verlaagde sterfte en een verlaagd risico op hart- en vaatziekten. Hoewel het mogelijk 
gunstige effect van het MD op het risico op kanker de afgelopen jaren in toenemende mate 
is onderzocht, is het huidige bewijs voor de meeste kankersoorten nog beperkt. Daarnaast 
waren de resultaten van onderzoeken niet altijd consistent en hadden veel studies een 
patiëntcontrole-opzet. Het patiëntcontrole-onderzoeksdesign is gevoelig voor bias, om 
welke reden cohortonderzoeken de voorkeur hebben. Tot slot verschilt het verband met 
het MD mogelijk tussen de geslachten en/of subtypen van kankersoorten. Dit is echter 
zelden in prospectieve studies onderzocht. Het doel van dit proefschrift was daarom om 
het verband tussen naleving van het MD en incidentie van zowel kanker in het algemeen als 
verscheidene kankersoorten (i.c. long-, borst-, slokdarm-, maag-, alvleesklier-, colorectaal-, 
prostaat- en blaaskanker) in Nederland te onderzoeken in een prospectieve setting. Hierbij 
hebben we ook aandacht besteed aan mogelijke verschillen in associaties tussen mannen 
en vrouwen en subtypen van de onderzochte kankersoorten. De mate van naleving van 
het MD werd vastgesteld met behulp van twee a priori gedefinieerde MD-scores, namelijk 
de ‘alternate Mediterranean diet score’ (aMED) en de ‘modified Mediterranean diet score’ 
(mMED). Alcoholconsumptie is een risicofactor voor meerdere vormen van kanker. Daarom 
hebben we gereduceerde varianten van aMED en mMED gecreëerd (respectievelijk aMEDr 
en mMEDr) waar alcoholconsumptie geen deel van uitmaakt. Vervolgens hebben we de 
‘performance’ van modellen met gereduceerde (zonder alcohol) en originele (met alcohol) 
MD-scores vergeleken. Onder ‘model performance’ verstaan we de mate waarin een 
statistisch model de geobserveerde data verklaart. Voor ons onderzoek hebben we met name 
gebruik gemaakt van data van de 120.852 deelnemers van de Nederlandse Cohortstudie 
naar voeding en kanker (NLCS). Bij aanvang van deze studie in september 1986 waren de 
deelnemers tussen de 55 en 69 jaar oud. Om de statistische power te vergroten, hebben 
we de relatie tussen naleving van het MD en het risico op alvleesklierkanker onderzocht 
door resultaten van de NLCS en het Nederlandse cohort van de European Prospective 
Investigation into Cancer and Nutrition (EPIC-NL) samen te voegen. Het EPIC-NL cohort is 
gevormd tussen 1993 en 1997 en bestaat uit 40.011 mannen en vrouwen in de leeftijd van 
20-70 jaar. NLCS-deelnemers zijn voor maximaal 20,3 jaar gevolgd voor het optreden van 
kanker. De mediane follow-up in EPIC-NL was 19,2 jaar.   
De performance van de modellen was voor de meeste kankersoorten vergelijkbaar of beter 
wanneer de naleving van het MD werd vastgesteld met behulp van aMEDr dan wanneer dit 
was gebeurd met mMEDr. Daarom hebben we besloten dat aMEDr onze belangrijkste maat 
was in de bepaling van naleving van het MD. Tevens heeft de score variant zonder alcohol 
de voorkeur, omdat alcoholconsumptie een risicofactor is voor verscheidene kankersoorten. 
Hogere MD-scores (aMEDr) waren geassocieerd met een niet statistisch significant verlaagd 
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risico op longkanker bij mannen en vrouwen (Hoofdstuk 2). De inverse verbanden leken het 
sterkst bij vrouwen en nooit-rokers. De sterkte van de associatie leek ook te variëren tussen 
de histologische longkanker-subtypen, met name bij mannen. Heterogeniteitstesten waren 
echter niet statistisch significant.
Een toename in aMEDr was ook geassocieerd met een niet statistisch significant verlaagde 
incidentie van postmenopauzale borstkanker bij vrouwelijke NLCS-deelnemers (Hoofdstuk 
3). Stratificatie op basis van oestrogeenreceptor (ER) status liet zien dat het inverse verband 
sterker en enkel statistisch significant was voor het ER-negatieve subtype. We zagen een 
vergelijkbaar patroon voor de progesteronreceptor (PR) en gecombineerde ER/PR subtypen. 
Tot slot hebben we de resultaten van de NLCS gecombineerd met resultaten van eerder 
gepubliceerde cohortstudies in random-effects meta-analyses. De resultaten van deze meta-
analyses kwamen overeen met de NLCS-bevindingen. MD-scores waren invers geassocieerd 
met het risico op postmenopauzale borstkanker, met name van het ER-negatieve subtype.  
Slokdarm- en maagkanker-subtypen, gedefinieerd op basis van respectievelijk histologie en 
anatomische locatie, verschillen mogelijk in etiologie. De relatie tussen naleving van het 
MD en het risico op slokdarm- en maagkanker-subtypen was het onderwerp van Hoofdstuk 
4. Hogere MD-scores waren bij mannen geassocieerd met een significant verlaagd risico 
op plaveiselcelcarcinoom van de slokdarm (ESCC). aMEDr was echter niet geassocieerd 
met het risico op ESCC bij vrouwen of het risico op adenocarcinoom van de slokdarm (EAC) 
bij zowel mannen als vrouwen. Wat betreft de maagkanker-subtypen vonden we inverse 
verbanden tussen aMEDr en risico’s op cardia en non-cardia adenocarcinoom van de maag 
(respectievelijk GCA en GNCA) bij beide geslachten. De gevonden verbanden waren echter 
alleen statistisch significant bij mannen.  
Het verband tussen naleving van het MD en het risico op alvleesklierkanker werd in 
Hoofdstuk 5 onderzocht met behulp van data verzameld in de NLCS en EPIC-NL cohorten. 
aMEDr was niet statistisch significant geassocieerd met het risico op microscopisch 
bevestigde alvleesklierkanker (MCPC) in gepoolde en cohort-specifieke analyses, ongeacht 
geslacht. Er was sprake van mogelijke effectmodificatie door rookstatus. Er leek een zwak 
en niet significant invers verband aanwezig te zijn bij nooit-rokers, terwijl hiervoor geen 
aanwijzingen waren bij onderzoeksdeelnemers die wel ooit hadden gerookt. De conclusie 
was vergelijkbaar wanneer ook niet-microscopisch bevestigde gevallen van alvleesklierkanker 
in de analyses werden meegenomen. 
aMEDr was eveneens niet statistisch significant geassocieerd met het risico op 
colorectaalkanker (Hoofdstuk 6). Dit was het geval voor alle onderzochte anatomische 
subtypen (i.e. colon, proximale colon, distale colon en rectum) bij zowel mannen als 
vrouwen. 
In Hoofdstuk 7 hebben we associaties tussen naleving van het MD en het risico op prostaat- 
en blaaskanker onderzocht. Associaties met prostaatkankerrisico zijn apart geschat voor 
‘advanced’ (oftewel van een gevorderd stadium) en ‘nonadvanced’ tumoren op het moment 
van diagnose. Deze tumoren verschillen mogelijk in etiologie en risicofactoren. De subgroep 
van ‘nonadvanced’ prostaatkankers bestaat met name uit minder agressieve tumoren die 
mogelijk nooit een klinisch relevant stadium zullen bereiken. Daarom beschouwen we het 
risico op ‘advanced’ prostaatkanker als de belangrijkste uitkomstmaat. aMEDr was in onze 
analyses niet geassocieerd met het risico op ‘advanced’ prostaatkanker. Een statistisch 
significant positief verband werd echter gevonden voor ‘nonadvanced’ prostaatkanker. 
Hierbij moet worden opgemerkt dat mannen met een hoger opleidingsniveau en een 
gezondere leefstijl zich mogelijk meer bewust zijn van prostaatkanker en wellicht ook 
eerder gebruik zullen maken van de zorg en deel zullen nemen aan screeningsprogramma’s. 
Daarom is het aannemelijk dat ‘nonadvanced’ prostaattumoren in dit deel van de populatie 
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vaker gediagnosticeerd worden. Er was geen indicatie voor een associatie tussen aMEDr en 
het risico op blaaskanker. Onze bevindingen waren vergelijkbaar voor blaaskanker in het 
algemeen, invasieve blaaskanker en niet-invasieve blaaskanker. De effectschattingen voor 
blaaskanker werden gebaseerd op zowel mannen als vrouwen. 
De relatie tussen naleving van het MD en het risico op kanker in het algemeen was de focus 
van Hoofdstuk 8. Hogere MD-scores waren geassocieerd met een niet significant verlaagd 
risico op kanker bij vrouwen. Er was echter geen sprake van een relatie bij mannen. Tevens 
hebben we kankersoorten ingedeeld in subgroepen op basis van de relatie met roken, obesitas 
en alcoholconsumptie. Associaties met aMEDr waren bij vrouwen voor de verschillende 
subgroepen vergelijkbaar. Ofschoon ook bij mannen de verschillen tussen de subgroepen 
klein en irrelevant leken, waren heterogeniteitstesten bij mannen significant voor alle 
vergelijkingen. Deze observatie kan wellicht worden verklaard door de hoge statistische power. 
Zoals eerder beschreven was in dit proefschrift aMEDr (zonder alcohol) de primaire maat 
voor vaststelling van naleving van het MD. Grotendeels vergelijkbare resultaten werden 
verkregen wanneer we de originele aMED (inclusief alcohol) gebruikten. De model 
performance was in de meeste gevallen echter vergelijkbaar of beter voor de MD-score 
variant zonder alcohol.   
In Hoofdstuk 9 hebben we geprobeerd om de bevindingen van dit proefschrift in perspectief 
te plaatsen door deze te relateren aan resultaten van eerdere studies en door beschouwing 
van enkele methodologische aspecten. Daarnaast worden hier implicaties voor de 
volksgezondheid en aanbevelingen voor vervolgonderzoek behandeld. 
Op basis van dit proefschrift kunnen we concluderen dat naleving van het MD mogelijk 
verband houdt met een verlaagd risico op verschillende kanker(sub)typen in Nederland. 
Het MD zou daarom wellicht een interessante voedingsstrategie zijn voor de preventie van 
kanker in de Nederlandse samenleving. Het huidige bewijs volstaat echter nog niet voor 
de formulering van definitieve conclusies omtrent het mogelijk risicoverlagend effect van 
het MD op kanker. De inverse verbanden die we in dit proefschrift vonden, waren niet 
altijd statistisch significant en het aantal prospectieve cohortstudies is voor sommige 
kanker(sub)typen nog steeds beperkt. Zowel onze bevindingen als de literatuur wekken de 
indruk dat associaties met naleving van het MD mogelijk verschillen tussen de geslachten 
en/of afhankelijk zijn van het kankersubtype dat wordt onderzocht. Onderzoeksresultaten 
worden in studies helaas nog lang niet altijd gespecificeerd naar geslacht en subtype. 
Toekomstige goed uitgevoerde cohort- en interventiestudies kunnen wellicht het bewijs 
leveren dat noodzakelijk is om de promotie van het MD in het licht van kankerpreventie te 
rechtvaardigen. Totdat dit daadwerkelijk het geval is kunnen beleidsmakers in Nederland 
overwegen om het MD als uitgangspunt te nemen voor de ontwikkeling van een gezond 
plantaardig voedingspatroon gericht op de preventie van chronische ziekten in het algemeen. 
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The term “valorization” refers to the process of creating societal or economic value from 
scientific knowledge. In addition to education and research, valorization by law constitutes 
the third core task of Dutch universities. In this section, we will discuss how our key findings 
with regard to the potential cancer-protective effect of the Mediterranean diet (MD) in a 
non-Mediterranean population can be of significance to society apart from their scientific 
value through publication in impact journals.  
Before elaborating on the valorization potential of our findings, we will first briefly introduce 
the concept of the MD and its key components. In this thesis, the traditional MD was 
defined as “the dietary pattern typical of the Mediterranean regions traditionally known for 
olive cultivation in the late 1950s and the early 1960s”. Consumption of plant foods (e.g., 
vegetables, fruits, legumes, nuts, and whole grains) was abundant in this dietary pattern, 
whereas the intake of animal foods (e.g., meat and dairy) was limited. Other characteristics 
of the traditional MD were the high ratio of monounsaturated to saturated fatty acids 
resulting from the generous consumption of olive oil and a moderate consumption of 
alcohol during meals [1, 2]. 
A considerable part of cancer cases is presumably preventable with healthy dietary 
habits. For the Dutch population, it has been estimated that approximately 10% of cancer 
diagnoses in 2010 could be ascribed to a less than optimal diet [3]. Society could benefit 
from nutritional research through the translation of results into dietary guidelines. For 
example, the World Cancer Research Fund/American Institute for Cancer Research (WCRF/
AICR) has formulated nine recommendations for cancer prevention in their Third Expert 
Report in 2018 [4] after systematic review of the scientific literature focusing on the 
relation of diet, nutrition, and physical activity to cancer. According to the Expert Panel, the 
evidence with respect to a “Mediterranean type” dietary pattern was still inadequate to 
allow a meaningful recommendation. The findings of this thesis may be included in possible 
future Expert Reports of the WCRF/AICR and in this way contribute to the formulation of 
international lifestyle guidelines for cancer prevention.    
Regarding the potential of the MD as a dietary strategy specifically aimed at cancer 
prevention, our results suggested that in the Netherlands, MD adherence may be associated 
with reduced risks of cancers of the lung, female breast (postmenopausal), esophagus 
(squamous cell carcinoma in men), and stomach. The prognosis of most of these cancer 
sites is relatively poor, stressing the importance of preventive strategies. However, as 
already discussed in Chapter 9 of this thesis, the currently available evidence does probably 
not suffice to recommend Dutch policymakers to promote the MD specifically for cancer 
prevention at this time. 
In addition to its potentially favorable effect on cancer risk, MD adherence may be associated 
with various other health benefits, including reduced mortality and lower risks of several 
chronic diseases. This enables the formulation of a clear, consistent (with respect to disease 
risk) message to society and is likely to enhance the usability of the MD as a dietary strategy 
to improve the health status of the population. Furthermore, the MD is generally considered 
a palatable dietary pattern with a relatively low impact on the environment. Policymakers in 
the Netherlands could possibly use the MD as a framework to develop a healthy plant-based 
dietary pattern with the purpose of preventing chronic disease in general (see Chapter 9 for 
a more elaborate discussion). 
The successful implementation of a healthy plant-oriented dietary pattern in the Dutch 
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population most likely requires an integrative approach involving organized efforts of the 
government and society as a whole [4]. Policies are warranted that enable and encourage 
the adoption of the promoted dietary pattern by the community. In order to achieve these 
aims, such policy actions should influence the three domains of food environment, food 
system, and behavior change communication [4]. The behavior change domain encompasses 
educating people about health effects of food and nutrition by raising public awareness 
[4]. In this respect, (inter)national media attention has been paid to the health benefits 
of the MD in recent years. For example, our scientific article concerning MD adherence 
and postmenopausal breast cancer risk has been highlighted on (inter)national news 
websites. In addition to “unregulated” media attention, which is often concentrated on 
recent research papers showing positive health effects of MD adherence, Dutch authorities 
could play a role in promoting and disseminating a MD-derived plant-oriented dietary 
pattern in a more organized manner. In this instance, the Health Council of the Netherlands 
(“Gezondheidsraad”) and the Netherlands Nutrition Centre (“Voedingscentrum”) could get 
involved. Over the past decades, the Health Council of the Netherlands has issued several 
recommendations for a healthy dietary pattern targeted at the general Dutch population, 
with the most recent update being published in 2015 [5]. The Dutch dietary guidelines 2015 
[5] were formulated by taking the latest scientific evidence concerning chronic disease 
risk into consideration and integrate information regarding nutrients, foods, and dietary 
patterns. According to the Dutch dietary guidelines 2015, recommended dietary patterns 
(including the traditional MD) characterized by a higher consumption of plant foods and a 
lower consumption of foods from animal origin, positively affect health [5]. The Netherlands 
Nutrition Centre is a leading authority that is committed to advising the public and health 
care professionals about healthy and more sustainable dietary habits and aims to encourage 
people to change their current eating habits accordingly [6]. The Netherlands Nutrition 
Centre has created the “Wheel of Five” (“Schijf van Vijf”) [5-7]. The “Wheel of Five” 2016 
(Figure 1) is a practical translation of the Dutch dietary guidelines 2015 for use in nutritional 
counseling, which has been complemented with specific recommendations in order to make 
sure that people meet their energy and nutrient requirements. Activities of the Netherlands 
Nutrition Centre promoting the dissemination of the “Wheel of Five” by health care 
professionals include educating this group about the “Wheel of Five” and its components in 
general, as well as its development and expected health benefits. Furthermore, information, 
materials, and tools (e.g., leaflets, posters, and explanatory videos) are provided to support 
the use of the “Wheel of Five” in clinical practice. For the general population, the website 
of the Netherlands Nutrition Centre contains a wealth of information and tools to help 
and encourage individuals to make healthier food choices. Along with a description of the 
“Wheel of Five”, the website features advice, recipes, daily meal plans, and e-tools (e.g., 
“Schijf van Vijf voor jou” and “Mijn eet-update”) to inspire people [6, 7].  
In addition to the actions suggested above, informative presentations concerning the potential 
health benefits of the MD could be given at conferences for health care professionals, who 
could in turn transfer this knowledge to patients via nutritional counseling. 
When confirmed, the findings of this thesis could contribute to a decrease in morbidity and 
mortality due to cancer (and possibly other chronic diseases) in the Netherlands through 
the formulation of dietary guidelines and an increased public awareness of the impact of 
diet and other lifestyle factors on people’s health. Interestingly, increasing adherence to 
the MD seemed to be especially associated with reduced risks of cancers with a relatively 
poor prognosis. In addition to a reduced social burden, the prevention of cancer may have 
economic benefits, such as decreased health care costs and a reduced loss of productivity 
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Figure 1  The “Wheel of Five” (“Schijf van Vijf”) 2016
at the workplace. Finally, adoption of a Mediterranean(-like) dietary pattern by the Dutch 
population is likely to have advantageous effects for the environment as well [8-13]. A study 
by Van Dooren et al. [11] compared greenhouse gas emissions and land use associated 
with six dietary patterns, including the average Dutch diet of 1998 and the MD, in female 
adults. Greenhouse gas emissions and land use for the MD were estimated to be clearly 
lower than for the average Dutch diet [11], which underscores the benefits of adopting a 
Mediterranean(-like) dietary pattern.    
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gezorgd voor de nodige gezelligheid en afwisseling. Ik ben blij dat ik jullie heb leren kennen!
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bod. Onze ‘kamelenrace’ en ‘manuscript rejection ranking’ mogen hier natuurlijk ook niet 
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